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1.1 Biocatalysis  
Traditionally both fine and bulk chemicals like pharmaceuticals and biofuel components, 
respectively, are chemically produced. However, more and more often, enzymes and 
microbes are replacing or being incorporated into chemical processes for manufacturing these 
products.[1] This application of natural catalysts in synthetic chemistry is called biocatalysis 
and started already over 100 years ago inter alia with the synthesis of (R)-mandelonitrile using 
a plant extract, which also marks the start in the history of biocatalysis.[2,3] So far, several 
distinct waves of technical innovations and research, have led to the current state of the 
biocatalytic field and these first applications are seen as the first of now four waves.[2,4]  
 
 
Figure 1: Scheme of the cyclic optimization process used in developing new biocatalysts. (Figure from Schmid et al. 2001[5]) 
 
One of the main advantages of using enzymes is that they often offer environmentally 
friendly alternative routes to the use of metallo- or organocatalysts.[2] Additionally, the 
enzymatic process usually shows high regio-, stereo- and chemoselectivity at ambient 
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temperatures, low pressure and they are mostly applicable in aqueous solutions. Therefore, 
enzymes are considered as environmentally friendly alternatives to the chemical synthesis 
routes they replace.[6]  
As enzymes have evolved for their natural purposes under physiological conditions and 
natural selection pressures, they show distinct characteristics like a certain pH optimum or 
substrate range that need to be optimized before being capable of surpassing their chemical 
alternative (Figure 1). Only if the improved properties are combined with a high turnover 
number (>500 min-1), the enzymatic process could be considered as a promising candidate to 
be applied in industry and be considered as economically feasible.[1,7]  
The development of a biocatalytic process starts by choosing the substrate and reaction 
type catalyzed, followed by the identification of possible enzymatic candidates, to catalyse 
this reaction by screening a library consisting of microorganisms or physical enzyme variants.[5] 
After the identification of a proper candidate, the biocatalyst can be engineered by using 
protein engineering tools. After these optimizations, in addition, the general reaction 
conditions with the engineered biocatalyst need further investigation. For example, cofactor 
regeneration or the reusability of the enzyme are key features for the final applicability of the 
biocatalyst. Additionally, the biocatalyst is first identified, followed by optimization for small 
scale reactions. In order to catalyze the reaction in large industrial processes, upscaling is 
needed.[8–11]  
Finally, at the end of every process, the product has to be separated and purified. Only if 
all steps in the optimization process have been conducted successfully, in the end an analysis 
concerning the economic feasibility decides whether the enzymatic process has surpassed the 
chemical alternative and will be applied on industrial scale.  
For this thesis, of special interest is the optimization of the biocatalyst itself. This so-called 
protein engineering includes many exciting and quite diverse approaches. 
1.2 Protein engineering 
Protein engineering comprises numerous different techniques for the optimization of 
proteins, including enzymes. These techniques can be categorized into directed evolution, 
rational protein design, and semi-rational approaches (Figure 2).[12] 
The start of using these protein engineering techniques also marks the start of the so-called 
second wave of biocatalysis.[2] The originally developed methods from the 1980s, were mostly 
structure-based. By employing those methods, it became possible to use enzymes as catalysts 
for the production of fine chemicals and pharmaceuticals, using substrates which were 





Figure 2: Scheme showing the different techniques used for protein engineering (Picture from the Protein Engineering 
Handbook[13]). 
 
In the year 2000, the third wave started, by the development of directed evolution 
methods. With new molecular biology methods, modification of biocatalysts became much 
easier and faster.[4] Those methods included important protein engineering techniques: error-
prone polymerase chain reaction (epPCR) and DNA shuffling. By combining those molecular 
biology methods with high-throughput screening assays, a rapid approach for identifying 
interesting mutants was developed.[4] 
For the rational design of proteins, a crystal structure and ideally mechanistic information 
have to be available, or an accurate homology model needs to be prepared. On the basis of 
structural information, interesting positions for mutagenesis are identified by computational 
methods, resulting in the creation of small, focused libraries.[7] Although the structural 
approach is extremely powerful, a clear limitation is found in the difficulties in identifying 
combinations of mutations. 
In the directed evolution approach, random mutations are introduced into the gene, for 
example by epPCR. Through this method, a much larger library of protein variants is 
generated, followed by a screening for activity.[1,7,14] The need for high-throughput screening 
and restraints in library design, for example through the degeneracy of the genetic code, 
resulting in only a fraction of possible amino acid substitutions possible through this method, 
hamper the effectiveness of this technique.[15] 
Variants exhibiting improved activity identified from either method can be used as 
template for further protein engineering rounds. As both methods show certain restrains, 
often also combinational approaches are chosen. When combined, most limitations of the 
single approaches can be overcome. By focusing, resulting from rational design, on smaller 
regions of the protein, and inserting random mutations in the selected region, the obtained 
library size is strongly reduced. Furthermore, the opposite is also true. By epPCR identified 
interesting sites can be further investigated by more systematic characterization. This usually 
results in the identification of more active variants.[7,12] 
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1.3 Screening and selection approaches for the investigation of protein libraries 
As mentioned above, for the development of an improved biocatalyst, rational protein 
design or directed evolution is needed. Besides choosing an appropriate candidate for 
optimization, having an efficient screening strategy is important, in order to identify improved 
variants. Each screening or selection approach has different requirements, and diverse 
approaches exist (Figure 3). Depending on the size of the investigated library, the different 
approaches are more or less suitable and have different advantages and disadvantages. 
 
 
Figure 3: Overview of different screening approaches for protein libraries, further explained in section 1.3. A) Steps needed 
from the gene library leading to the starting point of the screen, B) legend, C) agar plate screening and selection approaches, 
D) microtiter plate screening approach, E) single cells as microreactors, F) surface display approach, G) droplets carrying a 
single cell (which can be lysed or cultured), and H) in vitro compartmentalization by dispersing the aqueous phase as droplets 
in oil (Picture from Leemhuis et. al., 2009[16]) 
 
By using selective agar plates not containing a molecule essential for growth (i. e. C-source, 
N-source or essential amino acids), which can only be produced by the investigated enzymatic 
activity, the library can be screened (Figure 3C).[17] With this method, large libraries can be 
screened and only active variants are obtained. Therefore, this method is a high throughput 
method (~109 variants). Unfortunately, this can only be employed if the screened activity leads 
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to a growth advantage, which is rarely the case. Additionally, through selection pressure, 
microbes can adapt to the applied growth conditions very fast, which also might lead to the 
identification of false positive colonies. Another plate-based assay is the screening of activity 
in colonies grown on indicator agar plates. After normal growth, the colonies are incubated 
with the investigated substrate. Substrate conversion finally yields in the formation of the 
indicator molecule in a direct way or indirectly with for example a second coupled reaction. 
This is a relatively simple and easy method for medium throughput (~105 variants), but a visual 
signal as activity output is needed.[16] 
One of the most commonly applied methods for the screening of different protein variants 
is the use of microtiter plates (Figure 3D). In this format the activity can be investigated either 
in crude lysate or in the supernatant. Also, whole-cell biocatalysis can be performed, if the 
product is secreted from the cell, the product formation can be analyzed in the supernatant. 
Different analytical tools, but mostly absorbance or fluorometric measurements, can be used 
to determine the activity of the investigated protein variants. As a lot of handling is needed 
and the plates need to be replicated for sequencing the original clones later, this is a medium 
throughput method (~104 variants).[16]  
By flow cytometry, single cells can be used for screening of fluorescent substrates (Figure 
3E). After expression of the different protein variants, the investigated substrate is added and 
needs to diffuse over the cell membrane. After incubation, the cells can be sorted by FACS. 
For this approach, a substrate is needed that can easily enter the cell and remains in the cell 
after conversion, which is hard to accomplish. As single cells are sorted, this is a high-
throughput method (~109 variants).[16,18] 
Another concept based on single cells is the cell surface display method (Figure 3F). In this 
method, the enzymes are expressed in the cell and exported to the cell surface. By a linked 
autotransporter protein (AIDA-I), the expressed proteins (up to 105 per cell) are transported 
to the cell surface and stay attached to it. Additionally, if the cells should be sorted later, the 
product needs to also stay attached to the cell surface, hampering its applicability. The cells 
can then be analyzed by FACS or ELISA (~109 variants). [16,19] 
The single cells expressing the enzyme variants can also be incorporated into oil droplets 
(Figure 3G). In these droplets the cells are separated from each other and incubated with 
substrate. The product formed by active enzyme variants accumulates in the droplet, linking 
it to the genotype and obviating the need for products that remain trapped in cells, which is 
in general an important issue for all screening and selection approaches, as discussed above. 
As all single-cell methods subjected to different sorting techniques (microfluidics or FACS), this 
is also a high-throughput method (~109 variants).[16,20] The encapsulated single cells can also 
be lysed in those droplets, which is called in vitro compartmentalization (Figure 3H). Or single 
genes can be encapsulated combined with in vitro translation systems. These droplets can be 
analyzed on a chip in a microfluidics system or in a FACS device, where double emulsion 
droplets are needed in order to work in an aqueous system, leading to additional problems in 
the formation of these droplets. However, this field is getting more and more attention and a 
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lot of progress is leading to easier applications.[21] An advantage of this technique is definitely 
also the high throughput (~109 variants).[16,22] 
Besides choosing a good screening or selection assay, the choice of substrate is also 
important. For most approaches, a photometric detectable activity output is needed. 
Therefore, if neither the substrate nor the product shows the desirable properties, often 
surrogate substrates are used during the screening or selection process.[23,24] These surrogates 
consist of the original substrate, chemically linked to a reporter molecule, which is released 
upon enzymatic activity. Although, the usage of surrogate substrates facilitates the 
identification of active variants, also new problems arise from their application. These 
substrates are much bulkier than the actual substrate, and therefore need more space. This 
might lead to problems concerning substrate supply and binding. As the surrogate substrate 
differs from the actual substrate, an active variant found during the assay might show lower 
activity with the actual substrate than observed with the surrogate substrate. Therefore, all 
identified possible hits have to be reevaluated in a second round to circumvent false positive 
results.[25]  
Especially, the protein engineering and screening of cytochrome P450 monooxygenases, 
was the main focus of this thesis, therefore, this enzymatic family will be described further in 
the following paragraphs. 
1.4 Cytochrome P450 monooxygenases 
In general enzymes can be categorized in six different classes depending on their catalyzed 
reaction type: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. In 
each class, different enzyme families are found. One of these families in the class of 
oxidoreductases, are cytochrome P450 monooxygenases.  
The term “cytochrome P450” was introduced by Omura et. al. [26] in 1962 to designate the 
investigated liver microsomal membrane-bound “pigment”. This name has been used ever 
since to describe a large family of heme-thiolate proteins that can be found throughout all 
domains of life and that catalyze the insertion of single oxygen atoms from molecular oxygen 
into their substrate at a non-activated carbon atom in a stereo- and regioselective manner, 
which is a highly challenging task.[27–30] Characteristically, this enzyme class presents a 
distinctive absorption band at 450 nm due to the binding of a carbon monoxide molecule to 
the reduced heme-center. That these proteins function as oxygenases was finally elucidated 
in 1963 and led to growing interest in and extensive research on these enzymes.[31] One year 
later, Omura et al. showed that the enzyme contains a heme-group.[32] 
Nowadays a large variety of P450 monooxygenases have been discovered. In the CYPED 
database (biocatnet, v6.0) approximately 52.700 sequences can be found.[33] Through the 
extensive research on P450 enzymes, not only their broad spectrum of substrates has been 
investigated, but also the different reaction types they catalyze have been discovered. In this 
sense, their substrates range from fatty acids, prostaglandins and steroids to several different 
compounds like anesthetics, carcinogens, ethanol, drugs, organic solvents and pesticides.[34] 
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With these substrates they catalyze not only hydroxylation reactions, but also N-, O- and S-
dealkylation, epoxidation, deamination, peroxidation, sulfoxidation reactions, and N-oxide 
reductions.[34,35] 
Due to the wide spectrum of converted substrates and the different reaction types 
catalyzed by the enzymes, cytochrome P450 monooxygenases show a great potential for 
biotechnical application. However, some drawbacks must be taken into consideration prior to 
their application, such as their instability, complexity and often low catalytic activity.[34,36]  
1.4.1 Catalytic cycle of cytochrome P450 enzymes 
The reaction mechanism of the cytochrome P450 enzymes' hydroxylation reaction was 
elucidated by Estabrook et. al. in 1971, proposing the idea of a cyclic reaction mechanism that 
is, with slight modifications, still valid today.[37]  
This rather complex catalytic cycle (Figure 4) consists of several steps:[38,39] (1) The cycle 
starts with substrate binding in the active site, which leads to the dissociation of the water 
molecule previously bound during the resting state of the enzyme; (2) Subsequently, the iron 
moves from an almost planar position in the heme molecule, to a new position below the 
heme group, simultaneously becoming the high-spin form. This species is a better electron 
acceptor than the water-bound configuration and receives one electron from NAD(P)H from 
its electron transferring system; (3) This electron reduces the ferric ion (Fe3+) to the ferrous 
(Fe2+) form. This high-spin ferrous complex binds molecular oxygen, yielding the formation of 
the ferrous dioxygen complex. (4) The singlet spin state of this complex is again a good 
electron acceptor. Therefore, another electron is accepted resulting in the formation of the 
ferric-peroxo anion;[34] (5) This compound acts as a good Lewis base and subsequently accepts 
a proton, leading to the formation of the ferric-hydroperoxide complex, which is also often 
called Compound 0 (Cpd 0). (6) Afterwards, another proton is accepted by Cpd 0, which leads 
to cleavage of the O-O bond and the reduction of one oxygen atom to water. This newly 
formed water molecule is released from the active site, leaving the heme group in its ferryl 
state (Fe4+), which is also referred to as Compound I. (7) The activated single oxygen of Cpd I 
is then inserted into the substrate.[40] Afterwards the product dissociates from the active site, 
















Figure 4: Scheme of the catalytic cycle of cytochrome P450 enzymes, as described in section 1.4.1. Indicated with the red 
boxes, is the uncoupling of the catalytic cycle. The term uncoupling, refers to the unproductive decay of the highly active 
iron-oxygen complex at different stages, yielding in the formation of superoxide, hydrogen peroxide, or water. The porphyrin 
ring is depicted by a parallelogram with nitrogen atoms at the corners and iron in the center. (Figure from Yasui et. al. 2005[41]) 
 
This description of the catalytic cycle is of course simplified. The binding and electron 
transfer steps seem to be associated with conformational changes, as shown by X-Ray 
crystallography.[42,43] Additionally, it was shown for the human P450 2A6, that the substrate 
can dissociate from and reassociate with the enzyme.[43,44] Also the linear order of all steps is 
not mandatory, as the enzyme can be reduced with or without substrate bound to the active 
site.[45] As indicated in Figure 4, the reaction catalyzed by cytochrome P450 enzymes does not 
necessarily result in product formation. At two different points during the catalytic cycle, 
uncoupling can occur, yielding hydrogen peroxide or superoxide anion. 
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1.4.2 Spectral properties of cytochrome P450 monooxygenases 
Interestingly, upon substrate binding, the spectral properties of cytochrome P450 enzymes 
change. As described above, this is due to a spin shift from low-spin (LS) to high-spin (HS) 
induced by the substrate binding, which is detectable in a shift of the Soret band from 415-
417 nm (LS) to 390-394 nm (HS).[46] Therefore, correct binding of the substrate can be 
investigated photometrically by a difference spectrum (type-I spectrum). This spectrum shows 
a minimum at 420 nm and a maximum at 390 nm and is characteristically observed if the 
substrate replaces the water molecules in the active site. Depending on the amplitude of the 
spectrum, the total amount of cytochrome P450 converted from LS to HS can be estimated. 
Therefore, this allows an estimation whether the investigated substrate is a good substrate 
for the enzyme under investigation.  
Additionally, a reversed type I spectrum can be observed if a part of the enzyme population 
is already present in the HS state and titration of the substrate leads to a shift to LS. Observing 
this kind of difference spectrum indicates the presence of a weakly bound substrate, being 
replaced by the investigated substrate.[47] 
A third type of difference spectrum observed for substrate binding studies with cytochrome 
P450 enzymes is the type II spectrum. This spectrum shows a maximum at 425-440 nm and a 
minimum at 415 nm, indicating that a six-coordinated complex with a tightly bound ligand has 
been formed.[46] Usually, if an investigated compound leads to the formation of this spectrum, 
an inhibitory effect is presumed. Although often this kind of spectrum is formed by nitrogen-
containing ligands, which are indeed often inhibitors, some type-II ligands are also 
substrates.[48] 
Another important spectral property of cytochrome P450 monooxygenases is their typical 
absorption maximum at 450 nm upon reduction and incubation with CO, as mentioned 
before. If the enzyme in not properly folded, a characteristic absorption maximum at 420 nm 
can be observed. This distinctive difference spectrum builds the basis for concentration 
determination of cytochrome P450 samples. Hence, not only the concentration of the enzyme 
sample can be determined, but also the percentage of correctly folded enzyme can be 
estimated.[27,32] 
1.4.3 Uncoupling of the catalytic cycle of cytochrome P450 enzymes 
Additionally, the formation and release of reactive oxygen species (ROS) is a major concern 
for cytochrome P450 enzymes. In this case, instead of completing the reactive cycle, the 
generated iron-oxygen decays, resulting in the generation of different ROS. The type of ROS 
formed depends on the current stage of the iron-oxygen complex. At the different branch 
points (indicated with red boxes in Figure 4), either superoxide anion or hydrogen peroxide, 
which can be further reduced to water, can be formed.[49–51] This release of ROS from the 
active site is called “uncoupling” and is an unfavorable side reaction as it drains electrons from 
the system leading to a lower catalytic efficiency. [39] Moreover, the released ROS could then 
lead to protein oxidation by reacting with amino acids of the enzyme itself. This latter process 
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also influences the reaction efficiency by denaturing and thereby inactivating the enzyme. 
Interestingly, it has been shown that for some cytochrome P450 enzymes, also the reversed 
reaction can take place. Instead of releasing hydrogen peroxide, it can be used to catalyze 
reactions.[52,53] 
Uncoupling is influenced by different factors. These have to be investigated on a case by 
case basis. In several studies, different factors were identified for the cytochrome P450 
enzyme investigated in this study. Concerning the substrate, there seems to be a strong 
reverse correlation between proper substrate binding and uncoupling. Only if the substrate is 
bound correctly, the heme-spin shift can take place, leading to a coupled reaction.[54] In 
addition, substrate accessibility plays an important role, as well as the sufficient supply of 
oxygen and electrons.[55,56] Furthermore, the hydration of the active site is essential.[55] For 
microsomal cytochrome P450 enzymes, cytochrome b5 can alter the activity and act as an 
alternate electron donor.[56] Additionally, in artificial systems, lipid nature, salt composition, 
and the presence of detergents and additive agents have been reported to display an 
influence on both activity and uncoupling of the cytochrome P450 system under 
investigation.[56] The NADPH concentration also seems to influence the uncoupling rate. A 
study suggested that an optimal concentration exists. Below this concentration, productivity 
decreases and above it, the productivity stays the same while only uncoupling is enhanced.[49] 
Structurally, the size of the active site can be essential. In a study from Sibbesen et al. with the 
P450 camphor (P450cam), they demonstrated that adjusting the active site to the substrate 
size and shape could enhance the coupling efficiency.[57] Although it was found that the 
introduction of mutations yielded variants with increased uncoupling,[58] there are examples 
of protein engineering leading to a decreased uncoupling rate or even a fully coupled system. 
For instance, in another study with P450cam, the introduction of an unnatural amino acid led 
to a fully coupled system. It was suggested that the newly introduced methoxythreonine 
prevents solvent from entering the active site and, thereby, leads to an enhanced coupling 
efficiency.[59] Alternatively, by creating a fusion enzyme between the human P4502E1 and 
BMR (the reductive domain of BM3 from Bacillus megaterium: amino acids 473-1049) a higher 
conversion and a lower uncoupling rate were observed. In addition, the membrane anchor of 
the enzyme could be cleaved off and the expression of the enzyme was enhanced.[60] 
However, although the uncoupling of cytochrome P450 enzymes has been extensively 
investigated, it remains difficult to tell exactly which factors are the most crucial. 
1.4.4 Hydrogen peroxide detection methods 
In order to determine hydrogen peroxide concentrations, different methods have been 
described. Depending on intra- or extracellular usage, different methods have to be applied, 
especially due to the reductive intracellular environment. Additionally, continuous methods 
exist for the observation of the changes in hydrogen peroxide concentrations over time or 
methods only able to determine the concentration at a certain endpoint.  
A classic hydrogen peroxide detection method is the use of horseradish peroxidase (HRP). 
This enzyme can be combined with different probes to yield different fluorescent or absorbent 
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products, detectable at different wavelengths. The HRP reduces hydrogen peroxide to water 
and oxidizes the added probe with two electrons gained per hydrogen peroxide molecule. This 
usually results in a 1:1 stoichiometry between the hydrogen peroxide and the oxidized, 
photometrically detectable probe. Examples of probes used in combination with HRP are N-
acetyl-3,7- dihydroxyphenoxazine (Amplex® Red/AmplifluTM Red)[61], 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS)[62], homovanillic acid[63] or 7-hydroxy-6-
methoxycoumarin (scopoletin)[64]. 
For the determination of the uncoupling level of Cytochrome P450 enzymes also often 
applied is the Nash reagent.[65] For this method, the reaction is stopped with hydrochloric acid, 
followed by addition of the NASH reagent (consisting of ammonium acetate, acetylacetone 
and acetic acid). The hydrogen peroxide concentration can be photometrically determined 
after incubation. 
Another endpoint measurement method applied for the detection of hydrogen peroxide 
formation in the reaction of cytochrome P450 enzymes is the addition of ammonium sulfate 
and ammonium thiocyanate to the acidified sample.[66] Also resulting in a photometrical 
detection of hydrogen peroxide concentration. 
For intracellular measurements, the HyPer-3 protein could be used.[67] In E. coli a natural 
hydrogen peroxide sensing protein exists, the so-called OxyR protein, which undergoes 
conformational changes upon oxidation, resulting in the formation of a disulfide bridge. In 
HyPer-3, the circularly permuted yellow fluorescent protein (cpYFP) is integrated into the 
regulatory domain of the OxyR protein. The conformational changes in the OxyR protein also 
lead to conformational changes in the inserted cpYFP protein, which shows a change in the 
fluorescence excitation spectrum. Hydrogen peroxide levels can therefore be observed in a 
ratiometric fashion, observing the changes in fluorescence intensities at 500 nm and 
420 nm.[67] 
Additionally, 5-(and 6-)chloromethyl-2’7’-dichlorodihydrofluorescein diacetate (CM-DCFH-
DA) is used for the detection of intracellular hydrogen peroxide levels. Through covalent 
binding of the chloromethyl group of this probe with intracellular thiols, the probe is retained 
inside the cell. The diacetate diffuses passively into the cell, where intracellular esterases 
cleave the two acetate groups, resulting in the non cell membrane-permeable CM-DCFH. 
Upon oxidation, the highly fluorescent product CM-DCF is produced.[68] 
These methods only represent a few approaches used for hydrogen peroxide detection 
that are on the one hand used in the detection of uncoupling levels of cytochrome P450 
enzymes, and on the other hand are relevant for this thesis. 
1.5 Classification of cytochrome P450 enzymes 
As previously described, the activity of cytochrome P450 enzymes relies on an adequate 
transfer of electrons, which are provided by either, (i) a reductase domain within the protein, 
(ii) a separate reductase, or (iii) a separate reductase and an additional protein acting as an 




Figure 5: Scheme showing the different cytochrome P450 classes, further described in section 1.5. (Figure from Hannemann 




According to Hannemann et al., depending on the reductase, cytochrome P450 systems 
can be divided into at least 10 different classes (Figure 5).[69] 
Class I consists of most bacterial cytochrome P450 systems and the eukaryotic 
mitochondrial P450 systems. All these systems comprise three separate proteins: the 
ferredoxin reductase (FdR), the ferredoxin and the P450 enzyme. The first one is a FAD-
dependent enzyme whose role is to transfer the reducing equivalents from NAD(P)H to the 
ferredoxin (Fdx). Fdx contains an iron-sulfur cluster and shuttles electrons between the FdR 
and the cytochrome P450 enzyme, reducing the P450 enzyme and thus allowing catalysis. 
Depending on the origin of the system, the components are either all three soluble proteins 
(bacterial, Figure 5A), or only the shuttling Fdx is soluble, being FdR membrane-associated and 
the cytochrome P450 enzyme is membrane-bound to the inner mitochondrial membrane 
(eukaryotic, Figure 5B).[34,69] 
Class II contains mainly eukaryotic P450 systems, especially P450 systems from plants. 
These systems involve two separate integral membrane proteins (Figure 5C). In this class, the 
cytochrome P450 reductase (CPR) contains two prosthetic groups, FAD and FMN. This 
reductase is able to transfer the reducing equivalents from NADPH to different isoforms of 
cytochrome P450 enzymes.[69,70] 
Class III was reported for the first time by Hawkes et al in 2002.[71] This class is similar to 
the bacterial members of Class I (Figure 5D), yet it shows a difference: the shuttling protein is 
a flavodoxin (Fldx), containing a FMN as prosthetic group, instead of the iron-sulfur cluster 
mentioned above.[69,71] 
Class IV was identified by investigating the first thermophilic CYP119 from Sulfolobus 
solfataricus. This P450 system was the first system not using a pyridine nucleotide to obtain 
its electrons (Figure 5E).[69,72] 
Class V systems include two components, a pyridine nucleotide-dependent reductase and 
a fusion enzyme of an iron-sulfur cluster containing the ferredoxin domain linked via a flexible 
hinge to the cytochrome P450 enzyme (Figure 5F). A member of this class was for the first 
time described by Jackson et al. in 2002.[69,73] 
Class VI is similar to class V. The difference between these classes is that the fusion enzyme 
consists of a Fldx and the cytochrome P450 enzyme instead of a Fdx and the cytochrome P450 
enzyme (Figure 5G). The first member of this class was described by Rylott et al. in 2006.[69,74] 
Class VII comprises bacterial fusion systems with a rare structural organization (Figure 5H). 
Here, the P450 enzyme is fused to a special reductase domain, a phthalate dioxygenase 
reductase domain. Typically, this domain is not connected to the cytochrome P450. Here, the 
first member was described by Roberts et al. in 2002.[69,75] This unique domain has again three 
distinct domains: (i) a NADH-binding domain, (ii) a FMN-binding domain and (iii) a Fdx domain, 
containing an iron-sulfur cluster.[76] 
Class VIII members are self-sufficient monooxygenases. This means that the cytochrome 
P450 enzymes of this class are fused to their CPR like (class II) reductase (Figure 5I). Here, the 
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probably best-known and intensively studied P450, BM3 from Bacillus megaterium (B. 
megaterium), was first described by Fulco et al. in 1974.[69,77] 
Class IX is characterized by also being self-sufficient, but in contrast to class VIII, there is no 
CPR domain (Figure 5J). The first member, the nitric oxide reductase, is also the first soluble 
eukaryotic P450 to be described by Kizama et al. in 1991.[69,78] The enzyme is especially 
interesting for its function, as it converts nitric oxide to nitrous oxide, which resembles a 
unique process for P450 enzymes.[79] 
Class X consists of cytochrome P450 enzymes which use an intramolecular transfer system 
(Figure 5K). Therefore, they require neither O2 nor NAD(P)H. These enzymes use an acyl 
hydroperoxide as oxygen donor, to form a new carbon-oxygen bond.[69,80] 
As all classes can be distinguished on the basis of their reductase system, an obvious 
question arises. Why did so many different systems evolve? The answer to this question 
remains unclear, although it might be explained by the different redox potentials of the 
different systems.[69] 
1.6 Steroidogenesis 
As mentioned previously, cytochrome P450 monooxygenases have important physiological 
roles. One of these roles is their crucial function in steroidogenesis, the biosynthesis of steroid 
hormones (Figure 6). Along with the cytochrome P450 monooxygenases, hydroxysteroid 
dehydrogenases are also involved (HSD).[81]  
Regarding to the compounds formed, there are five different classes of steroid hormones, 
which are structurally similar and formed during this metabolic process. The differentiation 
between the groups of steroid hormones is based on their different physiological functions.[82] 
1) Mineralocorticoids were named for their ability to command the renal tubes to preserve 
sodium and 2) glucocorticoids for their involvement in mobilizing carbohydrates.[82] 3) 
Estrogens induce female secondary sexual characteristics and exert immunoenhancing 
activities.[82–84] 4) Progestins all show the progestogenic effect, leading to a characteristic 
change in the estrogen-primed endometrium.[85] 5) Androgens induce male secondary 






Figure 6: Overview of the biosynthesis of steroids, the so-called steroidogenesis. In this pathway, cytochrome P450s (CYPs) 
and hydroxysteroid dehydrogenases (HSDs) are involved, catalyzing the different steps throughout the pathways, yielding 
different groups of steroid hormones: Mineralcorticoids, Glucocorticoids, Estrogens, Progestagens, and Androgens. These 
groups as well as the biosynthesis pathways are further described in section 1.6 (Figure from supplementary information of 
DeVore et al. from 2012[86]) 
 
This pathway starts in the gonads and the adrenal cortex with cholesterol being converted 
by the CYP11A enzyme, yielding pregnenolone. This first step is rate-limiting and forms the 
basis for all following pathways.[87] Pregnenolone can then be further converted by the 3βHSD 
to progesterone. Both progesterone and pregnenolone are substrates for the CYP17 enzyme. 
This enzyme plays a key role in providing the precursors for the biosynthesis of cortisol and 
estradiol and all androgens.[88] All further modifications take place in different tissues. For 
instance, the production of androgens takes place in the gonads. In this pathway, the three 
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enzymes 17HSD3, CYP19, and 17HSD1 convert androstenedione to the final products 
testosterone and estradiol.[81] In the adrenal zona fasciculata and reticularis, progesterone 
and 17α-hydroxyprogesterone are further converted by CYP21 and CYP11B1 to corticosterone 
and cortisol, respectively. Corticosterone is then further converted by CYP11B2 to aldosterone 
in the adrenal zona glomerulosa.[81] 
1.7 CYP11A1 
One of the enzymes involved in steroidogenesis was investigated during this PhD thesis. 
The CYP11A1 is a mitochondrial membrane-bound P450 enzyme, which belongs to class I 
(Figure 5B). Therefore, it is dependent on adrenodoxin (Adx), a soluble ferredoxin containing 
an iron-sulfur cluster, and the membrane associated protein adrenodoxin reductase (AdR), a 
NADPH-dependent flavin reductase (Figure 7).[89] The enzyme is expressed in steroidogenic 
tissue and in the brain, where it is exclusively found at the mitochondrial membrane.[90] If the 
activity of CYP11A1 is impaired or completely lost, cholesterol accumulates in all steroidogenic 
tissues. As a consequence, the synthesis of all adrenal and gonadal steroids is affected.[91] The 
complete loss of the enzyme function is believed to be incompatible with human term 
gestation.[92] In mice, a knock-out of the gene leads to death shortly after birth. If steroids are 




Figure 7: Scheme of the reaction of the three-component system CYP11A1 (P450scc), adrenodoxin (Adx) and adrenodoxin 
reductase (AdR) with cholesterol as substrate. Shown is the electron flow from AdR to Adx to P450scc, which finally catalyzes 
the three consecutive monooxygenation steps, converting cholesterol to pregnenolone under the consumption of three 
molecules of molecular oxygen. Reducing equivalents are supplied by the oxidation of three molecules of NADPH. (Figure 
from Makeeva et al. 2013[89]) 
 
Cholesterol side-chain cleavage, mediated by CYP11A1, results in pregnenolone by 
following three consecutive monooxygenation steps. First, the carbon atom C22 is 
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hydroxylated, yielding 22R-hydroxycholesterol, which is further hydroxylated at carbon atom 
C20 to produce 20a, 22R-dihydroxycholesterol. Subsequently, the side chain is cleaved, 
forming the final product pregnenolone.  
Besides this important reaction, CYP11A1 is also involved in the conversion of vitamin D3. 
This substrate is hydroxylated at carbons 17, 20, 22 and 23, yielding in the production of at 
least 10 different vitamin D metabolites. This discovery points to the assumption, that the 
CYP11A1 enzyme also initiates vitamin D metabolism pathways. The products might have 
important physiological roles. Especially in the skin, it could be a new target for the treatment 
of skin disorders and skin cancer.[94,95] It was also found that desmosterol and the plant sterols 
campesterol and β-sitosterol can be converted to pregnenolone. Additionally, 7-
dehydrocholesterol, ergosterol, lumisterol 3 and vitamin D2 are substrates for CYP11A1.[96] 
With ergosterol, the vitamin D2 precursor, CYP11A1 can form epoxy, hydroxy, and keto 
derivatives, without catalyzing side chain cleavage.[97] 
Besides their activity, the structure of these proteins has also been studied. In this sense, 
the structure of the bovine P450scc enzyme was determined by Mast et al. in 2011[98] and the 
structure of the human P450scc enzyme in complex with Adx was determined by Mackenzie 
et al., also in 2011 (Figure 8).[99] For the bovine enzyme, 12 amino acids were identified within 
4 Å to the bound 22-hydroxy-cholesterol (22-HC). Amino acids M202, F203, T291 and I351 
form van der Waals interactions with residues of the aliphatic tail, whereas I85, L460 and W88 
interact with the sterol α-face and Q356, T354, V353 and S352 interact with the sterol β-face. 
The edge of sterol ring A is held in place by F458. Additionally, the residues S33, H40, E53, Y62, 
Y83, L210, N211 and Q377 form hydrogen bonds with water molecules in the active site.  
The crystal structure of the human enzyme in complex with Adx (PDB code: 3N9Y) allows 
conclusions concerning the interactions between the two proteins to be reached (Figure 8). 
Judging from the structure, first an initial electrostatic force-driven protein-protein 
association occurs. Subsequently, a conformational change in both proteins takes place, which 
leads to an optimal geometry and a close distance between the redox centers of both proteins. 
As the surface which is oriented towards the redox partner appears to be a conserved region 
of class I cytochrome P450 enzymes, it is very likely that the same applies for all members of 
that class.[99] The interactions of these proteins are accomplished by distinct structural 
features. The F-helix of Adx binds to the K-helix of the CYP11A1 enzyme at the proximal 
surface. Through its core domain, the loop region around the iron-sulfur cluster, Adx interacts 
with two helices of CYP11A1, C and L, which are also known as the heme-binding loops. At the 
interface between the enzymes, two salt bridges are established (K339CYP11A1-D72Adx and 
K343CYP11A1-D76Adx).[99] This observation in the crystal structure is in accordance to earlier 
studies where the modification of those positions also affected the protein-protein 
interaction.[100–103] It is likely that the same region of the surface of Adx is responsible for 




Figure 8: Crystal structure of the human CYP11A1 (green) with co-crystallized human Adx (blue) (PDB code: 3N9Y). The grey 
part of Adx was not well defined in this crystal structure and was therefore modeled on the basis of the bovine crystal 
structure (PDB code: 1AYF). The iron-sulfur cluster of Adx (orange and yellow), the heme-group of CYP11A1 (red) and the 
bound cholesterol (brown) in the active site of CYP11A1 are shown as sticks. (Figure from Mackenzie et al. 2011[99]) 
 
The residues responsible for the interaction with the inner mitochondrial membrane are 
found in the F-G loop, the G’-helix and the A’-helix.[99,105] Another factor that must be taken 
into account is that the composition of the membrane, that the CYP11A1 is embedded in, has 
an influence on its overall activity. Interestingly, the acyl-chain structure is important and 
cardiolipin was found to have an activity-enhancing effect on the enzyme.[106] Especially, the 
substrate binding, membrane integration and protein exchange in the membrane was 
discovered to be positively influenced by branched phosphatidylcholines.[107] 
1.8 CYP17A1 
The next step in the metabolic pathway is performed by CYP17A1 (CYP17A / P450 17A1 / 
P450 17a). This cytochrome P450 monooxygenase catalyzes a key step in the steroidogenesis 
of mammals, where pregnenolone and progesterone are accepted as substrates to be 
subjected to 17a-hydroxylation, followed by the C17-20 bond cleavage reaction. As a result, 
dehydroepiandrosterone (DHEA) and androstenedione are formed, respectively.[108,109] The 
17a-hydroxylated products are further converted to glucocorticoids, whereas the C17–20 






Figure 9: Scheme of the reactions catalyzed by P450 17a. The enzyme accepts both progesterone (upper reaction) and 
pregnenolone (lower reaction) as substrates and catalyzes first a hydroxylation reaction at C17. Subsequently, the C17-20 
bond is cleaved, yielding in androstenedione and dehydroepiandrosterone (DHEA) respectively. (Figure from Pallan et al. 
2015[111]) 
 
Interestingly, the human CYP17A1 enzyme has a side activity, the 16a-hydroxylation of 
progesterone.[108,112–114] However, the physiological role of 16a-hydroxyprogesterone 
remains unclear. No further conversion of this molecule has been reported for any enzyme. A 
possible role would be the inhibition of the C17-20 bond cleavage reaction, regulating the 
formation of the different precursors formed by the CYP17A1 enzyme, resulting in the 
formation of different products.[108] 
The enzyme is predominantly expressed in the gonads and adrenals of mammals and, to a 
lesser extent, also in the heart, brain, and placenta.[112,115] As it is dependent on the 
flavoprotein, cytochrome P450 oxidoreductase (POR), the system can be categorized as a class 
II system.[116] CYP17A1 also accepts electrons from other partners for the 17-hydroxylation 
reaction.[117] This seems not to be the case for the C17-20 bond cleavage reaction.[118] 
Furthermore, cytochrome b5 is of great relevance for the cleavage reaction[109,113,119–121], along 
with a serine phosphorylation of the enzyme itself, probably by facilitating the interaction 
between the enzyme and its reductase.[109] 
The structures of the human CYP17A1, in the presence of two inhibitors, TOK-001 (PDB 
code: 3SWZ) and abiraterone (PDB code: 3RUK), was elucidated by DeVore et al. in 2012.[86] 
Two years later, Petrunak et al. determined the crystal structure of the enzyme with its natural 
substrates pregnenolone (PDB code: 4NKW), progesterone (PDB code: 4NKX), and 17a-
hydroxyprogesterone (PDB code: 4NKY) bound in the active site.[110] Afterwards, in 2017, the 
crystal structure of the enzyme with the inhibitors (R)- and (S)-orteronel (PDB code: 5IRQ) and 
the inhibitor VT-464 (PDB code:5IRV) was determined.[122] Additionally, the structure of the 
CYP17A1 from Danio rerio with abiraterone (PDB code: 4R1Z) was elucidated by Pallan et al. 
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in 2015.[111] More recently, in 2018, a structure of the CYP17A2 from Danio rerio in complex 
with abiraterone was also solved (PDB code: 6B82).[123] 
Judging from the knowledge derived from the crystal structures solved to date, different 
amino acids in the active site seem to play important roles in the catalytic activity of the 
CYP17A1 enzyme. Those residues form an extensive network of hydrogen bonds, involving the 
substrate and several water molecules.[124] In the literature, the residues identified forming 
this network were Y201, N202, R239, G297 and E305.[108,110,112,124] In this sense, the amino acid 
N202 forms a hydrogen bond with the 3β-OH hydrogen of pregnenolone and is thus important 
for correct substrate positioning and binding.[86] Similarly, residue E305 forms a hydrogen 
bond with N202 and might also be important for substrate positioning. Through several water 
molecules, also R239 and the carbonyl backbone of G297 are involved in the hydrogen bond 
network. In some crystal structures, Y201 was also located within hydrogen-bonding 
distance.[86] 
A study from Swart et al. in 2010, focused on the production of 16a-hydroxyprogesterone 
as side-product formed upon conversion of progesterone by the human and chimpanzee 
CYP17A1.[108] Hence, they compared the active site residues of the human and chimpanzee 
enzymes with enzymes from pig, goat and baboon. In this comparison, they discovered that 
especially in position 105, human and chimpanzee enzymes differed from all other enzymes 
investigated. Human and chimpanzee enzymes harbor an alanine in this position, which 
corresponds to a leucine in the enzymes from the other species. Consequently, they 
exchanged A105 in the human enzyme with leucine and they exchanged the corresponding 
leucine in the pig, baboon and goat enzymes with alanine. Characterization of these variants 
revealed that this position did in fact have the foreseen influence on the side-activity of these 
enzymes. For the human enzyme, side-product formation was lowered from approximately 
30% for the wild-type to 9% for the A105L mutant. Regarding the other investigated enzymes, 
they could introduce the side-activity. Therefore, they concluded that the exchange of leucine 
to alanine leads to more flexibility in the substrate movement, thus allowing the substrate to 
also present the C16 atom to the iron-oxy complex, leading to 16a-hydroxyprogesterone 
production.[108] 
As already stated, androgens and estrogens are the final products of the steroid hormone 
synthesis pathways, where CYP17A1 is one of the participating enzymes. These metabolites 
are involved in the development of prostate cancer and hormone-responsive breast cancer. 
Therefore, understanding the reaction mechanism and finding possible inhibitors is especially 
interesting. This enzyme has already been studied as a possible drug target in both types of 
cancer.[110,125–127] In addition, approximately 100 mutations of CYP17A1 have been 
investigated due to their clinical relevance. These mutations are known to result in metabolic 
deficiencies in patients where either one or both functions of the enzyme are 
impaired.[116,128,129] As a result, patients suffer from hypokalemia, hypertension, sexual 
infantilism and primary amenorrhea.[116] Additionally, the fertility in both male and female 
patients is impaired/reduced.  
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1.9 Cytochrome P450 BM3 
Probably the most investigated cytochrome P450 is the P450 BM3 (CYP102A1) from 
Bacillus megaterium.[130] This P450 is a self-sufficient monooxygenase and belongs to class 
VIII.[77] The 119.5 kDa protein consists of two domains: a 55 kDa heme-containing P450 
domain (BMP) and a 65 kDa reductase domain (BMR), containing both FAD and FMN.[131,132] 
The physiological role of this enzyme remains unclear, as it accepts many different substrates. 
It is thought that the enzyme might naturally convert branched-chain saturated fatty acids 
and therefore be involved in the regulation of membrane fluidity.[133,134] 
With known rates of over 5000 min-1, which are reached in the conversion of arachidonic 
acid, P450 BM3 is the fastest P450 enzyme described so far.[135] In general, it hydroxylates a 
broad range of saturated and unsaturated fatty acids (C12 – C20). During the years of extensive 
research on the P450 BM3 enzyme, a large list of substrates was added to the known 
converted substrates, ranging from aliphatic hydrocarbons, aromatics or fragrance and 
pheromone precursors to pharmaceuticals and other biomolecules.[130] 
The crystal structure of the heme-domain of P450 BM3 (PDB code: 2HPD) was solved by 
Ravichandran et al. in 1993.[136] It revealed that the enzyme has a long, hydrophobic access 
channel, which is built out of mostly non-aromatic amino acids.[130] Based on the crystal 
structures and on different mutational studies, several catalytically relevant residues of P450 
BM3 were identified. In this sense, R47 and Y51 may regulate the admission of substrate, co-
solvent and water to the active site.[130,137] F87 seems to play an important role in displacing 
the axial water ligand for substrate binding and may also be involved in active site 
reorganization upon substrate binding.[138,139] In the substrate-free structure, the side chain of 
F87 is oriented perpendicular to the porphyrin system and is rotated in the substrate bound 
form. There it resides in a position between substrate tail and the iron-center.[140] In addition, 
position F87 influences the specificity and the activity of the enzyme. As for all cytochrome 
P450 enzymes and enzymatic variants, for some activity is enhanced,[141] for others especially 
the peroxide uncoupling rate is raised significantly.[142] As mutating this position creates more 
space in the active site, it is often mutated in protein engineering approaches, for the 
conversion of bulky substrates. Another noteworthy residue is E267 since its side chain forms 
a hydrogen bond with a water molecule in the substrate-free structure. Mutating this position 
leads to higher uncoupling rates and lower activity. On the basis of the results of different 
studies, it was concluded that this residue is involved in the proton delivery pathway and in 
correct substrate positioning.[58,143] Residue T268 might also position a water molecule in the 
active site, which is important for the catalytic activity of the enzyme.[144] Altering this residue 
results in the impairment of both NADPH consumption and uncoupling rates for a number of 
substrates.[62,144]  
Additionally, several other positions are significant for the catalytic activity of the P450 
BM3 enzyme. Depending on the reaction catalyzed, different residues are crucial and have to 
be considered on a case by case basis. A good overview of investigated mutations and 
substrates can be found in a review from Whitehouse et al. from 2012.[130] 
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1.10 Redox partner systems 
Cytochrome P450 enzymes need reductases, or a redox partner system, for electron supply 
and catalytic activity. Besides their natural reductases, reductases from other cytochrome 
P450 systems can also be used to drive catalysis. For example, in in vitro biocatalysis, if the 
natural redox partner system has not been identified or is not available, different redox 
partner systems can be investigated and can replace the natural system for studies of the 
activity of the cytochrome P450 monooxygenase. 
One of these reductases, described by Girhard et al. in 2013, is the reductase CPR from 
Candida apicola.[145] As cofactor, CPR harbors FAD and FMN in its active site. The optimized 
membrane-anchor truncated protein, shows a reducing activity towards cytochrome c with a 
KM of 13.8 µM and a kcat of 1.915 min-1. In the same study, Girhard et al. could also 
demonstrate activity of CYP109B1 and CYP145E1 in the presence of this reductase. They 
compared different reductases in combination with the two enzymes and demonstrated that 
CPR displayed the highest coupling rates and conversion rates with CYP109B1. Concerning 
CYP154E1, biocatalysis with CPR as reductase also displayed good conversion, although the 
putidaredoxin (Pdx)/ putidaredoxin reductase (PdR) system from Pseudomonas putida 
showed even higher conversion. 
The Pdx/PdR system is the natural redox partner system for the camphor hydroxylating 
cytochrome P450cam enzyme. Pdx is an iron-sulfur cluster containing ferredoxin and PdR, a 
FMN containing ferredoxin reductase.[146] The system was discovered in 1968 by growing P. 
putida on camphor as carbon source.[147] The whole system has been studied extensively ever 
since. As this redox partner system was one of the first to be described, it was very often 
employed for other enzymes, where the natural redox partner system was not yet identified.  
In another approach, the reductive domain of cytochrome P450 BM3 (BMR) was separated 
from the rest of the protein by cloning experiments and applied as a reductase for other 
cytochrome P450 enzymes.[49,60,130,145,148–152] The advantage of using this reductase is that only 
one protein needs to be expressed and purified, as is the case for CPR. Additionally, it is a 
soluble protein, therefore it has some major advantages in application, compared to 
membrane-bound reductases.  
1.11 Challenges in applying cytochrome P450 enzymes 
In general, P450 enzymes catalyze challenging reactions and are therefore very interesting 
enzymes for industrial applications. However, the use of these enzymes in chemical synthesis 
is hampered by many factors. The major drawbacks lie in their functional complexity, low 
activity and limited stability, which therefore need to be optimized.[153,154]  
The main focus of most studies to make cytochrome P450 enzymes more attractive 
candidates for industrial application lies in understanding how structural aspects are related 
to the catalytic mechanism; development of alternative electron-transfer systems; discovery 
of new sensitive high-throughput screening methods; and of course, in the generation of new 
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mutants that selectively convert certain substrates to products of interest.[154] The volumetric 
productivity needs to be optimized, not only by protein engineering, but also by optimizing 
the process concerning reaction media and different bacterial strains used for expression.[146] 
1.11.1 Structure-function relationships in P450 enzymes 
Thanks to the growing number of crystal structures of different cytochrome P450 enzymes, 
with different substrates and inhibitors bound to the active site, investigating structure-
function relationships is becoming the topic of more and more studies. When combining this 
data with dynamic information gained by NMR and MS, some key features are considered to 
be important for substrate recognition and binding.[155] Residues in the I helix, β3 and β5 
strands and for larger substrates also amino acids from the A helix, appear to be important for 
the determination of substrates binding in the active site. The B-C loop, the B’-helix and the 
F-G loop were described to determine the orientation of the bound substrate. These regions 
are reorganized in order to reach a catalytically active final conformation.[155] 
1.11.2 Engineering of cytochrome P450 enzymes by rational design and directed evolution 
Based on the information available on structure-function relationships, rational protein 
design of cytochrome P450 enzymes becomes possible.[28] For instance, P450 BM3 was the 
focus of many studies, along with P450cam. The examples here, which only represent a very 
small number of published examples, will focus on the engineering of P450 BM3. Ost et al. 
could enhance the affinity of P450 BM3 for alkanoic acids and fatty acids shorter than C12 by 
a rational approach.[156] In other studies, new activities could be achieved. Graham-Lorence et 
al. turned the P450 BM3 into a stereo- and regioselective (14S,15R)-arachidonic acid 
epoxygenase[157] and Li et al. turned it into 3-chlorostyrene epoxygenase, which showed high 
enantioselectivity.[158] Whitehouse et al. engineered the P450 BM3 to show higher coupling, 
NADPH consumption rates, and product formation rates for (+)-α-pinene, fluorene, 3-
methylpentane and propylbenzene. The first two substrates mentioned were not converted 
by the wild-type and the conversion of the last two was strongly enhanced.[159] A very relevant 
issue is the bioremediation of water, which contains a lot of chemical contaminants. 
Therefore, cytochrome P450 BM3 has been engineered for the conversion of naphthalene, 
fluorene and acenaphthene.[160] 
In other studies, cytochrome P450 BM3 variants were created by directed evolution with 
enhanced peroxide-driven hydroxylation activity.[53,161] Additionally, it was also shown that 
general characteristics like thermostability could be improved by (up to) 18°C.[162] Another 
example of the directed evolution approach is the use of error-prone PCR to improve the 
tolerance of P450 BM3 against solvents like DMSO and THF.[163]  
Both strategies can be combined for the identification of new interesting mutants. For 
example, cytochrome P450 BM3 has been engineered by combining directed evolution with 
site-directed mutagenesis. The purpose was altering the regio- and enantioselectivity of 
alkane hydroxylation. In the end, good mutants with 40% ee for the S-2-octanol and 55% ee 
for R-2-alcohols could be identified, achieving high activities with rates up to 400 min-1.[164] 
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A good summary of reactions catalyzed by wild-type and different engineered cytochrome 
P450 BM3 variants can be found in recent reviews by Whitehouse et al. and Fasan et al.[130,165] 
1.11.3 Screening methods for Cytochrome P450 enzymes 
After understanding the reaction mechanism and finding hotspots for the introduction of 
mutations, high-throughput screening methods are needed. Traditionally, assays used to 
investigate P450 activities were radiolabeling[166], the use of fluorogenic substrates,[167–169] 
and HPLC or GC/GC-MS[148,158] analysis.[153] Not all of these assays can be scaled up to a 
medium- or high-throughput level. Therefore, usually an NAD(P)H consumption assay is the 
method of choice.[170] The advantage of this assay is its applicability, which is independent of 
the substrates investigated. On the other hand, the drawback is that the activity itself is not 
measured by product formation and might therefore lead to erroneous results, as side-
reactions or for cytochrome P450 enzymes uncoupling can occur. An alternative approach is 
the measurement of activity by using surrogate substrates. Here, the substrate is chemically 
linked to a chromophore. If the reaction is catalyzed, the chromophore is released and this 
can be followed photometrically.[23] This approach can also be combined with flow cytometry 
and is therefore compatible with high-throughput assays.[171] Generally, this type of assay 
measures activity directly, but only of a surrogate substrate, which may be very different from 
the actual substrate. Although active variants can be identified with this method, it remains 
unclear whether more active variants could be found by using the cognate substrate. 
1.11.4 Challenges in applying membrane bound cytochrome P450 enzymes 
Additionally, new problems may arise if membrane-bound cytochrome P450s are studied. 
It is now commonly accepted that membrane proteins can not only be considered as such, but 
more as protein-lipid complexes. Therefore, some proteins might need specific lipid molecules 
acting as cofactors or that are needed for stability and correct folding.[172] Hence, heterologous 
expression of membrane proteins is not only dependent on the use of the right promoter, 
terminator, targeting signals and posttranslational processing, but also might be influenced 
by the lipid environment present in the host organism.[172] For CYP11A1, for example, 
reconstitution in vesicles with different compositions of phospholipids, had a strong influence 
on enzymatic activity.[106,173–175] 
1.11.5 Challenges in using cytochrome P450 systems requiring a separate reductase system 
In addition, the use of cytochrome P450 enzymes requiring a separate reductase system, 
increases the challenges of applying them in large scale processes. Due to the need for more 
than one protein, several factors from parallel expression of two or three proteins in one host 
cell might lead to new challenges, like the balance of the enzyme ratio and impairment of the 
growth of the cells. Additionally, the stability of more than one protein becomes an issue, 
independent of the in vivo or in vitro systems used. These problems have been addressed 
before by fusion of the cytochrome P450 2E1 to BMR. This did not only increase the soluble 
expression level, but also the stability of the fused cytochrome P450 enzyme without the need 
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for lipids or detergents.[176] In another study the chimeras of CYP2C9, CYP2C19 and CYP3A4, 
displayed the same enhanced solubility and similar activities to wild-type enzymes in 
reconstituted systems with their natural partners.[151] Additionally, electron supply can be 
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2 Scope of this PhD thesis 
The scope of this thesis was to investigate different characteristics of cytochrome P450 
monooxygenases. One major topic concerning the activity of cytochrome P450 
monooxygenases is the uncoupling of the catalytic cycle, resulting in the formation of reactive 
oxygen species. This not only reduces the overall activity, by draining electrons from the 
catalytic cycle, but also might lead to the inactivation of the enzyme itself, as reactive oxygen 
species can react with amino acids of the protein, leading to protein (per-)oxidation and finally 
to the denaturation of the protein. Therefore, reducing the extent of uncoupling of the 
catalytic cycle is a major topic in enhancing the overall activity of cytochrome P450 
monooxygenases.  
2.1 Development of an assay for the investigation of the uncoupling:  
In order to find variants with enhanced activity and reduced uncoupling, one main focus of 
the thesis was to find a reliable screening assay. With the assay, generated variants can be 
investigated, concerning their activity and uncoupling level. Furthermore, a high-throughput 
assay would enable the screening of large variant libraries. As the uncoupling process is to 
date not completely understood, rational protein design to influence the uncoupling level 
remains difficult. Therefore, random mutagenesis might be the method of choice to tackle the 
problems of enzyme inactivation resulting from uncoupling.  
2.2 Investigation of stability and activity of membrane-bound cytochrome P450 enzymes: 
Additionally, the overall stability and activity of membrane-bound cytochrome P450 
monooxygenases was a major topic of this thesis. Especially for the use of membrane bound 
proteins, the expression in artificial host systems is difficult. These proteins are often unstable 
if separated from their hydrophobic surrounding and might need special detergents or even 
lipid vesicles to remain in their active form. Furthermore, as for all proteins, optimal pH and 
temperature are important factors for the overall stability and activity of enzymes. Hence, the 
monooxygenases were investigated concerning pH and temperature stability.  
2.3 Alanine scanning for further investigation of the catalytic activity: 
As already mentioned, another focus lay on studying the overall activity of the investigated 
cytochrome P450 monooxygenases. Here, the active site was further investigated. An alanine 
scanning was the method of choice, followed by investigation of the activity of the variants 
obtained. With these results, the goal was to possibly identify important residues for catalytic 
activity. Although it is known that the reaction itself is catalyzed by the inherent prosthetic 
heme-group, other factors like substrate supply and especially substrate binding influence not 
only the activity but are also thought to influence the uncoupling rate. Especially substrate 
binding can be investigated by the alanine scanning as most likely positions in the active site 
are responsible not only for substrate binding, but also for correct substrate positioning, 






As described in the Scope of this PhD thesis section, one objective was the investigation of 
the uncoupling of cytochrome P450 enzymes. Therefore, a suitable assay for the detection of 
hydrogen peroxide production was needed. As most methods described in literature were 
endpoint measurements, these methods were not suitable for determining the hydrogen 
peroxide concentrations during the reaction, without taking time samples.[177] Additionally, 
initial high-throughput screening is often undertaken by only measuring NAD(P)H 
consumption rates. This measurement does not take the often-occurring uncoupling of 
cytochrome P450 enzymes into account and might, therefore, result in misleading results. 
Consequently, a method for simultaneously assaying NAD(P)H consumption and hydrogen 
peroxide production was established. 
3.1 Development of a hydrogen peroxide detection assay 
3.1.1 Expression of the enzyme cytochrome P450 BM3 
For the development of the assay, cytochrome P450 BM3 was used as model enzyme.[130] 
First, the expression and purification of the cytochrome P450 BM3 enzyme was investigated. 
Since the expression of this enzyme is well-established, the expression protocol was only 
slightly modified by using different inducer concentrations and different OD600 at time of 
induction (section 7.2.1.5.1). Finally, the enzyme was successfully expressed in soluble form 
in E. coli BL21 (DE3) harboring the pET22b_BM3 plasmid.  
 
 
Figure 10: SDS-PAGE showing the elution fraction of the purification of P450 BM3 with a cobalt column. The elution (e) was 
accomplished with 50 mM imidazole. 
 
For the purification, IMAC was used. Here, after optimizing the imidazole concentration in 
the washing buffer, in order to wash off other proteins and still obtain high concentrations of 
the investigated enzyme (section 7.1.8.5.1), a concentrated solution of cytochrome P450 BM3 
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could be obtained (Figure 10). The concentration of the 119 kDa protein was determined by a 
CO difference spectrum.[37] According to it, approximately 3 mg of cytochrome P450 BM3 
were obtained after purification from a 200 mL culture.  
3.1.2 Investigating HyPer-3 as a potential hydrogen peroxide reporter protein 
As first attempt, the Hy-Per3 protein was tested for suitability as hydrogen peroxide 
detector for the uncoupling assay. As described in the introduction, this protein can be used 
to investigate hydrogen peroxide concentrations by monitoring the emission ratio from 
500 nm to 420 nm.[67]  
To investigate the suitability and sensitivity of this hydrogen peroxide sensor, the protein 
was expressed and purified. With slight modifications, this was accomplished as described by 
Bilan et al. in 2013.[67] With this protocol, expression of the soluble recombinant protein could 
be accomplished (Figure 11). Although the flow-through (ft) also contained HyPer-3 protein, 
a high protein concentration of relatively pure HyPer-3 solution could be obtained after 
elution (e; Figure 11). 
 
 
Figure 11: SDS-PAGE of the purification of HyPer-3 on a cobalt column. A molecular weight marker (m), the supernatant (s) 
after lysate clarification, the flow-through (ft) fraction, and the elution (e) fraction were loaded on the gel. 
 
After obtaining the hydrogen peroxide sensing HyPer-3 protein in an enriched form, the 
protein was incubated with different concentrations of hydrogen peroxide and the 
fluorescence emission at 530 nm after ratiometric excitation at 420 nm and 500 nm 
monitored ( 
Figure 12). Judging from these results, the HyPer-3 protein was not sensitive enough for 
detection of hydrogen peroxide concentrations in the desired 100 nM to 50 µM range. Hence, 




Figure 12: Response of purified HyPer-3 (in 40 mM Tris-HCl buffer (pH 7.5) containing 150 mM KCl, 10 mM MgSO4 and 5 mM 
2-mercaptoethanol) in the presence of 20, 10, 5, 2.5, 1 and 0 mM of hydrogen peroxide. The ratio of fluorescence emission 
at 530 nm after ratiometric excitation at 420 nm and 500 nm is plotted. Duplicates were measured; therefore, no standard 
deviation was calculated. 
 
3.1.3 Comparison between AmplifluTM Red and ABTS 
A widely used system for the hydrogen peroxide detection is ABTS in combination with 
horseradish peroxidase (HRP).[178] Additionally, AmplifluTM Red can also be applied in the same 
fashion. Both molecules differ in their absorption spectra when in their oxidized and reduced 
forms. Therefore, from both molecules, absorption spectra of their oxidized and reduced 
forms were determined and compared to the spectrum of NADPH (Figure 13). As both 
concentrations need to be determined at the same time, it was essential that none of them 
interfered with each other.  
 
 
Figure 13: Overlay of the spectra of AmplifluTM Red (light grey), resorufin (magenta), ABTS (dark grey), ABTS* (green), and 
NADPH (black) between 275 nm and 700 nm. As buffer, 50 mM sodium phosphate buffer (pH 7.4) was used. Final 
concentrations of AmplifluTM Red and ABTS were 10 µM and 50 µM for NADPH. (Figure adapted from first publication: 
Morlock et al. 2018[179])  
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     From the comparison of the spectra, it became obvious that only by using AmplifluTM Red 
it was possible to investigate the NADPH concentration at the same time. As ABTS clearly has 
an absorption maximum at approximately 340 nm, which is the same wavelength as the 
absorption maximum of NADPH, they are incompatible with each other. Due to this finding, 
only the hydrogen peroxide detection with AmplifluTM Red was further investigated. 
3.1.4 Investigating the detection limits of AmplifluTM Red 
First, basic parameters of the system itself were examined. An important issue was the 
sensitivity of the assay. Therefore, the detection limits of the assay were determined. As the 
resorufin produced is a fluorophore, both absorbance and fluorescence measurements were 
performed. After incubating the AmplifluTM Red assay solution with different hydrogen 
peroxide concentrations, the lower and upper detection limits were found to be 0.5 µM and 
50 µM, respectively. For fluorescence measurements, an excitation wavelength of 550 nm and 
an emission wavelength of 590 nm were chosen. The upper limit was also found to be 0.5 µM, 
whereas the lower limit, at 50 nM, was significantly lower. Although fluorescent measurement 
was found to be more sensitive, absorbance measurement was used due to faster measuring 
time. 
3.1.5 Investigating the pH range, the signal stability and optimal enzyme concentration for 
the AmplifluTM Red assay 
Additionally, the pH range was investigated by incubating solutions with different hydrogen 
peroxide concentrations (0.5–50 µM) at different pH values; the AmplifluTM Red assay solution 
was adjusted to the same pH value. In general, a linear correlation between the absorbance 
of resorufin and hydrogen peroxide concentration was found for all pH values investigated 
(pH 6.0–9.0). The results were approximately the same for pH 7.0, 7.4, 8.0, 8.5, and 9.0. Only 
at lower pH (pH 6.0 and 6.5), the slope (and thus the extinction coefficient) of the observed 
linear regression decreased (Figure 14a). As most enzymes are usually naturally exposed to 
physiological pH values, pH 7.4 was chosen for all further investigations. 
Besides investigating the detection limits and the pH range, the stability of the signal was 
also examined. For this purpose, the experimental set-up stayed the same, but absorbance 
was observed over a time span of 20 min (Figure 14b). For the incubated samples, the signal 
stayed relatively stable over time. The deviation over the whole time of measurement for 
hydrogen peroxide concentrations ranging from 5 µM to 100 µM, was found to be around 4% 
when the final values were compared to the initial values. For lower concentrations, the 






Figure 14: Determination of signal stability, optimal pH, and enzyme concentration for the AmplifluTM Red assay. The assay 
solution consisted of 100 µM AmplifluTM Red, 0.2 U·mL-1 in 50 mM sodium phosphate buffer (pH 7.4). (a) For the investigation 
of the pH range, 100 µL assay solution adjusted to the investigated pH were incubated with 100 μL hydrogen peroxide 
solution (100, 50, 25, 10, 5, 2.5, and 1 μM) prepared with the same buffer. Only the results for pH 6.0, pH 6.5, and 7.4 are 
depicted since pH 8.0, 8.5, and 9.0 gave results not distinguishable from pH 7.4. (b) At pH 7.4, the signal stability was 
determined with the same concentrations of hydrogen peroxide as in (a). (c) The optimal Cytochrome P450 BM3 
concentration was determined by incubation of 50 μL containing different enzyme concentrations (5, 2.5, 1.2, and 0.6 μM) 
with the AmplifluTM Red assay solution supplemented with 75 μM NADPH. Absorbance was measured at λ = 560 nm. All 
experiments were performed in triplicates. (Figure from first publication: Morlock et al. 2018[179]) 
 
Different cytochrome P450 BM3 concentrations were incubated with NADPH in the 
absence of substrate. Both NADPH consumption (340 nm) and hydrogen peroxide production 
(560 nm) were followed simultaneously. The NADPH concentration was adjusted to the upper 
detection limit, which was found to be 50 µM as described above. Without substrate present, 
it must be presumed, that only uncoupling instead of product formation can result from 
NADPH consumption. Enzyme stock solutions with 0.6 µM, 1.2 µM, 2.5 µM, and 5 µM were 
prepared. In the final reaction, these stock solutions were diluted 1:4. The reactions were 
observed for 500 s (Figure 14c). At higher enzyme concentrations, the reaction went to 
completion faster; at the lowest concentration, the reaction did not go to completion within 
the measured time interval. To shorten measuring times, but still be able to follow the course 
of the reaction, the stock solutions with 1.2 µM cytochrome P450 BM3 (i.e., 0.3 µM final 
concentration) were used for further experiments. 
3.1.6 Investigation of the hydrogen peroxide formation by cytochrome P450 BM3 and five 
mutants in the reaction with different substrates 
Next, the established reaction conditions were tested in the reaction of different enzymes 
with different substrates. As enzymes, cytochrome P450 BM3 and five mutants found in 
literature (F87Y[141], R47L[180], Y51F[135], A82L[164] and T268A[181]), were used. These mutants 
were chosen for different reasons. Cytochrome P450 BM3 F87Y was described before, as an 
unproductive but correctly folded enzyme, which showed high uncoupling rates.[141] All other 
mutants have been reported to show different activities and different uncoupling rates in the 
reaction with different substrates. Therefore, this selection of cytochrome P450 enzyme 
variants allows the investigation of the reliability of the developed AmplifluTM Red assay. 
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Standard substrates for cytochrome P450 BM3 were used as follows: lauric acid (LA), 
palmitic acid (PA), pentadecanoic acid (PDA), 1-octanol (1-O), and oleic acid (OA).[130] 
Additionally the reaction without substrate (woS) was investigated.  
The results demonstrated that all variants showed preferences for different substrates. The 
total NADPH consumption, as well as the hydrogen peroxide production, varies for each 
variant-substrate combination (Table 1).  
 
Table 1: Consumed NADPH and produced hydrogen peroxide (H2O2) in the reaction of 0.3 µM purified enzyme with 50 µM 
NADPH and 100 µM substrate. 
 BM3 wt BM3 F87Y BM3 R47L  BM3 Y51F BM3 A82L BM3 T268A 
 NADPH H2O2 NADPH H2O2  NADPH H2O2  NADPH H2O2  NADPH H2O2  NADPH H2O2  
LA 48.2±1.7 0.3±1.0 20.8±0.8 7.0±1.5 30.0±6.1 3.3±4.2 21.6±1.5 0.3±0.2 24.5±2.0 1.0±0.7 34.2±3.0 0.4±0.7 
PA 40.7±0.9 1.6±0.8 11.3±1.6 7.9±1.4 30.7±1.3 6.2±0.6 13.0±1.4 2.2±1.3 32.7±3.5 2.4±0.8 28.3±2.8 1.4±0.2 
PDA 38.7±2.9 1.5±0.5 16.7±1.5 7.2±0.8 34.3±0.9 5.9±0.5 14.8±0.7 1.2±1.5 31.1±9.9 1.8±1.7 35.0±1.0 1.5±0.7 
1-O 30.1±0.9 1.0±0.8 21.6±0.3 6.6±1.1 38.5±1.0 5.5±0.8 20.8±1.2 0.6±1.2 24.1±0.8 1.4±1.5 20.8±0.9 1.5±2.1 
OA 38.4±3.3 1.6±0.5 21.3±0.9 6.4±0.1 36.6±4.2 4.0±0.2 19.2±1.7 0.8±0.4 38.9±1.6 1.1±0.9 26.9±9.6 1.7±1.4 
woS 32.1±3.7 12.0±2.3 5.1±1.5 8.0±0.9 23.6±0.8 8.1±0.2 12.5±2.5 4.2±2.3 22.4±0.7 7.4±0.8 22.5±0.1 9.9±6.6 
bg 1.5±1.2 0.2±0.3 0.0±2.1 0.7±0.0 0.0±2.1 0.9±0.2 1.6±0.4 0.2±0.3 1.6±0.4 0.2±0.3 1.5±1.2 0.2±0.3 
LA: lauric acid, PA: palmitic acid, PDA: pentadecanoic acid, 1-O: 1-octanol, woS: without substrate, bg: background/no enzyme 
and no substrate) in 50 mM sodium phosphate buffer (pH 7.4) at room temperature for 10 min reaction time. 
 
Assuming that the difference between hydrogen peroxide formation and NADPH 
consumption equals to some extent product formation (Table 2), the preferred substrate for 
each variant can be identified based on the data. For cytochrome P450 BM3 wild-type, as well 
as for the Y51F and T268A mutants, lauric acid is the best substrate. 1-octanol appears to be 
the best substrate for F87Y and R47L, and oleic acid the best substrate for A82L. On the other 
hand, lowest conversion seems to appear in the reaction of cytochrome P450 BM3 wild-type 
with 1-octanol as substrate. For A82L and T268A, 1-octanol also gives the lowest conversion 
among the tested substrates. For variants F87Y, R47L, and Y51F, the lowest conversion was 
observed using palmitic acid as substrate. 
 
Table 2: Subtraction of the produced H2O2 (µM) from the consumed NADPH (µM) in the reaction of 0.3 µM purified enzyme 
with 50 µM NADPH and 100 µM substrate. 
 BM3 wt BM3 F87Y BM3 R47L  BM3 Y51F  BM3 A82L  BM3 T268A 
LA 47.9 13.8 26.7 21.3 23.5 33.9 
PA 39.1 3.4 24.5 10.8 30.3 26.9 
PDA 37.2 9.5 28.4 13.6 29.2 33.5 
1-O 29.2 15.0 33.0 20.3 22.8 19.3 
OA 36.8 14.9 32.6 18.4 37.7 25.2 
woS 20.2 -2.9 15.5 8.3 14.9 12.6 
bg 1.3 0.3 -0.7 1.6 1.6 1.3 
LA: lauric acid, PA: palmitic acid, PDA: pentadecanoic acid, 1-O: 1-octanol, woS: without substrate, bg: background/no enzyme 




In general, cytochrome P450 BM3 wild-type is known as a well-coupled enzyme;[170] this 
was also confirmed by the results obtained applying the AmplifluTM Red assay. Variant F87Y 
showed almost no conversion and higher uncoupling than the wild-type for all tested 
substrates, which is in accordance to the literature.[141] This variant was described to show 
high uncoupling rates, resulting in the formation of water. Herein, the presented data 
however suggest that the variant F87Y also shows high hydrogen peroxide formation. The 
difference between consumed NADPH and produced hydrogen peroxide might in addition 
account for water formation, yielding no to very little product. 
Furthermore, positions R47 and Y51 are involved in correct substrate positioning and 
substrate binding and, therefore, influence efficient catalysis.[135] When exchanging these 
residues, the resulting variants will show different uncoupling rates, as the substrate 
positioning will be influenced. For the investigated substrates, there is no literature data 
available for variant R47L. Only variants with other amino acid exchanges in this position have 
been investigated with lauric acid as substrate. With alanine or glycine in position 47, kcat Km-1 
drops in the conversion of lauric acid, from 17.8 ± 1.4 µM-1 min-1 for cytochrome P450 BM3 
wild-type to 4.6 ± 0.7 µM-1 min-1 and 4.2 ± 0.6 µM-1 min-1, respectively. The kcat Km-1 for the 
conversion of laurate was less influenced for variant Y51F, which was found to be 
14.2 ± 1.0 µM-1 min-1.[135] Additionally, cytochrome P450 BM3 Y51F was described as a well-
coupled enzyme for the oxidation of laurate, which is also in accordance with the results for 
this variant presented in this thesis. 
Variant T268A showed good conversion for pentadecanoic acid with approximately 90% of 
the wild-type conversion. With only 70% and 68% of wild-type product formation, lauric acid 
and palmitic acid, respectively, were found to be worse substrates for this variant. These 
findings are supported by data found in the literature, where similar coupling efficiencies to 
wild-type were described for pentadecanoic acid, although lower conversions could be 
achieved for lauric and palmitic acid.[181] Only higher uncoupling rates, which were reported 
by Cryle et al. in 2008, could not be verified with the assay. However, it is possible that the 
variant might show uncoupling, forming water, which would not be detected with the 
hydrogen peroxide assay. 
For variant A82L, no data is available in the literature for the conversion of the substrates 
investigated. For all substrates tested, this variant was found to show average to high 
conversion and low uncoupling rates when compared to wild-type enzyme. 
Since all variants showed a clear difference between consumed NADPH and produced H2O2 
in reactions performed without substrate, it is likely that water formation accounts for a high 
percentage of uncoupling products. 
In addition to investigating the conversion of the six enzyme variants with different 
substrates, the uncoupling of cytochrome P450 BM3 wild-type without substrate was 
investigated. Here, the focus was on the other possible uncoupling products, superoxide anion 
and water. When subtracting hydrogen peroxide formation from NADPH consumption in the 
absence of substrate, the difference accounts for the other two uncoupling products. In 
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general, the aim of this experiment was to see which uncoupling product was the most 
prominent one in catalysis of cytochrome P450 BM3. However, it must also be noted that 
these results might differ from substrate to substrate. In addition, without substrate present, 
uncoupling is usually more prominent. Judging from the results obtained, hydrogen peroxide 
is the most pronounced uncoupling product for cytochrome P450 BM3 wild-type (Figure 15). 
The addition of superoxide dismutase did not result in a big difference, when compared to the 
same reaction without the superoxide dismutase, indicating that the formation of the 
superoxide anion as uncoupling product is less significant. 
 
 
Figure 15: Control reactions with the AmplifluTM Red assay. With cytochrome P450 BM3 wild-type (0.3 µM final concentration 
in 50 mM sodium phosphate buffer; pH 7.4) without NADPH (- NADPH), without substrate and horseradish peroxidase (- 
HRP), without substrate and with 20 U·mL-1 catalase (+ Cat), without substrate and with 2 U·mL-1 superoxide dismutase (+ 
SOD) and without substrate (woS). (Figure adapted from first publication: Morlock et al. 2018[179]) 
 
To confirm that only hydrogen peroxide was detected by the AmplifluTM Red assay, several 
negative controls were included (Figure 15). If only NADPH was incubated with the AmplifluTM 
Red assay solution, no signal was detected. Without NADPH and only enzyme, substrate, and 
the assay solution present, again, no signal was detected. The same could be observed if no 
horseradish peroxide was added to the reaction. This indicated that the signal must be 
mediated by HRP. When adding catalase to the reaction mixture, the signal was lowered 
significantly, leading to the assumption that predominantly hydrogen peroxide is detected by 
the assay. 
3.1.7 Investigating the hydrogen peroxide formation by CPR from C. apicola with the 
AmplifluTM Red assay 
Another test of the reliability of the AmplifluTM Red assay was performed by investigating 
the uncoupling reaction of the reductase CPR from C. apicola.[145] As reductases are thought 
to produce only hydrogen peroxide and superoxide anion as uncoupling products, the 
difficulty of investigating water formation was abolished.[182] When adding superoxide 
dismutase, which converts the superoxide anion to hydrogen peroxide, all uncoupling 
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products produced can be detected using the same assay. The reductase CPR consumed 
14.7 ± 0.6 µM, 7.1 ± 0.9 µM, and 2.5 ± 1.3 µM of the initially applied 22 µM, 12 µM, and 6 µM 
NADPH, while producing 14.4 ± 0.4 µM, 6.7 ± 0.1 µM, and 3.1 ± 0.2 µM hydrogen peroxide, 
respectively (Table 3). As the differences between these values were as little as 0.3 µM, 
0.4 µM and 0.6 µM, respectively, it can be assumed that the assay gives reliable results. 
 
Table 3: Consumed NADPH, produced H2O2, and the difference between both values in the reaction of CPR incubated with 
different NADPH concentrations. 
Initial NADPH concentration [µM] NADPH [µM] H2O2 [µM] NADPH-H2O2 [µM] 
22 µM 14.7 ± 0.6 14.4 ± 0.4 0.3 
12 µM 7.1 ± 0.9 6.7 ± 0.1 0.4 
6 µM 2.5 ± 1.3 3.1 ± 0.2 -0.6 
For each sample, 0.2 µM CPR was incubated with 22 µM, 12 µM, or 6 µM NADPH in 50 mM sodium phosphate buffer (pH 7.4) 
at room temperature for 30 min. All samples were investigated as triplicates. 
 
The negative controls showed that the reductase cannot directly interact with AmplifluTM 
Red. By adding catalase, the signal was significantly lowered, but not completely abolished, 
with 20% residual signal. As the horseradish peroxidase and catalase activities competed, the 
signal could not be completely suppressed but only strongly reduced. If the reductase would 
have interacted directly with AmplifluTM Red, the addition of catalase would have had less 
influence on the result of the experiment. 
3.1.8 Applicability of the AmplifluTM Red assay in cell lysate 
Although purified enzyme was used in the first tests mentioned above, for high-throughput 
measurements cell lysate is usually used. Therefore, the signal stability and the results of 
cytochrome P450 BM3 also needed to be investigated in crude cell lysate. 
First, the signal stability was examined. With 50 µL E. coli TOP10 cell lysate (1 mg wet cell 
pellet per 5 mL buffer), the AmplifluTM Red assay solution and different concentrations of 
hydrogen peroxide were incubated in a total volume of 200 µL (Figure 16). The solutions were 
incubated at room temperature for 3 h. Here, it could be shown that the signals were stable 
over the investigated time span as was observed for samples incubated in buffer. Only for 
lower concentrations the signal increased over time. This deviation might be explained by the 
sensitivity of AmplifluTM Red towards oxygen and light.[183] If small amounts of the probe are 
oxidized, this would have a greater influence at lower concentrations of hydrogen peroxide.  
After finding that the signal was also stable when incubated with cell lysate, the reaction 
of cytochrome P450 BM3 wild-type and variant T268A in cell lysate was investigated to 




Figure 16: Determination of the signal stability of the AmplifluTM Red assay when incubated with cell lysate. Assay solution 
(100 µL) consisting of 100 µM AmplifluTM Red, 0.2 U·mL-1 in 50 mM sodium phosphate buffer (pH 7.4) were incubated with 
50 μL hydrogen peroxide solutions prepared with the same buffer (400, 200, 100, 40, 20, 10, and 4 μM) and 50 µL E. coli 
Top10 cell lysate. The stability of the signal was observed at room temperature over 3 h. (Figure adapted from first 
publication: Morlock et al. 2018[179]) 
 
The assay was performed under the same conditions as used for the purified enzymes 
(Table 4). Although the absolute values for the measurements with purified and crude enzyme 
preparations differed, the tendency for the substrate conversion profiles of both enzymes 
stayed the same. In both experiments, lauric acid was identified as the best substrate for both 
enzymes; 1-octanol was least accepted by both enzymes. Noteworthy, all values were higher 
when investigating the reaction in cell lysate. Upon the addition of NADPH, there might be 
some other reactions occurring in the unpurified samples. In the cell lysate there are many 
proteins and molecules present, making it hard to judge which factor exactly is interfering 
with the measured reaction. However, apparently these influences were small enough to still 















Table 4: Consumed NADPH, produced hydrogen peroxide (H2O2), and difference between the values for the investigated 
reaction of Cytochrome P450 BM3 wild-type and T268 with different substrates.  
 BM3 wild-type BM3 T268A 
 NADPH [µM] H2O2 [µM] subtraction NADPH [µM] H2O2 [µM] subtraction  
LA 50.8±0.3 1.3±0.3 49.5 56.2±1.1 3.1±3.4 53.1 
PA 53.3±0.8 4.5±0.8 48.8 54.5±0.6 5.8±0.6 48.7 
PDA 49.9±0.2 4.8±0.2 45.1 56.0±0.9 5.4±3.5 50.6 
1-O 45.0±1.2 5.2±2.5 39.9 54.7±0.1 11.9±3.0 42.8 
OA 54.4±0.7 4.9±0.3 49.5 55.1±0.4 3.6±3.7 51.6 
woS 54.8±0.6 23.0±0.3 31.8 55.2±1.5 35.4±7.4 19.8 
bg 0.5±0.6 2.8±0.0 -2.2 0.0±0.7 0.3±0.1 -0.3 
0.3 µM enzyme in cell lysate was incubated with 50 µM NADPH and 100 µM substrate (LA: lauric acid, PA: palmitic acid, PDA: 
pentadecanoic acid, 1-O: 1-octanol, woS: without substrate, bg: background/no enzyme and no substrate) in 50 mM sodium 
phosphate buffer (pH 7.4) at room temperature within 10 min. 
 
3.2 Investigating the bovine CYP11A1 system 
For the investigation of the CYP11A1 system, all three proteins, CYP11A1, Adx, and AdR, 
needed to be expressed and purified. For each protein, different approaches for expression 
and purification were necessary. In general, expression optimization can be achieved by 
changing different parameters including the expression host, temperature, expression vector, 
inducer concentration, cell density at the time of induction, and the co-expression of 
chaperones. Especially, the co-expression of chaperones can help to enhance the amount of 
soluble protein obtained, as chaperones facilitate proper protein folding.[184,185] They are also 
known to resolubilize aggregates.[186] There are various kinds of chaperones, some of which 
are essential for the correct folding of many proteins and are constitutively expressed in the 
cell (e.g., GroEL and GroES), whereas others are only expressed in cellular stress responses 
(e.g., heat-shock proteins).[187] 
Additionally, adding precursors for co-factors might be important. For example, during the 
expression of cytochrome P450 enzymes, the addition of the heme-precursor δ-
aminolevulinic acid is well-established to be important for achieving high expression levels.  
3.2.1 Expression optimization of bovine CYP11A1 
For the expression of the bovine CYP11A1 enzyme, different E. coli strains harboring the 
pTrc99A_P450scc plasmid were initially investigated. E. coli TOP10 (DE3), BL21 (DE3), C41 
(DE3), C43 (DE3), and E. coli Shuffle T7 were used as hosts. Expression was performed at 30°C 
overnight. With the obtained samples, CO difference spectra were recorded (Table 5) and 
expression analyzed by SDS-PAGE (Figure 17). 
The results of the CO difference spectra indicated that no soluble expression of bovine 
CYP11A1 occurred. This was confirmed by SDS-PAGE. The results show that all protein was 
obtained in the insoluble fraction. Next, the expression temperature was lowered to 17°C and 
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the cultivation time increased to two days. Unfortunately, still no properly folded protein was 
detected by the CO difference spectra (Table 5). 
 
Table 5: Results of the CO difference spectrum measurement of the obtained cultivation samples. at 30°C (overnight) and 
17°C (two days) for bovine CYP11A1 production in the E. coli strains TOP10 (DE3), BL21 (DE3), C41 (DE3), C43(DE3), and 
SHuffle (DE3). After expression, cells were lysed in 50 mM sodium phosphate buffer (pH 7.4) containing 0.2% Triton X-100 
and 1 mM EDTA. 
 
E. coli strain 
                        30°C 
P450 [nmol L-1]     P450 [µg L-1] 
                       17°C 
P450 [nmol L-1]     P450 [µg L-1] 
TOP10 (DE3) 0.05 3.0 0.01 0.6                    
BL21 (DE3) 0.19 11.5 0.05 3.3     
C41 (DE3) 0.12 7.3 0.03 1.8 
C43 (DE3) 0.10 6.0 0.02 1.3 
SHuffle T7 - - - - 
Expression of bovine CYP11A1was performed in the E. coli strains TOP10 (DE3), BL21 (DE3), C41 (DE3), C43(DE3), and SHuffle 
(T7)at 30°C (overnight) and 17°C (two days) for production. After expression, cells were lysed in 50 mM sodium phosphate 
buffer (pH 7.4) containing 0.2% Triton X-100 and 1 mM EDTA. 
 
 
Figure 17: SDS-PAGE of the cultivation samples of the E. coli strains TOP10 (DE3), BL21 (DE3), C41 (DE3), C43 (DE3) and, 
Shuffle T7 harboring the pTrc99A_P450scc plasmid. All samples were taken after overnight expression and normalized to 
7/OD600. After cell lysis by sonication in 50 mM sodium phosphate buffer (pH 7.4) containing 0.2% Triton-X-100 and 1 mM 
EDTA, the soluble fraction (s) was separated from the insoluble fraction (p) by centrifugation for 30 min at 4.000g. 
 
Subsequently, the established protocols for the expression of the bovine CYP11A1 in E. coli 
described in literature were tested. Similar to the protocol published by Janocha et al. in 2011, 
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E. coli JM109 (DE3) cells were transformed with pTrc99A_P450scc, cultured and harvested.[188] 
Since there was no soluble expression visible according to SDS-PAGE analysis, a new protocol 
with a solubilization step of the membrane bound P450scc was tested.[189] Neither a clear 
band after SDS-PAGE, nor a positive result from the CO-assay could be observed. Therefore, 
the protocol of Lepesheva et al. from 1998 was investigated.[190] Different cultivations were 
carried out with E. coli JM109 (DE3) transformants containing pTrc99A_P450scc, E. coli JM109 
(DE3) co-transformants containing pTrc99A_P450scc and pGro7, and E. coli JM109 (DE3) 
transformed with pTrc99A_P450scc and the addition of 3% (ν/ν) ethanol, which introduces 
the production of heat-shock proteins, to the culture medium. 
 
Table 6: Results of the expression optimization of CYP11A1 using the protocol of Lepesheva et al. from 1998.[190]  












75 mL) [mg] 
pTrc99A_P450scc 0,022 0,007 5 0,035 
pTrc99A_P450scc, pGro7 0,005 0,012 5 0,060 
pTrc99A_P450scc 
+ 3 % EtOH 
0,003 0,014 3 0,042 
E. coli was transformed with pTrc99A_P450scc or in combination with pGro7. Further, the effect of the addition of 3% ethanol 
to the culture was investigated. The differences in total volume are achieved by harvesting cells and resuspending in different 
volumina, depending on wet cell weight 
 
The approach with the added ethanol showed the best ratio between correctly and 
incorrectly folded CYP11A1. The highest total amount of correctly folded enzyme was 
obtained by co-expression of the chaperones GroEL and GroES from pGro7.  
As the co-expression of GroEL and GroES was successful, the co-expression of other 
chaperones was also investigated, using the same expression protocol as before. Here, four 
different chaperone plasmids from the Takara Chaperone Plasmid Set (Section 7.1.6) were 
investigated (Table 7). Additionally, two different E. coli JM109 (DE3) strains were compared, 
one with and one without T1 phage resistance. The resistance is achieved by a knockout of an 
outer membrane protein receptor for ferrichrome, involved in the transport of the 
ferrichrome-iron over the outer membrane.[191] Time samples of the cultivation were taken 
after two and three days and the concentration of correctly folded and incorrectly folded P450 







Table 7: Result of the CO-spectrum measurement.  
Chaperone 
plasmid 


















































The + indicates that CYP11A1 was expressed in E. coli JM109 (DE3) with phage resistance. The - indicates that P450scc was 
expressed in E. coli JM109 (DE3) without phage resistance. The plasmid pTrc99A_P450scc encoding the CYP11A1 gene was 
used in all approaches. The plasmid pKJE7 harbors the genes dnaK, dnaJ, and grpE; the plasmid pGTf2 harbors the genes groEL, 
groES, and tig; the plasmid pGro7 harbors the genes groEL and groES; the plasmid pTf16 harbors the tig gene. 
 
As shown above, the co-expression of GroEL and GroES enhanced the P450scc expression 
level. By using cells without phage resistance, the expression was improved further. After 
three days cultivation of an E. coli JM109 (DE3) cell culture without phage resistance harboring 
the plasmids pTrc99A_P450scc and pGro7, expression levels of approximately 14 mg l-1 
correctly folded CYP11A1 were achieved, which equals a concentration of 240 nmol LL-1. 
Besides pGro7, co-expression of chaperones from pKJE7 (dnaK, dnaJ and grpE), pGTf2 (groEL, 
groES and tig) and pTf16 (tig) was tested, but did not result in further improvement of the 
soluble expression level. 
As described in the work of Janocha et al. in 2011, the exchange of one amino acid of 
CYP11A1 (K193E) leads to a 4-fold increased expression rate and a 3-fold increased solubility 
of the enzyme, while having no effect on enzymatic activity.[188]  
Therefore, this mutation was introduced by site-directed mutagenesis. Both, the variant 
and wild-type were expressed under the best conditions identified before. The results of the 
CO difference spectra showed that the expression of the CYP11A1 K193E variant is only 
enhanced after two days, whereas after three days the expression of wild-type P450scc was 
the best, with approximately 14 mg per liter culture compared to 2.1 mg per liter for the 








Table 8: Results of the CO difference spectrum measurement of the expression comparison of CYP11A1 and CYP11A1 K193E.  
























The + indicates that P450scc was expressed in E. coli JM109 (DE3) with phage resistance. The - indicates that CYP11A1 was 
expressed in E. coli JM109 (DE3) without T1 phage resistance. In all four expression approaches GroEL and GroES were co-
expressed. 
 
To determine the best time to harvest the cells during cultivation, the expression of 
CYP11A1 was monitored over time. Besides determining the CYP11A1 content of the cell 
cultures, the OD600 was determined (Table 9). For this experiment, two separate cultivation 
flasks under the established standard conditions were monitored and time samples were 
taken alternating from each flask. As for the CO assay 50 mL sample volume was needed, two 
flasks had to be used for the amount of time samples investigated. The resulting differences 
in the OD600 of both cultures might result from better oxygen supply after sampling. 
 
Table 9: Over a cultivation time of 72 hours the optical density (OD600) and the CYP11A1 content was monitored. 
 OD600 
Time [h] flask 1 flask 2 CYP11A1 [mg L-1] 
0 0.7 0.7 - 
16 3.8 3.4 6.9 
20 4.3 3.9 9.5 
24 5.0 4.2 7.8 
40 9.9 5.6 11.9 
44 10.5 6.3 10.3 
48 12.7 7.0 12.0 
64 12.0 8.8 10.9 
68 16.7 8.8 13.8 
72 16.5 14.7 20.1 
For each day three samples of 50 mL each were taken from the two different flasks in a sequential order. For the sample time 
point of each flask, the OD600 is shown with a light gray background. The initial volume in each flask was 500 mL of TB medium. 
 
Both the concentration of CYP11A1 and the OD600 increased over time. The highest 
concentration of CYP11A1 was achieved after 72 h cultivation time with a final concentration 
of 20.1 mg L-1.  
Additionally, a substrate binding spectrum of the last sample was recorded with cholesterol 
in order to investigate whether the obtained CYP11A1 enzyme was capable of binding the 
substrate (Figure 18). The substrate was added from a 10 mM stock solution in 45% (ω/ν) 
aqueous 2-hydroxypropyl-β-cyclodextrin, resulting in a final concentration of 0.2 mM. As 
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baseline, the spectrum of the same CYP11A1 solution was measured, before adding the 
substrate solution. The resulting difference spectrum is a type-I spectrum, which is typical for 
substrates correctly bound in the active site of cytochrome P450 enzymes.[46] 
 
 
Figure 18: Substrate binding spectrum of CYP11A1 incubated with 0.2 mM cholesterol, added from a 10 mM stock solution 
in 45% (w/v) aqueous 2-hydroxypropyl-β-cyclodextrin. As blank, the same CYP11A1 solution, without substrate present was 
measured first. The spectrum was recorded over a wavelength range from 350 nm to 500 nm. 
 
3.2.2 Purification of bovine CYP11A1 
To obtain pure enzyme, a C-terminal His-tag was introduced into the P450scc coding 
sequence on the pTrc99A plasmid.  
In a study by Mosa et al. from 2015, the purification of the His-tagged CYP11A1 was 
described.[192] By following this protocol, with slight modifications, CYP11A1 was found in the 
elution fraction (Figure 19). The eluted enzyme solution had a concentration of 4 µmol L-1, 
which equals a concentration of 242 mg L-1. Unfortunately, high amounts of CYP11A1 are 
found in the flow-through and in the washing fraction. This result indicates a problem with 
binding to the Ni-NTA column used, which might have been due to the additives (sodium 
cholate, sodium acetate and TWEEN 20) in the buffers used for purification. As the washing 
buffer did not contain imidazole, the problems with binding did not occur due to a too high 
imidazole concentration. Some of the additives might interfere with the availability of the His-
tag, by shielding it, for example.  
Therefore, the purification in 50 mM sodium phosphate buffer (pH 7.4) without additives 
was also investigated. Although the purity of CYP11A1 was further enhanced, the protein 





Figure 19: SDS-PAGE analysis of bovine P450scc purification by IMAC. After after cell lysis, the His-tagged enzyme was purified 
from the supernatant on a Ni-NTA column. A molecular marker (M), the flow-through (ft), the washing (w) fraction, and the 
eluate (e) from the purification were loaded onto the gel. 
 
Alternatively, purification with SP Sepharose resin was examined. As the enzyme was only 
stable in the buffer used in the study of Mosa et al., this buffer was also used for this 
purification approach. Unfortunately, the CYP11A1 protein did not bind to the column under 
the investigated conditions and was exclusively found in the flow-through (data not shown). 
3.2.3 Expression of bovine Adx 
For the investigation of the CYP11A1, Adx is needed as electron shuttle between AdR and 
CYP11A1. Therefore, the expression and purification of this protein were also investigated. 
Adx is a soluble, iron-sulfur containing protein with a molecular weight of 14 kDa.[193] 
First, the expression was tested for the two different plasmids pBad_Adx and pKKHc_Adx 
in E. coli BL21 (DE3) and E. coli JM109 (DE3). This first test indicated a higher expression level 
with the pKKHc_Adx plasmid, judging from SDS-PAGE analysis (Figure 20). Hence, E. coli BL21 





Figure 20: SDS-PAGE analysis of the expression of Adx from pBad_Adx in E. coli BL21 (DE3) and pKKHC_Adx in E. coli BL21 
(DE3) and JM109 (DE3). Besides the marker, samples at the time point of induction (t0) and a sample after one day (t1) and 
two days (t2) of cultivation were loaded on the gel. 
 
3.2.4 Purification of bovine Adx 
After finding cultivation conditions for successful expression of soluble bovine Adx, the 
purification of the protein was investigated. A study from Suhara et al. from 1972 suggested 
that purification of the protein could be accomplished by using anion-exchange 
chromatography with DEAE-cellulose as column material.[194] In that study, however, the 
protein was purified from bovine adrenal cortex tissue samples. 
As buffer, 10 mM potassium phosphate (pH 7.4) was used. For elution, different gradients 
were tested. A 0–1 M KCl gradient over 10 CVs showed the best results (Figure 21). For the 
elution fraction, a spectrum of wavelengths ranging from λ = 500 nm to λ = 280 nm was 
recorded (Figure 22A). This spectrum shows the three typical absorption maxima of the iron-
sulfur cluster of Adx and is in accordance to the published spectrum (Figure 22B).[194] 
Since adding another purification step might enhance the purity of the obtained protein 





Figure 21: SDS-PAGE analysis of bovine adrenodoxin (Adx). The enzyme was purified from the supernatent after cell lysis on 
a DEAE-cellulose column. A molecular marker (M), the supernatant (s), the pellet (p) after cell lysis, and the eluate (e) of the 
purification were loaded onto the gel. 
 
    
Figure 22: A) Absorption spectrum of the elution fraction from a purification of bovine Adx on a DEAE-cellulose column. B) 
Characterisic absorption spectrum of bovine Adx. The iron-sulfur clustur in the active site causes these characteristic peaks. 
(Figure from Suhara et al. 1972 [194]) 
 
After gel filtration on a Superdex 200 column, using 10 mM potassium phosphate buffer 
(pH 7.4), the purity of the bovine Adx was further enhanced (Figure 23). Unfortunately, the 
protein fraction had completely lost the typical brown color. This might indicate that the iron-
sulfur cluster was lost during gel filtration. Therefore, a spectrum was recorded for this elution 
fraction and none of the typical three peaks were detected anymore, supporting the 






Figure 23: SDS-PAGE analysis of a bovine Adx sample. The enzyme was purified from the supernatent after cell lysis on a 
DEAE-cellulose column and further purified on a Superdex 200 column. A molecular marker (M) and the elution (e) fraction 
of this purification were loaded on the gel. 
 
As a last approach, hydrophobic interaction chromatography was tested for the purification 
of bovine Adx. As the calculated pI of the protein is 4.72, Adx in 10 mM potassium phosphate 
buffer (pH 7.4) was used on a Phenyl Sepharose column. Unfortunately, the protein did not 
bind to the column material under these conditions. As changing the pH of the used buffer 
might help with protein binding. If the protein would be unstable at a different pH, this would 
however not be advantageous. Therefore, the pH stability of the enzyme was of interest for 
the optimization of the purification procedure using anion exchange chromatography.  
3.2.5 Expression of bovine AdR 
In addition to the soluble Adx, the membrane-bound protein AdR with a size of 51 kDa is 
needed for the electron supply of CYP11A1.[195]  
As before, expression was investigated using E. coli JM109 (DE3) and E. coli BL21 (DE3) as 
host organisms with the plasmids pBar1607_AdR and pET28_AdR. Additionally, the co-
expression of groEL and groES was investigated.  
From all cultivations, SDS-PAGE analysis was performed for samples taken at different time 
points. The best result was obtained for E. coli BL21 (DE3) harboring the plasmids pET28_AdR 





Figure 24: SDS-PAGE analysis of the expression of AdR from pBar1607_AdR in E. coli JM109 with and without chaperone co-
expression (groEL and groES from pGro7) and pET28_AdR in E. coli BL21 (DE3) with and without chaperone co-expression. 
Besides the marker, samples at the time point of induction (t0) and a sample after one day (t1) and two days (t2) of cultivation 
were loaded on the gel for all four cultivations. 
 
3.2.6 Purification of bovine AdR 
For purification of the bovine AdR protein, a similar approach as used for Adx was chosen. 
First, an anion-exchange chromatography was tested on a DEAE Sepharose resin. As buffer, 
sodium phosphate (pH 8.5) was used and elution accomplished by a linear gradient over 10 
CVs from 0 to 1 M KCl. The eluate was collected in 2 mL and analyzed by SDS-PAGE. 
Afterwards, the most concentrated fractions were pooled and again analyzed by SDS-PAGE 
(Figure 25). As the elution fraction obtained was not sufficiently pure, further purification 





Figure 25: SDS-PAGE analysis of bovine adrenodoxin reductase (AdR) expression. after cell lysis the enzyme was purified from 
the supernatant on a DEAE column. A molecular marker (M), the supernatant (s), and the pooled eluates (el) of the 
purification were loaded onto the gel. 
 
As the pI of the bovine AdR protein was calculated as 6.79, another anion-exchange 
chromatography approach was tested. As proteins interact differently with different column 
materials, a Source Q resin was used with 10 mM potassium phosphate buffer (pH 8.0) 
supplemented with 1 mM EDTA. Here, no binding was observed, and no good elution fraction 
obtained. 
Next, purification on a 2'5' ADP Sepharose column was investigated. This resin has a 
structural NADP analog immobilized on Sepharose and is, therefore, used for the purification 
of NADPH dependent enzymes. Here, again, a potassium phosphate buffer (pH 8.5) was used 
and elution performed with a linear gradient from 0 to 500 mM KCl over 5 CVs. Unfortunately, 
no protein bound to the column.  
3.2.7 Biocatalysis transformation with the bovine CYP11A1 
As the purification and expression of bovine AdR remained difficult, different redox partner 
systems were investigated with the purified recombinant bovine CYP11A1 enzyme. Therefore, 
the Pdx/PdR system from P. putida and CPR from C. apicola were expressed and purified 
(Figure 26). Additionally, Adx was combined with PdR as alternative redoxin. Furthermore, 





Figure 26: SDS-PAGE analysis of different redox partners. The His-tagged enzymes were purified from the supernatant after 
cell lysis via IMAC (Ni-NTA). (A) CPR from C. apicola: molecular marker (M) and the eluate (e) were loaded on this gel. (B) Pdx 
and PdR from P. putida. A molecular marker (M) and the eluates containing Pdx (1) and PdR (2) were loaded on this gel. 
 
Biocatalysis was performed overnight at 37°C, 300 rpm for 16 h. After extraction and 
derivatization with MSTFA, the samples were analyzed by GC-MS (Table 2). 
 
Table 10: Results of the first biocatalytic approach for the conversion of cholesterol with purified, recombinant bovine 
CYP11A1 enzyme in combination with different redox partner systems. 
Sample description ret. time Cholesterol [mM] 
CYP11A1 + Pdx/PdR + GDH 10.302 0,38 
CYP11A1 + CPR + GDH 10.296 0,60 
CYP11A1 + Adx/PdR + GDH 10.292 0,45 
CYP11A1 w/o redox partner system 10.390 1,53 
w/o P450 + Pdx/PdR + GDH 10.381 1,44 
w/o P450 + CPR + GDH 10.401 1,69 
w/o P450 + Adx/PdR + GDH 10.377 1,60 
CYP11A1 + Pdx/PdR 10.299 0,53 
CYP11A1 + CPR 10.304 0,66 
CYP11A1 + Adx/PdR 10.303 0,53 
Substrate only 10.387 1,86 
CYP11A1 + Pdx/PdR + GDH (t=0 h) 10.383 1,80 
1.75 mM cholesterol were incubated with 0.4 µM of the purified bovine CYP11A1 enzyme in combination with different redox 
partner systems (5 µM Pdx/0.5 µM PdR from P. putida, 0.4 µM CPR from C. apicola, or 0.5 µM bovine Adx combined with 
0.5 µM PdR from P. putida) in 20 mM HEPES-HCl buffer (pH 7.3) containing 50 mM KCl and 0.1 mM DTT at 37°C, 300 rpm for 
16 h. For some samples, GDH 0.1 mM glucose were added for co-factor recycling. As co-factor 1.5 mM NADH was added for 




The GC-MS results showed decreased cholesterol concentrations for all samples containing 
a redox partner system and the cytochrome P450 enzyme with the substrate and necessary 
co-factor. The negative controls without cytochrome P450 enzyme showed only slight 
decrease in cholesterol concentration, presumably resulting from extraction problems. 
Additionally, the negative control containing the bovine CYP11A1 but no redox partner system 
also showed no substrate consumption. 
Unfortunately, no pregnenolone was detected, although the analytical method used was 
thoroughly investigated regarding the extraction procedure and the simultaneous detection 
of substrate and product by GC-MS analysis. Hence, analytical problems could be excluded. 
Due to the negative controls, impurities in the concentrated protein fractions could be 
excluded, since only applying the redox partner system or the cytochrome P450 enzyme did 
not result in a decrease of cholesterol concentration. Another possibility could be that 
cholesterol is trapped in the active site of the enzyme, but since the concentration of P450scc 
was only 0.4 µM and the concentration of cholesterol was 1.75 mM this seems unlikely.  
As no product formation was detected, neither an additional product peak was found, nor 
an explanation was found, the experiment was repeated with CYP11A1 and Pdx/PdR as redox 
partner system. Different time samples were taken to investigate whether the decrease in 
cholesterol concentration occurs over time. This time, no decrease in cholesterol 
concentration was observed in the samples containing CYP11A1 and the redox partners. 
Negative controls showed no decrease in cholesterol concentrations, as expected. These 
results indicate, that the first observed reduced cholesterol concentrations might have been 
erroneous.  
3.2.8 Fusion protein of CYP11A1 and the reductive domain of BM3 (BMR) 
In literature, fusion proteins of type-I cytochrome P450 enzymes with the reductive domain 
of BM3 (BMR) have been described to not only enhance the activity, but also the soluble 
expression levels of these enzymes.[49,60,151,152] 
Therefore, a plasmid for the expression of the fusion construct consisting of CYP11A1 and 
BMR was constructed by FastCloning.[196] As template, the pET28a_BMR plasmid was used 
and amplified with primers containing 30 bp long overhangs coding for the terminal 
nucleotides on both sides of the CYP11A1 gene. From the pTrc99A_P450scc plasmid, the 
CYP11A1 gene without stop codon was amplified with 30 bp long overhangs coding for the 5’-
nucleotides of BMR and a portion of the pET28a plasmid backbone. After obtaining both 
fragments, FastCloning was performed and the plasmid sequenced. The newly assembled 
plasmid contained the correct fusion sequence (Figure 27). Subsequently, expression 
experiments were performed in E. coli BL21 (DE3) using different expression temperatures 
and inducer concentrations. CO difference spectra were recorded to investigate the final 
concentration of the CYP11A1_BMR fusion protein. Unfortunately, in none of the investigated 




Figure 27: Plasmid map of the pET28a(+)_P450scc_BMR plasmid constructed by FastCloning. 
In parallel, in vitro biocatalysis was performed with both separate proteins the purified 
CYP11A1 and the BMR present. The activity of BMR was investigated before by adding NADPH 
and DCPIP. Here, a fast NADPH depletion was observed along with the conversion of dark blue 
DCPIP to its colorless reduced form. The conversion of 1.2 mM cholesterol was investigated 
at 20°C and 30°C with the GDH system for NADPH recycling. Unfortunately, for none of the 
samples a decrease in cholesterol was detected; new product peaks could not be detected 
either. 
Therefore, no further investigations on the expression of the CYP11A1_BMR fusion protein 
were conducted. The focus was shifted to the CYP11A1 system regarding the pH and thermal 
stability of all three proteins. 
 
3.2.9 Stability experiments with the CYP11A1 system 
Christopher Grimm (Master thesis student under my co-supervision) performed 
investigations on the stability of all three proteins of the CYP11A1 system during his master 
thesis. Briefly, the cell pellets of the individually expressed proteins were lysed in various 
buffers at different pH and incubated at different temperatures.  
For the CYP11A1 enzyme in crude lysate, the above described buffers of Mosa et al. (50 
mM potassium phosphate buffer with 20% (w/v) glycerol, 1.5% (w/v) sodium cholate, 500 mM 
sodium acetate, 1.5% (w/v) TWEEN 20, 0.1 mM EDTA, and 0.1 mM DTT as additives)[192] and a 
HEPES-HCl buffer (pH 7.4) without additives were used. Incubation was performed at 20°C to 
60°C for 1 h. At 20°C, the highest concentration of correctly folded CYP11A1 was found in the 
described buffer with additives. Therefore, further investigations were exclusively performed 
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in this buffer. Next, the pH optimum was determined by adjusting the potassium buffer to pH 
7, 8, 9 and 10. Here, the highest stability with 91.4 ± 1.1% at pH 7was determined by CO-assay 
after 1 h incubation time. Further, the stability over 6 h was investigated under the same 
conditions with shaking (800 rpm). After 6 h, approximately 63.2 ± 3% of the initial 
concentration of CYP11A1 were still found to be correctly folded as determined by CO-assay. 
For Adx, the purification was further optimized by using a more distinct elution gradient 
between 400 mM and 600 mM KCl (instead of 0 mM to 1 M). Thereby, a high purity of Adx 
with 0.51 mg total protein from 100 mL culture volume were obtained. Afterwards, stability 
experiments were performed with purified Adx and crude lysate as described for the CYP11A1 
enzyme. First, the pH stability was investigated in 100 mM Davies buffer ranging from pH 2 to 
pH 12. Interestingly, the purified protein was found to be stable at a very broad range from 
pH 6 to 12 with over 96% protein stability after 1 h incubation. As the CYP11A1 enzyme 
showed the highest stability at physiological pH, further investigations were performed at pH 
7.4. The Adx protein remained stable at temperatures up to 40°C, with 91.3 ± 0.5% after 1 h 
incubation time in HEPES-HCl buffer pH 7.4. At 50°C and 60°C, the stability decreased, with 
only 57.0 ± 0.5% and 29.0 ± 0.3% remaining after 1 h incubation, respectively. 
For AdR, further expression experiments were performed. The expression in different 
E. coli strains from two AdR-coding plasmids – pET28a_AdR and pBar1607_AdR – was 
investigated. Most protein was found in the insoluble fractions. Although only visible as a 
minor band after SDS-PAGE analysis, AdR was best expressed in TOP10 cells harboring the 
pBar1607_AdR plasmid. With these cultivation conditions, purification was investigated on 
DEAE Sepharose using 50 mM potassium phosphate buffer (pH 9.0). Elution was accomplished 
by a 100–200 mM KCl gradient. No further improvement to the above described purification 
strategy was achieved (Section 3.2.6). It remains unclear if the protein was obtained, as the 
recorded spectra hardly differed from the recorded spectra of the empty vector E. coli cell 
lysate. Usually, an absorption peak at 425 nm can be observed for AdR. Also, an assay 
investigating the reductivity of the protein hardly differed between E. coli cell lysate and the 
AdR sample.  
Therefore, further experiments with different unnatural redox partner systems were 
performed. With the cytochrome c assay, different redox partner systems can be compared. 
If cytochrome c is incubated with the redox partner system only, the reduction can be 
monitored over time. When adding CYP11A1 to the same sample, the difference in 
cytochrome c reduction equals the amount of reduced CYP11A1 by the investigated redox 
partner system. This assay showed that apparently none of the investigated redox partner 
systems (CPR, BMR, Pdx/PdR, and Adx/PdR) were suitable for transferring electrons to the 
CYP11A1 enzyme. 
Therefore, in vivo biocatalysis was investigated using the pBar_Triple plasmid, kindly 
provided by Dr. Ludmila Novikova (Lomonosov Moscow State University, Russia).[89] 
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3.2.10 Whole-cell catalysis with the CYP11A1 system 
With E. coli TOP10 (DE3) cells harboring the pBar_Triple plasmid, encoding all three 
proteins, whole cell biocatalysis was performed as described by Mekeeva et al. in 2013.[89] The 
0.27% conversion of the substrate cholesterol observed after 24 h was comparable to the 
0.22% conversion reported in the literature.[89] 
Christopher Grimm investigated the whole-cell biocatalysis approach further by 
investigating a different detergent to enhance the possibly enhance the solubility of 
cholesterol. Makeeva et al. could already demonstrate, that the employed solubilization agent 
influences the conversion, by comparing two different detergents: Tween 80 and methyl-β-
cyclodextrin (MCD).[89] As the employment of 33% (w/v) MCD showed a 3-fold increased 
conversion the whole-cell approach, additionally the conversion of cholesterol solved in 45% 
(w/ν) 2-(hydroxypropyl)-β-cyclodextrin (HPCD) was investigated. By employing HPCD the 
substrate supply could be further optimized. This increased substrate conversion 10-fold to 
2.2 ± 0.6%. 
Concluding from all experiments performed with the CYP11A1 system, the CYP11A1 
enzyme seems to be unstable. Additionally, the activity determined for whole-cell 
transformations was low. The aim of this work was to introduce different mutations and study 
their influence on both the overall activity and the uncoupling of the catalytic cycle. However, 
enzyme variants are likely to have reduced activity, compared to the wild-type, suggesting 
that the whole-cell biocatalysis assay would not be sensitive enough to detect the activity of 
important mutants. Taking in consideration that the expression and purification of AdR 
remained difficult, in vitro biocatalysis could not be performed, and the focus was shifted to 
another cytochrome P450 enzyme, the human CYP17A1. Work on this enzyme described in 
the following section. 
3.3 Investigating the CYP17A1 enzyme 
Next, the activity of the CYP17A1 enzyme, catalysing the next step in steroidogenesis was 
investigated. For the human enzyme, the crystal structure was solved.[124] Additionally, the 
bovine enzyme showed in a whole-cell approach, described in literature using 100 µM 
substrate, full conversion after 24 h.[197] Therefore, this enzyme seemed to be better suited 
for the investigation of the influence of different active site variants. 
For the CYP17A1 enzyme, the natural redox partner system was not available. 
Consequently, for in vitro activity tests, a suitable reductase or redox partner system for 
efficient electron transfer to the active site of CYP17A1 had to be identified. It has been shown 
that a reductase present in S. cerevisiae are suitable partners for this enzyme.[197] Hence, 




3.3.1 Expression and purification of the human CYP17A1 enzyme 
Expression of the human CYP17A1 was accomplished by cultivating E. coli JM109 (DE3) cells 
harboring the pCW17A1Δ19H plasmid. Following the cultivation protocol by Petrunak et al. 
from 2014, human CYP17A1 was expressed successfully, yielding approximately 4 mg of 
soluble protein per 100 mL culture.[110] Although purification of the protein was investigated, 
no optimal purification conditions could be identified. For all purification conditions 
investigated, the protein did either not bind to the column and was found in the flow-through, 
or the protein did in fact bind to the resin, it was unstable in the buffer used and therefore no 
longer correctly folded after purification. Hence, further investigations were carried out using 
crude lysate. 
3.3.2 Comparison between Pdx/PdR and CPR as potential redox partner systems for human 
CYP17A1 
Biotransformations were performed using the expressed recombinant human CYP17A1. In 
vitro transformations using this enzyme have not been described in literature. As mentioned 
above, the natural redox partner was not available. Thus, the often-applied system Pdx/PdR 
from P. putida and CPR from C. apicola were tested.  
 
 
Figure 28: Results of the in vitro biocatalysis approach using lysate from E. coli JM109 (DE3) expressing human CYP17A1. 
For each sample, 100 µM progesterone was incubated with 4 µM CYP17A1, 0.5 µM PdR, 2.5 µM Pdx or 2.5 µM CPR, and 
25 µM NAD(P)H. For the Pdx/PdR system and CPR, NADH and NADPH were used, respectively. All samples were incubated at 
30°C, 600 rpm for 24 h. Samples: 1: 0 h (no incubation); 2: Pdx/PdR; 3: Pdx/PdR without (w/o) NADH; 4: CPR; 5: CPR w/o 
NADPH; 6: no redox partner system; 7: no CYP17A1. All samples were extracted with ethyl acetate and analyzed by HPLC. All 
samples were measured as duplicates, from two separat biocatalytic approaches. Therefore, standard deviation was not 
calculated. 
 
In vitro biocatalysis using the Pdx/PdR system resulted in 90.2% conversion of the substrate 
with 9.8% progesterone remaining after 24 h (Figure 28, sample 2). In contrast, the samples 
containing CPR had 78.1% progesterone remaining in the sample after 24 h incubation (Figure 
28, sample 4). The negative controls without CYP17A1 (Figure 28, sample 7) or without redox 
partner system added (Figure 28, sample 6) showed no conversion. No product formation 
observed in the sample (1) immediately after addition of NAD(P)H, i.e. without incubation. 
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Only the negative controls without addition of NAD(P)H showed conversion. In case of the 
Pdx/PdR system (Figure 28, sample 3), same conversion was achieved for both samples, 
whereas for CPR the conversion was lower without addition of NADPH (Figure 28, sample 5). 
For the sample containing CPR without addition of NADPH, 89.7% progesterone remained 
after 24 h incubation time, which is 11.6% more than the CPR sample with addition of NADPH. 
As the conversion of progesterone by human CYP17A1 with the Pdx/PdR system was much 
higher compared to the conversion with CPR as redox partner system, the Pdx/PdR system 
was chosen for further experiments. 
3.3.3 In vitro biocatalysis using the human CYP17A1 enzyme 
As a next step, more negative controls were added to investigate the conversion of 
progesterone using CYP17A1 in combination with the Pdx/PdR system. As the samples without 
adding NADH showed conversion in previous experiments, the uncoupling variant T306A was 
investigated as a potential additional negative control. The T306A variant was described by 
Khatri et al. in 2014.[198] As the CYP17A1 T306A variant is also applied in crude cell lysate, 
possible side reactions in the cell lysate can be investigated. Additionally, in this approach 
ultrafiltration using a centrifugal filter with a 30 kDa cutoff was used in an attempt to reduce 
the NADH/NAD+ concentration present in the cell lysate. 
 
 
Figure 29: Results of the in vitro biocatalysis approach with E. coli JM109 (DE3) cell lysate containing human CYP17A1 wild-
type (wt) or variant T306A. For each sample, 100 µM progesterone was incubated with 4 µM CYP17A1, 0.5 µM PdR, 2.5 µM 
Pdx, and 25 µM NADH. All samples were incubated at 30°C, 600 rpm for 24 h. Samples: 1: no enzyme, 0 h (no incubation); 2: 
no enzyme; 3: wt; 4: wt with 50 µM NADH concentration; 5: wt without (w/o) NADH; 6: wt w/o Pdx/PdR; 7: wt w/o substrate; 
8: T306A; 9: T306A with 50 µM NADH; 10: T306A w/o Pdx/PdR; 11: T306A w/o NADH. All samples were extracted with ethyl 
acetate and analyzed by HPLC. All samples were measured as duplicates, from two separat biocatalytic approaches. 
Therefore, standard deviations were not calculated. 
 
The samples containing NADH and wild-type CYP17A1 showed almost full conversion with 
only 4.2% progesterone remaining after 24 h (samples 3–4, Figure 29). The sample of CYP17A1 
wild-type without added NADH showed lower conversion with 28.1% progesterone remaining 
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after 24 h incubation. The negative control without added substrate also showed no product 
formation. Without enzyme present and for all samples containing the variant CYP17A1 
T306A, no product formation was observed (samples 8–11, Figure 29).  
Judging from these results, the CYP17A1 T306A variant could be used as a suitable negative 
control for subsequent experiments.  
3.3.4 Alanine scanning of the active site of recombinant human CYP17A1  
For an alanine scanning of the active site of human CYP17A1, all residues within 4 Å of the 
bound substrate progesterone were identified using PyMol (PDB code: 4NKX) and exchanged 
with alanine by site-directed mutagenesis (Table 11). After confirming the correct sequence 
of all mutated pCW17A1Δ19H plasmids, the alanine variants were expressed in E. coli JM109 
(DE3). Concentrations were determined by the measurement of CO difference spectra (Table 
11) and biocatalysis was performed using the previously established conditions. As electron 
transfer can be impaired for the mutants, both CPR and Pdx/PdR were investigated as redox 
partner systems.  
 
Table 11: Results of the CO difference spectra measurements of the investigated human CYP17A1 wild-type and variants.  
CYP17A1 variant P450 [µmol L-1] P450 [mg L-1] P420 [µmol L-1] 
Wild-type 3.7 203.5 1.7 
F114A - - 1.4 
Y201A 0.4 23 1.1 
N202A - - 0.6 
I205A - - 1.2 
I206A - - 1.4 
L209A - - 0.7 
R239A - - 1.2 
G297A 0.2 11 1.1 
G301A 0.04 2.2 0.9 
E305A* n.a. n.a. n.a. 
V336A - - 2.0 
I371A* n.a. n.a. n.a. 
V482A - - 1.9 
V483A - - 0.9 
*the correct plasmid was not obtained, therefore no experiments with this mutant were performed 
All enzymes were expressed in E. coli JM109 (DE3) from the pCW17A1Δ19H plasmid under the conditions described by 
Petrunak et al. with slight modifications.[110] For each sample, 100 mL culture were centrifuged and the cell pellets 
resuspended in 2 mL of 50 mM sodium phosphate buffer (pH 7.4) containing 20% (w/v) glycerol. 
 
Biocatalysis was performed with CYP17A1 wild-type and each variant, 0.5 µM PdR, 2.5 µM 
Pdx or 2.5 µM CPR, and 25 µM NAD(P)H. All samples were incubated at 30°C at 600 rpm 
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shaking velocity for 24 h. As negative controls, samples lacking the redox partner system were 
prepared. An additional sample was incubated without adding substrate. 
Unfortunately, none of the variants showed product formation. Only the wild-type showed 
results comparable to those obtained before. As most variants showed only incorrectly folded 
protein (P420; Table 11) as determined by CO difference spectra, a stability test using different 
buffers was conducted. 
3.3.5 Investigating the stability of the human CYP17A1 wild-type and alanine variants 
To investigate whether exchanging the buffer influences the stability of the human 
CYP17A1 wild-type and alanine variants, different tests were performed. After cultivation, 
using the old glycerol stocks and freshly bought E. coli JM109 (DE3) transformed with the 
plasmids, the cell pellets were lysed in different buffers and the concentrations were 
determined by CO difference spectra. Additionally, melting curves were recorded and 
substrate binding was investigated. 
As before, sodium phosphate buffer (50mM sodium phosphate, 20% (w/v) glycerol, pH 7.4; 
buffer 1), Tris-HCl (50mM Tris-HCl, 1 mM EDTA, 20% (w/v) glycerol, pH 8; buffer 2), the buffer 
best suitable for CYP11A1 (50 mM potassium phosphate, 20% (w/v) glycerol, 1.5% (w/v) 
sodium cholate, 500 mM sodium acetate, 1.5% (v/v) TWEEN 20, 0.1 mM EDTA, 0.1 mM DTT, 
0.1 mM PMSF, pH 7.4 ; buffer 3),[192] another Tris-HCl buffer (50mM Tris-HCl, 1 mM EDTA, 600 
mM sorbitol, pH 8.0; buffer 4),[199] potassium phosphate buffered saline (100 mM potassium 
phosphate, 50 mM NaCl, pH 7.4 ; buffer 5),[198] and a MOPS buffer (50 mM MOPS, pH 7.4; 
buffer 6)[200] were used. For all variants and for the wild-type enzyme, expressed from the old 
glycerol stocks (see page x), the highest concentrations of correctly folded P450 were found 
in buffer 2, in the cultivation inoculated from glycerol stocks (old). Therefore, only the results 
for buffer 2 are shown in Figure 30.  
 
 
Figure 30: Protein concentrations of human CYP17A1 wild-type (wt) and 12 alanine variants expressed in E. coli JM109 (DE3) 
cells. After harvesting the cells, cell lysis was performed in buffer 2 (50mM Tris-HCl, 1 mM EDTA, 20% (w/v) glycerol, pH 8), 
followed by determination of protein concentration by CO difference spectra. Based on the recorded spectra, the amounts 




The obtained concentrations of the different CYP11A1 variants could not be improved. 
Additionally, approximately 48% of the wild-type enzyme was incorrectly folded. This might 
be due to the cleaved membrane anchor of the plasmid construct used. This plasmid was 
originally used for expression and crystallization of the enzyme.[86] Therefore, it was assumed 
that the cleavage of the membrane anchor did not influence the protein stability. The long-
term stability in fact was not investigated in the publication of the crystal structure. 
The same samples were analyzed using the NanoTemper Prometheus NT.48 to see whether 
the melting temperatures of the different CYP17A1 variants were influenced by the different 
buffers. In this experiment, no significant differences were found between the variants and 
the wild-type. Importantly, the buffers did not seem to have a strong influence on the melting 
temperatures. As these meassurements were performed in cell lysate, it remains unclear, 
whether the protein concentrations were high enough to detect the melting temperatures or 
the observed melting events are observed for cell lysate in general. 
Additionally, substrate binding of progesterone was investigated by recording difference 
spectra after adding progesterone to samples prepared in buffer 2. For all variants except 
L209A and R239A, type I binding spectra were observed, which indicated that the substrate 
was still correctly bound in the active site of these enzyme variants. The type II spectra 
observed for the L209A and R239A variants indicated that the substrate might interact like an 
inhibitor. 
3.3.6 Whole-cell biocatalysis using the bovine CYP17A1 enzyme 
As the alanine mutants of the human enzyme showed only little to no stability, and 
consequently no conversion in vitro, a whole-cell approach was chosen to study the activity 
of CYP17A1. Whole-cell biocatalysis using bovine CYP17A1 expressed in yeast had previously 
been reported in the literature.[197] Therefore, this pre-established system, kindly provided by 
Dr. Stephan Mauersberger (TU Dresden, Germany), was used for further investigations. This 
system consists of the S. cerevisiae GRF18 strain harboring the YEp5117a plasmid.[197] 
The wild-type bovine CYP17A1 activity of this system was investigated by incubating 
100 µM progesterone with the whole-cell cultivation for 24 h. Samples were taken at several 
timepoints and analyzed by HPLC (Figure 31). After 4 h reaction time, the first product 17a-
hydroxyprogesterone was detected. The second product is most likely 17a,20a-
dihydroxyprogesterone and appeared after 10 h of incubation. The formation of the second 
product has been reported in the literature to not be caused by the heterologously expressed 





Figure 31: Whole-cell biocatalysis using the bovine CYP17A1 expressed in S. cerevisiae GRF18. The conversion of 100 µM 
progesterone was followed over 24 h. The sample composition is displayed in concentration (%) with the substrate 
progesterone (black squares), the product 17α-hydroxyprogesterone (dark grey diamonds), and the 17α,20α-
dihydroxyprogesterone by-product (light grey triangles). All samples were analyzed as triplicates by HPLC. (Figure from 
second publication[202]) 
 
In negative controls performed using S. cerevisiae GRF18 (not transformed with the bovine 
CYP17A1 expression vector), no conversion of progesterone could be observed. This was also 
found in other studies.[197,203,204] The natural second product androstenedione (Figure 43)was 
not found in the whole-cell biocatalysis approach employing S. cerevisiae.  
3.3.7 Homology model of the bovine CYP17A1 enzyme 
The activity of the bovine CYP17A1 enzyme was further investigated by alanine scanning of 
the active site. However, since the structure of the bovine CYP17A1 had not been determined 




Figure 32: Homology model of bovine CYP17A1. The homology model was generated using YASARA and was based on the 
template structures with PDB codes 4NKW,[110] 4NKY,[110] 5IRQ,[122] 4R1Z,[111] and 4R20.[111] The image was prepared using 
PyMol. The heme-group is shown as sticks in magenta and the bound inhibitor (R)-orteronel is shown as sticks in green. 
 
A model was created with the homology modeling function of YASARA[205] (Figure 32). The 
BLAST search performed by the program chose the crystal structures on which the homology 
model is calculated. For the homology model of the bovine CYP17A1, the human CYP17A1 
(71% sequence identity compared to bovine CYP17A1) with its substrate pregnenolone (PDB 
code: 4NKW[110]), the first product 17a-hydroxyprogesterone (PDB code: 4NKY[110]), and the 
inhibitor orteronel bound in the active site (PDB code: 5IRQ[122]) were included. Additionally, 
the crystal structures of the CYP17A1 (46% sequence identity compared to bovine CYP17A1; 
PDB code: 4R1Z[111]) and CYP17A2 (43% sequence identity compared to bovine CYP17A1; PDB 
code: 4R20[111]) of zebrafish were chosen; both had the inhibitor abiraterone bound in the 
active site. The program created several different possible homology models. Ultimately, a 
model constructed from the best parts, of all homology models generated, was used. After a 
refinement conducted with YASARA, the final construct was evaluated with MolProbity with 
a score of 1.23 (Table 12).[206] Although the homology model evaluation reveals, that some 
parameters are not optimal, it was assumed that especially the sequence identity to the 
human enzyme with 71% was high, therefore making it more likely for the homology model 
to be accurate. It also needs to be taken in consideration, that for all of the crystallized 
proteins, the membrane anchor was cleaved off. This membrane anchor however is in the 








Table 12: Result summary of the MolProbity[206] analysis for the homology model of bovine CYP17A1. The color code is added 
by the software and indicates that the values were evaluated as good (green), okay (yellow) or bad (red). 
All-Atom 
Contacts 
Clashscore, all atoms: 0.38 100th percentile* 
(N=456, 2.20 Å ± 0.25 Å) 
Clashscore is the number of serious steric overlaps (> 0.4 Å) per 1000 atoms. 
Protein 
Geometry 
Poor rotamers 13 3.03% Goal: <0.3% 
Favored rotamers 398 92.77% Goal: >98% 
Ramachandran outliers 2 0.41% Goal: <0.05% 
Ramachandran favored 470 96.51% Goal: >98% 
MolProbity score^ 1.23 100th percentile* 
(N=10167, 2.20 Å ± 
0.25 Å) 
Cβ deviations >0.25Å 1 0.22% Goal: 0 
Bad bonds: 12 / 4000 0.30% Goal: 0% 
Bad angles: 13 / 5428 0.24% Goal: <0.1% 
Peptide 
Omegas 
Cis Prolines: 0 / 27 0.00%  Expected: ≤1 per 
chain, or ≤5% 
Twisted Peptides: 1 / 488 0.20%  Goal: 0 
In the two column results, the left column gives the raw count, right column gives the percentage.  
* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For 
clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.  
^ MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, 
normalized to be on the same scale as X-ray resolution. 
 
3.3.8 Alanine screening of the active site of bovine CYP17A1  
Based on the bovine CYP17A1 homology model, residues in the active site, within 4 Å from 
the bound substrate progesterone, were identified as: L105, F114, V201, N202, I205, L206, 
R239, G297, D298, G301, E305, T306, V366, I371, L482, and V483. Additionally, the active site 
residues are conserved throughout the different CYP17A1 enzymes, also shown in a sequence 
alignment of the amino acid sequences of the proteins used as basis for the creation of the 
homology model (Figure A 1). 
By site-directed mutagenesis, these residues were exchanged with alanine in the enzyme-
coding ORF in the YEp5117a plasmid. After sequencing all plasmids, whole-cell biocatalysis in 
S. cerevisiae was performed, as described for the wild-type enzyme. 
The different alanine variants showed different activities with the substrate progesterone 
(Figure 33). For variants V201A, D298A, V366A, and L482A, the overall activities were hardly 
influenced. The activities of the variants N202A, I205A, E305A, T306A, and I371A were 
completely or almost completely lost. As described in the literature for the human CYP17A1, 
position N202 is thought to be involved in correct substrate positioning, as it forms a hydrogen 
bond with the C3-OH of progesterone in the crystal structure.[110] As substrate positioning is 
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very important for enzymatic activity, the finding that the N202A variant of bovine CYP17A1 
was inactive was not surprising. Also based on the crystal structure, E305 was described to be 
involved in an extensive H-bond network in the active site.[124] Position T306 is thought to be 
important for efficient proton delivery and, therefore, important for efficient catalysis. 
Furthermore, variant T306A was discovered as almost complete uncoupling variant with only 
0.7% coupling efficiency.[198] This is in agreement with the whole-cell biocatalysis results, in 
which the T306A bovine CYP17A1 showed only 0.6% of wild-type activity. As the hydrogen 
peroxide formation in whole-cells is difficult to investigate, no information on uncoupling 
activity was obtained. 
 
 
Figure 33: Comparison of the whole-cell biocatalysis of wild-type (WT) bovine CYP17A1 and 16 variants in S. cerevisiae GRF18. 
Progesterone was used as substrate. The resulting products are displayed relative to the wild-type conversion (16α-
hydroxyprogesterone in light grey, 17α,20α-dihydroxyprogesterone in grey, and 17α-hydroxyprogesterone in dark grey). All 
samples were investigated as triplicates of separate biocatalytic approaches. (Figure from second publication[202]) 
 
The variants L206A, R239A, and G297A had only 19.5%, 7.2%, and 26.3%, respectively, of 
the wild-type activity. Of these residues, two were mentioned in the study of DeVore et al. 
from 2012, which elucidated the crystal structure of the human CYP17A1 with the inhibitors 
abiraterone and TOK-001 bound in the active site.[86] In the structure with TOK-001, the 
guanidino group of Arg239 was found to be oriented towards the C6 atom of the inhibitor. 
Additionally, they also observed an extensive hydrogen bond network. In this network, 
residues N202, E305, and R239 are involved besides several water molecules and the 
carbonyl-backbone of residue G297.[86] As mutating these positions clearly affected the 
activity of the bovine CYP17A1 towards progesterone, it might be that these residues also 
form a hydrogen bond network when progesterone is bound to the active site. Furthermore, 
this network might also play a role in correct substrate positioning and/or substrate binding 
in general. 
The variants F114A, L105A, and G301A also showed decreased activities, with 71.3%, 
45.2%, and 32.9%, respectively, of wild-type activity. Only residue Leu105 had been 
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investigated before.[108] In 2010, Swart et al. analyzed the influence of residue 105 on the side-
product formation by human CYP17A1 in the conversion of progesterone, yielding 16a-
hydroxyprogesterone. Generally, the human wild-type enzyme catalyzes side-product 
formation of up to 30% and harbors an alanine at position 105. They compared the CYP17A1 
enzymes of different species and found that only enzymes harboring alanine at this position 
showed significant side-product formation, whereas enzymes with leucine at position 105 
showed very little to negligible side-product formation. Therefore, they exchanged A105 in 
the human CYP17A1 enzyme with leucine and could demonstrate that the wild-type side-
product formation dropped drastically to non-significant values. For enzymes of other species, 
they could introduce the side-activity by introducing L105A, as described in the Introduction. 
This finding, however, does not seem to apply to the bovine CYP17A1 investigated here. The 
wild-type enzyme with a leucine at position 105 shows little (1.3%) side-product formation. 
Contrary, the L105A mutant does not produce measurable side-product levels anymore. 
More interestingly, variants L206A, V366A, and V483A showed an increased side-product 
formation compared to wild-type bovine CYP17A1. The overall activity of variant L206A was 
decreased to 19.5% of wild-type activity and showed with 2.6% of total product formation the 
least side-product formation. Variants V366A and V483A showed good substrate conversion 
and variant V483A was found to produce the highest amount of 16a-hydroxyprogesterone 
with 32.6% of total product formation in this first approach.  
As this was a very interesting result, preparative biocatalysis with variant V483A was 
performed to characterize the side-product by NMR. 
3.3.9 Preparative biocatalysis with bovine CYP17A1 V483A 
In the preparative biocatalysis approach, 100 mg progesterone were converted in a 1 L 
culture of S. cerevisiae harboring the plasmid YEp5117a_V483A. After 72 h of incubation, 2 mL 
of the supernatant was extracted with ethyl acetate and analyzed by HPLC (the HPLC analysis 
can be found in the Appendix: Figure A 2). The chromatogram showed that the substrate was 
fully consumed and the final ratio of 17a:16a product was 1:0.67. In the preparative 
biocatalysis approach, the 16a-hydroxyprogesterone formation was even higher than 
observed before, at approximately 40% of total product formation. 
With the remaining supernatant, preparative HPLC was used to separate the presumed 
16a-hydroxyprogesterone from the other steroid products. Here, the final yield of isolated 
side-product was 30%. With the separated compound, NMR analysis was performed by Sascha 
Grobe, confirming that the side-product was 16a-hydroxyprogesterone. The NMR results can 
be found in the Appendix: 1H NMR: Figure A 4; 13C NMR: Figure A 5. 
Furthermore, to investigate whether the yield of obtained 16a-hydroxyprogesterone could 
be enhanced further, all three possible double mutants were created by site-directed 
mutagenesis. Whole-cell biocatalysis, using plasmids encoding the three double mutants, was 
performed by Sascha Grobe. Unfortunately, all double mutants showed very low activities and 
the ratio of 17a:16a product could only be enhanced by the L206A/V483A double mutant. 
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This double mutant, however, had only 1% residual activity, compared to the wild-type 
enzyme. 
3.3.10 Molecular docking using the wild-type and V483A bovine CYP17A1 homology models 
To investigate possible structural reasons for the enhanced 16a-hydroxyprogesterone 
formation of variant CYP17A1 V483A, molecular docking experiments were performed with 
Dr. Kathleen Balke. Therefore, the V483 in the homology model of the wild-type was 
exchanged with alanine, followed by another energy minimization and refinement. For the 
wild-type enzyme and the V483A variant, progesterone was docked into the active site (Figure 
34). As different orientations of the substrate were observed, only those resembling 
approximately the same positioning as observed in the crystal structures (with bound 
substrates) were used (PDB code: 4NKW and 4NKX).[110]  
 
 
Figure 34: Overlay of the docking results of the homology model of bovine CYP17A1 wild-type and V483A mutant with the 
substrate progesterone. The active sites of both models are overlaid. The heme-group is shown in light grey, wild-type is 
shown in yellow and V483A in dark blue. The image was created using YASARA. (Image from second publication[202]) 
 
For the docking, different orientations of the substrate were observed, therefore, the 
distances of the closest C-atoms to the heme-iron were measured, using YASARA (Table 13). 
Of the in total 14 docking results, in 8 the substrate was found in the active site above the 
heme-group. Of these 8 docking results, in 3 C15, C16 and C17 were found closest to the 
heme-group as also observed in all crystal structures of CYP17A1 enzymes with bound 
substrate elucidated (1,3 and 5; Table 13). Therefore, only these docking result with the 
substrate being orientated with the C15, C16 and C17 atoms close to the heme group were 
taken in consideration. In two of these three docking results, the C16 atom was found closest 
to the heme-iron with 4.1 Å and 4.0 Å. Only in one docking, the C15 atom was found to reside 
the closest to the heme-iron, a bit further away with 4.9 Å. Also, for this result, the C16 atom 
was the second closest with 5.1 Å. For the wild-type enzyme, the C17 atom (3.8 Å) was found 
to be closer to the iron atom than the C16 atom (4.1 Å). 
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Therefore, it seems as if the slightly smaller alanine at position 483 instead of valine allows 
the bound substrate to rotate a bit in the active site, facilitating the hydroxylation of position 
C16 of progesterone by this variant. 
 
Table 13: Docking results of progesterone in the active site of the CYP17A1 V483A prepared and evaluated with YASARA. A 
scheme of the progesterone molecule with the numbering of the C-atoms can be found in Figure 9. 
Docking result Distances of closest C-atoms to the heme-iron 
1 C16: 4.0 Å; C17: 4.3 Å; C15: 4.7 Å 
2 C3: 5 Å; C2: 5.4 Å 
3 C15: 4.9 Å; C16: 5.1 Å; C17: 6.7 Å;  
4 C2: 2.9 Å; C1: 4.0 Å; C3: 4.1 Å  
5 C16: 4.1 Å; C17: 5.1 Å; C15: 4.5 Å 
6 C4: 5.6 Å; C6: 5.2 Å 
7 C2: 7.6 Å 







*the substrate molecule was not found in the active site, but somewhere else in the structure of the homology model 
 
3.4 First investigations on a dual screening assay 
In addition to investigating the structural background for P450 activity, as demonstrated 
with the alanine scanning of CYP17A1, another goal of this thesis was to develop suitable 
screening assays for application in high-throughput screening. The AmplifluTM Red assay 
simultaneously measured NADPH consumption and hydrogen peroxide formation. 
Absorbance measurement was used for the detection of NADPH consumption, which is not 
applicable to fluorescence-based sorting methods in the attempted droplet-based final 
application. Therefore, another assay was investigated, applying a substrate coupled to the 
fluorophore 7-hydroxy-4-trifluoromethylcoumarin. Upon hydroxylation by the cytochrome 
P450 enzyme, a hydroxylated fatty acid is formed and the fluorophore released. This reaction 
can be followed by excitation at 400 nm and detection of fluorescence emission at 500 nm. In 
combination with the AmplifluTM Red probe or another fluorescent probe for hydrogen 
peroxide detection, both hydrogen peroxide and product formation can be measured at 
different wavelengths.  
Results 
 66 
3.4.1 Substrate synthesis and verification by NMR spectroscopy 
As the substrate for this approach was not commercially available, it needed to be 
synthesized. Substrate synthesis was accomplished following the protocol by Neufeld et al. 
from 2014.[24] The first methylation step was omitted by using the commercially available 
methyl ester of 11-bromoundecanoic acid. Furthermore, the final product differed from the 
product synthesized by Neufeld et al. since the fatty acid used was undecanoic acid instead of 
dodecanoic acid (Figure 35). 
After substrate synthesis, the final product was purified by silica gel chromatography. In 
total, 120.9 mg, which equals 0.29 mmol of product was obtained (22.0% based on the used 
amount of 1.32 mmol free methyl 11-bromo undecanoate). Using 10 mg of the product, NMR 
analysis was performed. The NMR result can be found in the Appendix: Figure A 6. When 
compared to the 1H-NMR for 12-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid, the 
spectra were very similar. Differences resulted from the one missing CH2-group in the product 
synthesized in this thesis. 
 
 
Figure 35: Substrate synthesis of 11-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid (4). The synthesis was performed 
similar to the synthesis of 12-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid, described by Neufeld et al. in 2014.[24] (1: 
7-hydroxy-4-trifluoromethylcoumarin; 2: methyl 11-bromoundecanoate; 3: 11-(4-trifluoromethylcoumarin-7-
yloxy)undecanoate) 
 
The goal was to use this substrate to develop a dual screening for simultaneous product 
formation and hydrogen peroxide formation catalysed by cytochrome P450 enzymes. An 
assay compatible with microfluidically generated droplets was envisaged (sorting by 
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fluorescence-activated droplet sorting (FADS)).[207] Therefore, a probe to report the hydrogen 
peroxide concentration was needed. 
 
3.4.2 Investigation of a suitable hydrogen peroxide detection probe 
Next, potential hydrogen peroxide detection probes were investigated. It is essential that 
such probes are compatible with the substrate in terms of the wavelengths used for their 
detection. The sensitivity towards hydrogen peroxide was is equally important.  
Therefore, the hydrogen peroxide-sensitive probe HDCF-DA was investigated, a probe used 
for the detection of oxidative stress in whole cells. It diffuses into the cell, where the 
chloromethyl group reacts with glutathione and other thiols. After oxidation, highly 
fluorescent DCF probe remains inside the cells.   
 
  
Figure 36: Investigation of the detection limit of HDCF-DA when incubated with (A) 0.5, 1.25, 2.5, 5, 12.5, 25, 50, and100 µM 
H2O2. Fluorescence values were obtained at λexcitation = 490 nm and λemission = 520 nm (gain: 50%) in 96-well plates at the Tecan 
device using the i-controlTM software. (B) Display of the results of 0, 0.5, 1.25, 2.5, 5 and 12.5 µM. 
A linear relationship between the hydrogen peroxide concentration and fluorescence was 
clearly observed (Figure 36A). Unfortunately, the detection limit was 2.5 µM (Figure 36B), 
whereas the detection limit using AmplifluTM Red was significantly lower, at 50 nM. 
Additionally, the excitation and emission wavelengths of AmplifluTM Red are further separated 
from the wavelengths used for the detection of the 7,4-HFC. Hence, further investigations 
were performed with the AmplifluTM Red probe (section 3.1.4). 
3.4.3 Signal stability test of (7-hydroxy-4-(trifluoromethyl)coumarin and resorufin in the HFE 
7500 oil 
Since the goal was to develop an assay compatible with droplet microfluidics, the question 
arose whether the two fluorescent products (7-hydroxy-4-(trifluoromethyl) coumarin, 
resulting from P450 activity, and resorufin, resulting from AmplifluTM Red oxidation) would 
stay in the droplets or diffuse into the HFE-7500 oil used for encapsulation. If the probes 
tended to partition into the oil phase, the fluorescent signals would be lowered, especially if 




on model reactions with suitably water-soluble substrates. However, due to limited flexibility 
in fluorophore selection in this study, the compatibility of (7-hydroxy-4-
(trifluoromethyl)coumarin and resorufin with water-in-oil emulsions had to be investigated. 
The fluorescence of many dyes is influenced by the pH dependent ionisation of one or more 
functional groups. For example, both 7,4-HFC and resorufin have ionisable OH groups, with 
the deprotonated forms being more fluorescent. Since this ionisation also influences 
hydrophobicity (and thus the likelihood of these molecules escaping into the oil phase), the 
retention of 7,4-HFC (pKa 7.26) and resorufin (pKa 6.0) in the aqueous phase was investigated 
at several pH values, above and below their respective pKa values.  
The HFE-7500 oil was overlaid with sodium phosphate buffers (50 mM with pH ranging 
from 6.0 to 9.0), containing 50 µM resorufin or 7,4-HFC in a ratio of 10:1 in screw cap tubes. 
Afterwards, these tubes were incubated in a shaker at 30°C and 1,200 rpm for 24 h. Time 




Figure 37: Incubation of 50 µM resorufin in 50 mM sodium phosphate buffer adjusted to different pH values. A volume of 
100 µL buffer was pipetted on top of 1000 µL HFE-7500 (oil used for droplet formation for FADS). The two-phase system was 
incubated at 25°C at 14,000 rpm shaking velocity for 24 h. At different timepoints, samples were taken and fluorescence was 
measured at λexcitation = 560 nm and λemission = 590 nm (gain: 84%) in 96-well plates at the Tecan device using the i-controlTM 
software.  
 
For resorufin (Figure 37), the buffers adjusted to different pH values had a big influence on 
the probes diffusion tendency from the water into the oil phase. For buffer pH >7.0, 100% of 
the probe was found in the aqueous phase after 24 h; in systems employing buffers adjusted 
to pH <6.5, partial diffusion of the probe into the oil phase was observed. For the buffer with 
pH 6.0, only 18% of the probe was still found in the water phase after the 24 h incubation. 





Figure 38: Incubation of 50 µM 7-hydroxy-4-(trifluoromethyl)coumarin in 50 mM sodium phosphate buffer adjusted to 
different pH values. A volume of 100 µL buffer was pipetted on top of 1000 µL HFE-7500 (oil used for droplet formation for 
FADS). The two-phase system was incubated at 25°C at 14,000 rpm shaking velocity for 24 h. At different timepoints, samples 
were taken and fluorescence was measured at λexcitation = 400 nm and λemission = 500 nm (gain: 100%) in 96-well plates at the 
Tecan device using the i-controlTM software. 
 
For 7,4-HFC (Figure 38), the results were not as consistent as those for resorufin. For 
samples taken at 8 h incubation time, apparently a mistake occurred. As only 10 µL samples 
were taken, pipetting mistakes most likely account for it. Nevertheless, also for this probe 
differences were detectable corresponding to the different pH values. As seen for resorufin, 
also for the 7,4-HFC, buffers adjusted to lower pH values led to a decrease in fluorescence of 
the probe during incubation in the aqueous phase. For pH ≥7.4, the concentrations remained 
stable with ≥83% fluorescence intensity after 24 h incubation time. For buffers with lower pH, 
fluorescence decreased over time, indicating that only 74% (pH 7.0), 68% (pH 6.5), and 65% 
(pH 6.0) of the dye remained in the aqueous phase after 24 hours.  
The diffusion into the oil, depends on the ionization of the molecules and is therefore 
dependent on the pKa values of both probes. The pKa value of resorufin is 6.0 and for the 7,4-
HFC, 7.26. At lower pH, the probes become less hydrophilic through loss of charge, making it 
more likely the probes will diffuse into the oil. Definitely a pH above the pKa values above both 
probes should be used. 
In the assay, the droplets might be incubated for reaction times most likely shorter than 
24 h. Thus, pH of 7.4 was chosen for subsequent experiments. For resorufin, pH 7.4 is optimal; 
for 7,4-HFC, 83% were still found in the water phase after 24 h. In addition, cytochrome P450 
BM3 activity assay, as well as the AmplifluTM Red assay, were previously shown to work at pH 
7.4 (section 3.1.5).  
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3.4.4 Investigation of the optimal substrate to NADPH ratio 
For optimal screening, reaction parameters need to be optimized initially. Therefore, the 
conversion of the substrate was investigated with cytochrome P450 BM3 wild-type and two 
variants in microtiter-plates. In the publication, showing the substrate synthesis of 12-(4-
trifluoromethylcoumarin-7-yloxy)undecanoic acid, the variant A74G/F87V exhibited strongly 
enhanced substrate conversion compared to the wild-type.[24] Hence, it was used as positive 
control for the investigation of the substrate to NADPH ratio. The variant F87Y was used as 
negative control. This variant was already investigated with the AmplifluTM Red assay (section 
3.1.6) and showed high uncoupling and very low product formation, which was also described 
in the literature.[130] 
 
 
Figure 39: Conversion of 11-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid (4) by cytochrome P450 BM3, resulting in 
the formation of the unstable hemiacetal intermediate (5), which spontaneously decomposes, resulting in the formation of 
an aldehyde (6) and the free fluorophore 7-hydroxy-4-(trifluoromethyl)coumarin (1). 
 
First, NADPH was used in excess, as cytochrome P450 BM3 is known to perform multiple 
hydroxylations of some fatty acids. If the substrate gets hydroxylated, the unstable hemiacetal 
is formed, which spontaneously decomposes to yield the free product and the fluorescent 7,4-
HFC (Figure 39). If the free aldehyde gets hydroxylated, no further fluorophore is released, 
which will not be detected by the assay. Hence, the ratio of consumed NADPH per substrate 
molecule could be higher than 1:1.  
First, the conversion of 10 µM substrate with 150 µM NADPH present was investigated 
(Figure 40). The investigated cytochrome P450 BM3 A74G/F87V produced the highest amount 
of fluorophore (Figure 40(A)). Additionally, when compared to wild-type, the reaction rate 
was higher, with a especially fast, initial rate. The highest 7,4-HFC concentration was reached 
after approximately 200 s and 400 s for cytochrome P450 BM3 A74G/F87V and the wild-type, 
respectively. For the wild-type, substrate conversion was detected, whereas no product 
formation was observed with the uncoupling mutant (F87Y). The production of hydrogen 
peroxide was the highest for the wild-type without substrate, followed by the uncoupling 
variant with substrate, and the wild-type with substrate(Figure 40(B)). The double mutant 
showed in the reaction with substrate the lowest hydrogen peroxide formation. Both the 
uncoupling variant F87Y and the A74G/F87V variant rapidly produced hydrogen peroxide. The 
highest hydrogen peroxide concentration was reached after 100 s. For wild-type, again, 400 s 







Figure 40: Conversion of 10 µM 11-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid with 0.5 µM cytochrome P450 BM3 
wild-type (wt) and the variants A47G/F87V and F87Y with substrate (+). For BM3 wt, two negative controls were added 
(without NADPH (wt - NADPH), without substrate (wt - S)), as well as one sample without enzyme (no enzyme). If added, a 
concentration of 150 µM NADPH was used. The following parameters were determined: (A) The formation of free 7,4-HFC 
(λexcitation = 420 nm and λemission = 500 nm (gain: 100%)), (B) the formation of hydrogen peroxide with the AmplifluTM Red assay 
(λexcitation = 550 nm and λemission = 590 nm (gain: 50%)), and (C) the depletion of NADPH (absorption measured at λ = 340 nm). 
 
NADPH was consumed over time in all samples containing enzymes (Figure 40(C)). Fast 
depletion of NADPH was observed for the samples containing the variants F87Y and 
A74G/F87V; the wild-type enzyme consumed NADPH more slowly. In the study of Neufeld et 






0.458 min-1 µM-1 for the substrate 12-(4-trifluoromethylcoumarin-7-yloxy)dodecanoic acid 
investigated in their study.[24] Unfortunately, Neufeld et al. did not identify kinetic parameters 
for the wild-type. They only demonstrated that, in crude lysate, the activity of the wild-type 
cytochrome P450 BM3 is 8-fold lower than that of the most active mutant, A74G/F87V. 
Next, lower NADPH concentrations in combination with the substrate were tested, as the 
ratio of NADPH to the substrate was most likely too high. In case of limited substrate access 
and high NADPH excess, also the presumable good variants will show uncoupling, as no 
substrate is bound in the active site.[130] 
Therefore, the ratio of substrate to NADPH was optimized. Additionally, the enzyme 
concentration was decreased. Furthermore, the total amount of cells was calculated by 
measuring OD600 at the end of the cultivation. With the total cell count, the concentration of 
all samples was adjusted to 1 cell per 4 pL, which equals approximately the concentration 
obtained when a single cell is lysed in a 20 µm diameter droplet.  
The best results were obtained by using 100 µM substrate in combination with 25 µM 
NADPH (Figure 41). For the best variant, cytochrome P450 BM3 A74G/F87V, equimolar 
concentrations of hydrogen peroxide and 7,4-HFC were detected. The variant F87V was also 
described by Neufeld et al. to catalyze good conversion of the substrate investigated in their 
study and showed approximately a 7-fold increased conversion compared to the wild-type.  
 
 
Figure 41: Dual detection of the substrate (100 µM 11-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid) conversion and 
hydrogen peroxide formation by cytochrome P450 BM3 wild-type and variants F87V and A74G/F87V in 50 mM sodium 
phosphate buffer (pH 7.4) supplemented with 25 µM NADPH. As negative controls, only NADPH (N only), only substrate (S 
only) and substrate with NADPH were incubated. For the detection of hydrogen peroxide AmplifluTM Red was used (Assay 
solution: 100 µM AmplifluTM Red, 0.2 U mL-1 in 50 mM sodium phosphate buffer (pH 7.4); detection: λexcitation = 560 nm and 
λemission = 590 nm) and substrate conversion was measured by detection of 7,4-HFC (detection: λexcitation = 400 nm and 
λemission = 500 nm). 
 
Here, 25 µM NADPH was used, the product and hydrogen peroxide concentrations were 
much lower. It is possible that a part of the NADPH was used to hydroxylate the free fatty acid 
at different positions, not leading to a detectable signal. Another possibility might be that the 
cytochrome P450 BM3 and the variants are able to perform side reactions with other 
molecules in the cell lysate. To determine which NADPH-dependent reaction is catalyzed, 
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further analysis would be necessary including reaction scale-up to analyze the resulting 
products by GC-MS or NMR, for example. Additionally, controls for each experiment without 
substrate present would have had to be performed. Unfortunately, these measurements 
could not be performed due to time constraints. 
3.4.5 Application of the dual screening to investigate five Cytochrome P450 BM3 variants 
After finding good conditions for investigating the three cytochrome P450 BM3 variants 
(A74G/F87V, F87V, and F87Y), six other variants were created and investigated: R47L, Y51F, 
A82L, T268A, and I401P. The first five variants are the enzymes used to test the suitability of 
the AmplifluTM Red assay, described in Section 3.1.6. They show uncoupling, depending on the 
substrate used. I401P was added as a variant with increased coupling efficiency in the 
oxidation of non-natural substrates[28] and showing a higher rate of NADPH consumption in 
the absence of substrate (referred to as leak rate).[130] 
 
 
Figure 42: Dual detection of the substrate conversion (100 µM 11-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid) and 
hydrogen peroxide formation by cytochrome P450 BM3 wild-type and variants I401P, F87Y, R47L, Y51F, A82L, and T268A in 
50 mM sodium phosphate buffer (pH 7.4) containing 25 µM NADPH. As negative controls, only NADPH (N only), only substrate 
(S only), and substrate with NADPH were incubated. For the detection of hydrogen peroxide, AmplifluTM Red was used (Assay 
solution: 100 µM AmplifluTM Red, 0.2 U mL-1 in 50 mM sodium phosphate buffer (pH 7.4); detection: λexcitation = 560 nm and 
λemission = 590 nm) and substrate conversion was measured with detection of 7,4-HFC (detection: λexcitation = 400 nm and 
λemission = 500 nm). 
 
Interestingly, of the five variants investigated, cytochrome P450 BM3 T268A showed 
enhanced product formation (600% compared to wild-type and 210% compared to the F87V 
variant). In comparison to the best variant A74G/F87V, the product formation was lower (28%, 














4.1 Development of the AmplifluTM Red assay 
In the first part of this PhD thesis, the aim was developing an assay for the characterization 
of cytochrome P450 monooxygenases, in terms of their activities and uncoupling rates.  
First, the HyPer-3 protein was examined as a possible reporter for the detection of 
hydrogen peroxide formed during cytochrome P450-catalyzed reactions. After successful 
expression and purification, the protein was investigated in terms of its sensitivity towards 
hydrogen peroxide. It became clear that the signals obtained using this protein would not be 
sensitive enough for in vitro detection of hydrogen peroxide at µM concentrations. 
Furthermore, the signal is based on a ratiometric measurement, at two wavelengths, which 
would lead to additional complications in the application of this assay for high-throughput 
screening. Additionally, Bilan et al. reported that, upon contact with hydrogen peroxide, the 
signal is only stable for approximately 2 min.[67] Hence, the protein is not suitable for the 
determination of the total hydrogen peroxide formed during reactions that need longer 
incubation times. 
Therefore, two other probes were investigated that are suitable hydrogen peroxide 
reporters when used in combination with the HRP enzyme. Both probes have been described 
for the determination of uncoupling levels during the reaction of cytochrome P450 
enzymes.[61,178] In order to determine whether the two probes are compatible with a parallel 
measurement of the NADPH consumption at λ=340 nm, which has not been reported before, 
a spectrum of each probe and its reduced form was recorded. Unfortunately, it was found 
that the ABTS probe absorbs light at λ=340 nm (Figure 13). Therefore, if this probe were used, 
the NADPH consumption could only be monitored if the reaction were stopped at a certain 
point and the ABTS/HRP system necessary for hydrogen peroxide detection were added 
afterwards. As this was not the goal and the spectrum of AmplifluTM Red and the oxidized form 
resorufin showed no absorption at λ=340 nm, this probe was chosen for further 
characterisation concerning its suitability in the parallel screening approach. 
After finding that the AmplifluTM Red assay can be performed at physiological pH of 7.4, the 
signal stability was investigated. Although the signal remained stable for concentrations above 
5 µM, the deviation of the signal obtained for 0.5 µM hydrogen peroxide increased to 15% 
over the 20 min incubation period. This deviation results most likely from the sensitivity of the 
AmplifluTM Red probe towards light.[183] It is logical, that small signals are influenced more 
significantly by the photooxidation of small amounts of AmplifluTM Red, as the same amount 
of AmplifluTM Red molecules influenced lead to the same change of signal in each sample, 
resulting in a higher percentage for the lower signals. Therefore, the reaction should be 
performed in a dark environment. Additionally, if a high-throughput assay is performed, with 
the usage of good positive controls the threshold for the sorting can be adjusted to a good 
valu, in order to find all variants matching the screening criteria.  
Discussion 
 76 
Moreover, the assay was further investigated with cytochrome P450 BM3 as model 
enzyme. The clear advantage of using this enzyme is that it is a self-sufficient enzyme, not 
needing additional proteins for its catalytic activity. The cytochrome P450 BM3 is also one of 
the most studied cytochrome P450 enzymes and shows a high overall activity.[130] After 
successful expression and purification, first tests were performed to find a good working 
concentration of the enzyme for the assay. A cytochrome P450 concentration of 0.4 µM in the 
assay was found to be optimal in order to provide a fast reaction, but also provide the chance 
to monitor the hydrogen peroxide formation over time. 
To further evaluate the assay, the reaction of cytochrome P450 BM3 wild-type and five 
variants, in combination with different substrates, were investigated. The results were in 
agreement with data found in literature. [135,141,170,181] 
 One of the goals was to investigate the uncoupling process and thereby possibly contribute 
to the understanding of the uncoupling process. In this context, the results of variants R47L 
and Y51F were especially interesting. Both residues (R47 and Y51) are known to be responsible 
for substrate binding and substrate access, due to the close localization to the substrate-
access channel.[137] Additionally, one theory concerning uncoupling is that too loose binding 
of substrates leads to uncoupling, as well as to difficulties in substrate accessibility.[54] 
Therefore, it was very interesting to find that both variants catalyzed the formation of 
hydrogen peroxide more rapidly than the wild-type, for all substrates investigated.  
By assaying different negative controls in the reaction of cytochrome P450 BM3 wild-type 
without substrate, it was demonstrated that the observed change in absorbance is clearly 
mediated by hydrogen peroxide formation and its reaction with HRP. After reduction of 
hydrogen peroxide, resulting in the formation of water, the HRP oxidizes AmplifluTM Red, 
leading to the formation of one molecule of resorufin per molecule of hydrogen peroxide. The 
formation of resorufin is then detected by a change in absorbance.[208] By adding catalase and 
obtaining a strong reduction of the signal, it was demonstrated that it is indeed hydrogen 
peroxide that is detected. As both the catalase and HRP compete for the same hydrogen 
peroxide, the signal is only reduced rather than completely eradicated. By performing a 
measurement without HRP and obtaining no signal, possible side reactions, that might directly 
convert the AmplifluTM Red to resorufin, were ruled out. Additionally, in contrast to NADH, 
which was described to interfere with the measurement by interacting with the probe,[183] this 
was not observed for NADPH, as negative controls with only NADPH, HRP and the probe 
showed no resorufin formation.  
As most high-throughput assays are performed on crude cell lysate, it was also necessary 
to determine the signal stability in crude cell lysate. The signal showed was as stable in crude 
cell lysate as in buffer (Figure 14, Figure 16). Additionally, similar results, concerning hydrogen 
peroxide formation and NADPH consumption, were obtained when either crude cell lysate or 
purified enzymes were used in enzyme assays. Despite differences between the absolute 
values measured (using crude or purified enzyme), the relationships between variants, in 
terms of P450 activity and uncoupling rate, were the same using both assay strategies.  
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By investigating the uncoupling of the reductase CPR of C. apicola, it was shown that the 
AmplifluTM Red assay produced reliable results. As uncoupling by reductases do not result in 
the formation of water,[182] the addition of superoxide dismutase (which converts superoxide 
to hydrogen peroxide) enables the detection of all possible uncoupling products with the 
AmplifluTM Red assay. In this approach, the NADPH consumed equaled the detected formation 
of hydrogen peroxide.  
Concluding from all data, the suitability of the AmplifluTM Red assay could be demonstrated, 
not only for the detection of hydrogen peroxide formation, but also for the parallel detection 
of NADPH consumption (compatible absorbance maxima). Although several methods of 
studying the extent of uncoupling of cytochrome P450 monooxygenase-catalyzed reactions 
have been developed,[56,63,66,209] none of these methods were so far suitable for investigating 
hydrogen peroxide formation in parallel (i.e. in the same well of a microtiter plate) with 
NAD(P)H consumption.  
Measurement of NAD(P)H consumption is a general and often-applied strategy for the 
indirect determination of enzymatic activity.[210] Although this might be a useful approach for 
other enzymes, this can lead to erroneous results, especially for cytochrome P450 enzymes, 
as the NAD(P)H consumption due to uncoupling cannot be distinguished from NAD(P)H 
consumption due to enzyme activity. Therefore, only by monitoring NAD(P)H consumption 
and hydrogen peroxide formation simultaneously, can the activities of a cytochrome P450 
enzyme towards different substrates be estimated, without the need for quantification of the 
unique products of each reaction. The major advantage of the method developed during this 
thesis, over other assays described so far, is that it enables, for the first time, reliable detection 
of uncoupling.[179] 
A minor limitation of the assay is that water as possible uncoupling product cannot be 
detected. Superoxide anion formation, however, can be detected indirectly, by the addition 
of superoxide dismutase, which converts the superoxide anion to hydrogen peroxide. The 
assay thereby also enables the determination of the amount of uncoupling resulting in water 
formation. If the product is quantified, in addition to measuring NAD(P)H consumption, 
hydrogen peroxide formation, and superoxide formation, the formation of water could be 
calculated (H2O = [NAD(P)H] - [product + H2O2 + O2-]). As this however was not the aim of this 
thesis, this aspect was not further investigated. 
4.2 Investigating the CYP11A1 system 
In this part of the thesis, the stability and activity of the bovine CYP11A1 monooxygenase 
system was investigated. As the CYP11A1 monooxygenase is a class I cytochrome P450 
enzyme, a redox partner system is needed for its activity. Therefore, also the stability of the 
natural redox partner system, consisting of Adx and AdR, was investigated.  
Although already described in literature, the heterologous expression and purification of 
the membrane-bound bovine CYP11A1 proved to be challenging. First, expression 
experiments were performed, comparing the expression in different E. coli (DE3) strains at 
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30°C. Almost no cytochrome P450 was obtained in the soluble fraction, but rather in the 
insoluble fraction, presumably as inclusion bodies. Aggregation is a common problem in 
heterologous expression, especially for membrane proteins.[211] The insoluble aggregates 
formed consist of misfolded or partially folded proteins. If proteins are not (yet) properly 
folded, hydrophobic motifs are exposed, resulting in intermolecular interactions between the 
partially folded molecules, finally leading to aggregation.[212] In order to recover correctly 
folded protein from inclusion bodies, solubilization and refolding needs to be performed. As 
this approach can be quite time consuming and differs for each protein, expression 
optimization was investigated instead.[213] Therefore, lowering the expression temperature 
from 30°C to 17°C was investigated, which might help obtain correctly folded protein. 
Lowering the expression temperature is thought to slow down protein expression, giving the 
recombinant protein more time for correct folding and thus improving the yield of soluble 
protein. As this did not result in a higher level of soluble protein expression, different protocols 
found in the literature were investigated. 
These protocols differ especially with respect to the composition of the buffer in which the 
protein was solubilized. This step of solubilization is crucial in the investigation of membrane 
proteins, and necessary in order to separate the protein from the membrane fraction. The 
solubilization components help to cope with the hydrophobic membrane anchor but need to 
enable the hydrophilic parts of the protein to be exposed to the aqueous phase.[211] Hence, 
optimization not only of the expression conditions, but also of the buffer and detergent 
compositions, was crucial. 
After unsuccessfully trying to reproduce the expression and solubilization protocols 
described by Janocha et al.[188] and Woods et al.,[189] the protocol of Lepesheva et al. from 
1998 was investigated.[190] In parallel with investigating the third protocol, the use of 
chaperones was studied, as well as the natural induction of expression of heat shock proteins 
by the addition of ethanol.[214] Although the addition of ethanol resulted in an increase in the 
amount of correctly folded protein, chaperone co-expression from a second plasmid was more 
effective in improving the yield of correctly folded protein. Additionally, the growth of the 
culture with added ethanol was strongly impaired. Hence, although the maintenance of a 
second plasmid results in an additional metabolic burden on the cell, this approach was 
chosen for further investigations. The plasmid used encodes the chaperones GroEL and 
GroES.[185] Next, the influence of using other chaperones was studied in order to further 
increase the obtained yield of correctly folded protein. Additionally, the expression in T1 
phage-resistant E. coli JM109 (DE3) cells as used in this thesis before, was compared to the 
expression in non-T1 phage resistant E. coli JM109 (DE3) cells. T1 phage resistance is 
accomplished by the knockout of the gene encoding FhuA, an outer membrane protein 
receptor for ferrichrome, involved in the transport of ferrichrome-iron over the outer 
membrane.[191] It was hypothesized that the knockout of this gene might also influence the 
transport of the heme-precursor δ-aminolevulinic acid over the cell membrane. Although the 
use of different chaperones resulted in a decrease of obtained correctly folded protein, when 
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compared to the co-expression of GroEL and GroES, the use of a non-T1 phage resistant E. coli 
JM109 strain almost doubled the yield of soluble, properly folded cytochrome P450, from 
7.8 mg L-1 to 14.4 mg L-1. The aspect whether the T1 phage resistance itself is influencing the 
accessibility of the heme-precursor or if other factors in the cell influence the expression rate 
cannot be answered by the conducted experiments. 
As the K193E variant of CYP11A1 was described in literature to show a fourfold increased 
expression rate and threefold increased yield of soluble protein, this mutation was introduced 
by site-directed mutagenesis and the expression compared to the expression of the wild-type 
enzyme.[188] The during this thesis obtained results contradicted these findings, where only 
after two days the expression of the variant was higher compared to wild-type with 6.1 mg L-
1 and 0.7 mg L-1. After three days of expression the wild-type yielded 14.1 mg L-1, whereas the 
expression level for the variant was decreasing already, yielding only 2.1 mg L-1. Although 
reducing the expression time would be advantageous, the goal of obtaining more correctly 
folded, wild-type protein was prioritized.  
For the expression, the best time to harvest the cells, containing the highest amount of 
correct folded CYP11A1, was investigated. By taking time samples during cultivation this was 
achieved. On the basis of this cultivation experiment, it seemed as if longer cultivation time 
resulted in higher yields of correctly folded protein (up to three days investigated, Table 9). 
Although for some proteins, protein degradation exceeded expression after a certain time, 
resulting in a decrease in soluble protein yield if cultivated too long, this was not found for the 
conducted cultivation. Furthermore, the substrate binding was investigated with the last time 
sample, obtained after three days of cultivation, resulting in obtaining a type-I spectrum upon 
addition of cholesterol to the enzyme. A type-I spectrum is only observed when the heme-
group of the enzyme is transformed from its low-spin form to the high-spin form upon 
substrate binding. After observing a high amount of presumably correctly folded protein, 
indicated by the CO-difference spectrum, purification was investigated. 
For purification of the CYP11A1 enzyme, a C-terminal His4-tag, as used by Mosa et al., was 
successfully introduced into the pTrc99A_P450scc plasmid. As the expression and IMAC 
purification of a His-tagged variant of the CYP11A1 protein was described by Mosa et al. in 
2015, their protocol was followed.[192] After purification, the obtained CYP11A1 eluate showed 
a concentration of 242 mg L-1. The protein was obtained in a relatively pure form, since only 
one other major band was observed after the SDS-PAGE analysis, as reported by Mosa et al. 
(Figure 19).[192] As a high amount of CYP11A1 was found in the elution fraction and the buffer 
used contained glycerol, sodium cholate, sodium acetate, and TWEEN 20, the observed 
problems with protein binding to the column, might arise from interference of the detergence, 
by for example shielding the His-tag. There was no imidazole in the washing buffer. Next, the 
purification in a buffer without additives was investigated. Although the purity of the protein 
was strongly enhanced, as well as the binding of the protein to the column, the protein was 
found to be incorrectly folded after purification, indicating the importance of these additives 
in the originally used buffer. Additionally, these results might indicate, that the His-tag of the 
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correctly folded protein might also not be freely accessible. As a last approach for purification 
optimization, cation exchange chromatography on a SP Sepharose column was investigated, 
using a similar buffer to the above-mentioned buffer (20 mM potassium phosphate, pH 7.4, 
20% (w/v) glycerol, 0.1 mM DTT, 0.1 mM EDTA, 10 mM imidazole, 1% sodium cholate, and 
0.1% Tween-20). This approach was chosen, based on the calculated pI of 8.82 for the His-
tagged protein. Hence, it was assumed that the protein might be positively charged in the 
buffer at pH 7.4. Unfortunately, CYP11A1 could not bind to the SP Sepharose column under 
the applied conditions. Although the calculated pI of the protein might be accurate, the actual 
pI of all amino acids on the protein surface might differ from the calculated value. By changing 
the pH of the buffer, the purification method might be optimized. As the CYP11A1 proved in 
general to be sensitive to buffer conditions, first investigations on the pH stability had to be 
performed, before optimizing the purification. 
In parallel, the expression and purification of Adx (14 kDa, solubly expressed) was 
investigated. The expression was successfully established. The addition of FeSO4 to the 
cultivation medium at timepoint of induction is important to supply the E. coli cells with high 
amounts of iron and sulfur in order to build the iron-sulfur cluster of the Adx protein. 
For purification a protocol of Suhara et al. from 1972 was followed, resulting in an 
approximately 50% pure protein solution. The elution fraction showed all characteristic 
absorption peaks necessary for clear identification of the iron-sulfur protein. Afterwards, a 
size exclusion chromatography approach was investigated, resulting in a relatively pure 
protein fraction, which had lost the typical brown color of the protein. This color loss most 
likely indicated the loss of the iron-sulfur cluster, which was confirmed by investigation of the 
absorption spectrum, which did not show the characteristic peaks anymore. Also, a 
hydrophobic interaction chromatography approach remained unsuccessful. Hence, also for 
the Adx protein the investigation of the pH stability might help to optimize the purification 
strategy by being able to adjust the pH of the buffer and investigating anion and cation 
exchange chromatography steps further. 
The expression and purification of the third protein, the membrane-bound AdR, was also 
studied. The expression with two different plasmids (pBar1607_AdR and pET28_AdR) in 
combination with two different E. coli host strains (E. coli JM109 (DE3) and E. coli BL21 (DE3)) 
was investigated. Additionally, as the co-expression of chaperones increased the amount of 
correctly folded protein for the other membrane-bound protein investigated, the influence of 
co-expression of groEL and groES was investigated. Judging from SDS-PAGE analysis and the 
spectral properties of the proteins obtained, the best result was obtained for E. coli BL21 (DE3) 
harboring plasmids pET28_AdR and pGro7. 
With the protein solution obtained, purification experiments were performed. As the pI of 
the AdR molecule was calculated to be 6.79, two different anion exchange chromatography 
approaches at pH 8 and pH 8.5 as well as an affinity chromatography approach using a 2'5' 
ADP Sepharose column was tested. Only by anion exchange chromatography at pH 8.5, AdR 
was obtained in the final elution fraction, along with other proteins. Also, the investigation of 
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the typical spectrum of the FAD-containing protein, indicated that only very small amounts of 
AdR were obtained by these purification methods, therefore also the pH stability of this 
protein needed to be investigated first to optimize the purification strategy further. 
As the main goal was to investigate the overall activity of the CYP11A1, in vitro biocatalysis 
was performed with purified CYP11A1. As the expression and purification of AdR remained 
difficult, other redox partner systems were investigated. Although the first biocatalytic 
approach showed a clear substrate decrease for samples containing the P450 enzyme along 
with a redox partner system, no product or side-product formation was detected. 
Additionally, background activity was ruled out by different negative controls. The substrate 
or product also cannot be still attached to the enzyme, as only 0.4 µM enzyme was used in 
the conversion of 1.2 mM substrate. As a consequence of not identifying the problem, the 
experiment was repeated, and the scanning method of the GC-MS broadened, in order to find 
possible side-products. Unfortunately, the first positive results were not reproducible.  
Therefore, a different redox partner system, the reductase domain of cytochrome P450 
BM3 (BMR) was investigated. On the one hand as a fusion protein consisting of CYP11A1 and 
BMR and on the other hand in in vitro biocatalysis with purified enzymes. The idea, of using a 
fusion construct, arose from other studies indicating that the soluble expression level of 
membrane bound cytochrome P450 enzymes can be increased by fusion to the BMR domain, 
along with an increase in activity of the created self-sufficient fusion protein.[49,60,151,152] 
Hence, the plasmid for the expression of the fusion protein was created by FastCloning[196] 
and first expression experiments performed, which resulted in no expression of the fusion 
construct. As no spacer was used to link the two proteins, the construct might have been too 
rigid, resulting in incorrectly folded or insoluble fusion protein.[215–217] In parallel, in vitro 
biocatalysis was performed, which showed no product formation. Hence, it seemed most 
likely that the BMR domain was not able to transfer electrons to the cytochrome P450 
monooxygenase. As not all redox partner systems are compatible with all cytochrome P450 
enzymes, the focus was switched back to the investigation of the natural redox partner 
system. 
As the pH stability is important for the optimization of ion-exchange purification strategies 
and the temperature stability is a key factor for successful biocatalytic approaches, both 
properties were investigated for all three proteins in the Master thesis of Christopher Grimm. 
Although the investigated CYP11A1 system originated from mammals, it was surprising to see 
that its temperature optimum was found to be at 20°C. On the other hand, the pH optimum 
for long-term stability was found to be around physiological pH. As the purification was 
already performed at pH7.4, no further optimization concerning ion exchange 
chromatography could be achieved. The small, soluble Adx protein remained remarkably 
stable over a broad pH spectrum, but purification optimization was rather achieved by 
improving the salt gradient in the already established purification method. The previously 
used gradient was quite broad, and the optimal elution concentration could be estimated 
from the previous purification. Therefore, the use of a washing step with a salt concentration 
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below the elution concentration, followed by an elution step with a narrow salt concentration 
range succeeded in obtaining a relatively pure protein solution. The temperature stability of 
the Adx protein was found to be higher when compared to CYP11A1, which will therefore 
most likely not lead to problems in biocatalytic approaches. These problems would more likely 
result from the stability issues of the CYP11A1 enzyme. Additionally, further expression 
optimization and purification approaches with the AdR protein did not result in any 
improvement. As a consequence, further activity investigations were conducted using a 
whole-cell system approach, with an already published plasmid encoding all three proteins.[89] 
The published conversion level was reproduced in a first approach and a 10-fold increase was 
achieved by the use of a different solubilization detergent for the cholesterol substrate. This 
increase might be associated with an improved substrate supply over the cell membrane 
caused by the new detergent. In total, the conversion was still very low (2.2% optimization).  
Concluding, from the data obtained, the CYP11A1 monooxygenase is a membrane-bound 
enzyme with low activity and stability, even in whole-cell biocatalysis experiments. By using 
an approach with growing cells, the observed activity compared to in vitro biocatalysis should 
be improved for unstable proteins, by continuous production of fresh protein. As the creation 
of alanine variants most likely results in obtaining variants with reduced activity, the very low 
activity of the CYP11A1 proved to be a problem. Although described in literature, the use of 
radioactive labeled substrates was not an option. As additionally no high concentrations of 
AdR could be obtained, the focus was shifted to a different membrane-bound cytochrome 
P450 monooxygenase, the CYP17A1. 
4.3 Investigating the CYP17A1 enzyme 
As the goal was to investigate the general activity of the CYP17A1 enzyme, the expression 
of the human wild-type enzyme was first investigated. By following the protocol of Petrunak 
et al. the human CYP17A1 was successfully expressed in E. coli JM109 cells transformed with 
the pCW17A1Δ19H plasmid.[110] This plasmid encodes the human CYP17A1 with a 19-residue 
N-terminal truncation and C-terminal His-tagged version of the enzyme, also used for the 
crystallization of the protein. Although different conditions for purification of the His-tagged 
protein were investigated, no proper binding to the column was achieved. For His-tag based 
purification, the His-tag has to be freely accessible for binding to the column material. For 
some proteins, the His-tag can be incorporated into the tertiary structure and therefore, no 
interaction with the column material is possible. Additionally, the used buffer contained 
Emulgen 913, a detergent used for the solubilization of membrane-bound proteins along with 
glycerol. As both detergents were also present in the buffer used for purification of the 
CYP11A1 protein, also showing difficulties to bind to the column, it is possible, that the 
detergent somehow interfere with the binding ability of the His-tag to the column.  
Hence, the general activity was investigated in crude cell lysate. For the CYP17A1 enzyme, 
the natural redox partner system is not known, therefore, other redox partner systems were 
investigated. Here, the CYP17A1 in combination with the Pdx/PdR system from P. putida 
Discussion 
 83 
showed the highest activity. Interestingly, the negative control without addition of NADH 
showed the same conversion as the sample with added NADH. In general, E. coli lysate 
contains NADH, therefore observing activity without adding NADH can occur. It was however 
not expected to see the same extent of conversion in both samples. In an approach of Zhou 
et al. from 2013, the intracellular NADH levels of different E. coli strains were investigated and 
found to range between approximately 0.5 mM and 0.75 mM.[218] As approximately 400 µL 
cell lysate in a total volume of 1 mL were used for the biocatalytic approach, this might result 
in a final NADH concentration of 0.2 mM when calculating with the lowest measured 
concentration. Therefore, the conversion of 0.1 mM substrate would also be possible without 
external addition of NADH. The reason for obtaining only 90.2% conversion instead of full 
conversion in both samples although applying enough NADH might indicate an activity loss 
over time or a high uncoupling level, also resulting in activity loss.  
In order to investigate the NADH problems observed with the negative control further, for 
the next biocatalysis, the CYP17A1 protein from the cell lysate was washed with the used 
buffer, using centrifugal filters with a cutoff value of 30 kDa. By this washing step, the NADH 
concentration in cell lysate should at least be reduced. Additionally, as possible negative 
control for further investigations, the T306A variant was created by site directed mutagenesis 
and successfully expressed. This mutant was described in literature as an uncoupling variant, 
showing only 0.9% coupling in the reaction with progesterone.[198] The results confirmed that 
the NADH concentration in cell lysate might have been responsible for the high activity in the 
sample without addition of NADH, as the cell lysate treated with the centrifugal filters showed 
a decreased activity without addition of NADH. Additionally, the sample with the 200 µM 
NADH added showed the exact same conversion as the sample with 100 µM of added NADH. 
Although the observed conversion was a little higher with 95.8%, full conversion could not be 
achieved independent of the NADH concentration used. This further strengthens the theory 
of problems with protein stability of uncoupling resulting in protein instability might be an 
issue. Furthermore, the biocatalysis performed with the T306A resulted in no product 
formation, resembling a good negative control. Here all components of the biocatalysis are 
present, even cytochrome P450 enzyme. Therefore, biocatalysis performed with T306A could 
be regarded as good control to observe any background reaction. 
Next, the importance of all active site residues in 4 Å proximity to the bound substrate were 
identified with PyMol and exchanged with alanine by site-directed mutagenesis, followed by 
expression. Although expression of soluble protein was achieved, the recorded CO difference 
spectra showed that all expressed variants were mostly or completely incorrectly folded. 
Although introducing mutations in proteins in general can lead to misfolding of the proteins, 
observing this for all variants was unexpected. The folding of proteins is a complex process 
and therefore, small differences can result in significant effects.[219,220] In addition, the His-tag 
of the protein, might also negatively influence the stability of the protein.[221] Even the wild-
type protein was observed to be 31.5% incorrectly folded from the very start, indicating 
stability problems with the construct used.  
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Next, all variants were again expressed, and different buffers were used for the 
resuspension of the pellets followed by cell lysis. In total six different buffers were used with 
different detergents. In none of the used buffers an increase of obtained correctly folded 
protein concentration was achieved. Therefore, a whole-cell system, expressing the bovine 
CYP17A1 in its native form, with its membrane anchor and without His-tag, of the protein was 
investigated.  
The first whole-cell biocatalysis approach, using the S. cerevisiae strain GRF18 transformed 
with the YEp5117α plasmid following the protocol of Shkumatov et al.[197] showed almost full 
conversion of progesterone over 24 h. The first product 17α-hydroxyprogesterone was 
detected along with a second product, not resembling the natural occurring second product 
androstendione, but rather 17α, 20α -dihydroxyprogesterone. The formation of this product 
is most likely performed by an endogenous enzyme of S. cerevisiae (Figure 43b). The search 
of an analogue to mammalian 20a-hydroxysteroid-dehydrogenase (20a-HSD), an enzyme 
being capable of performing the observed reaction, revealed two possible candidates.[222] 
Szczebara et al. found in their study the proteins Gcy1p, the yeast galactose-inducible 
crystalline-like protein and Ypr1p, which resembles a yeast aldo-keto reductase. 
This was also found in other studies.[197,203,204] Therefore, the formation of 20-
hydroxyprogesterone does not occur and only 17a-hydroxyprogesterone is converted to 17a-
,20a-dihydroxyprogesterone. If the activity of the CYP17A1 enzyme is investigated, both 
products need to be considered, as the double-hydroxylated product is only formed if the 
single-hydroxylated product is present. 
 
 
Figure 43: Comparison between conversion of progesterone in mammalian cells (a) and whole-cell biocatalysis in S. cerevisiae. 
a) Under physiological conditions, the CYP17A1 enzyme catalyzes a 17α-hydroxylation followed by a C17-20 bond cleavage 
reaction, resulting in conversion of progesterone to androstendione. b) In S. cerevisiae however, progesterone is converted 
to 17α-hydroxyprogesterone by the bovine CYP17A1, which is a substrate for the 20α-hydroxysteroid dehydrogenase (20α-
HSD) analogue from S. cerevisiae. This enzyme converts 17α-hydroxyprogesterone to 17α-20α-hydroxyprogesterone. (Figure 




The natural second product androstendione (Figure 43a) was not found in the whole-cell 
biocatalysis approach employing S. cerevisiae. On the one hand, a study by Estrada et al. from 
2013 showed that interaction with cytochrome b5 seems to facilitate the C17-C20 bond 
cleavage reaction through an allosteric interaction with the enzyme.[223] On the other hand, 
post-translational phosphorylation was also found to influence the formation of 
androstenedione to a certain extent.[109]  
Hence, the missing post-translational phosphorylation might influence the absent C17-C20 
bond cleavage reaction in S. cerevisiae. Additionally, it is possible that the affinity of the 20a-
HSD analogue towards 17a-hydroxyprogesterone is higher and, therefore, also the favored 
reaction over the catalyzed C17-C20 bond cleavage reaction by the investigated bovine 
CYP17A1 enzyme. 
Next, the influence of different active site residues on the overall activity of CYP17A1 was 
investigated. After obtaining a homology model with YASARA, all residues in 4 Å proximity to 
the bound substrate were identified and exchanged with alanine by site-directed 
mutagenesis. The activities of all variants were investigated by whole-cell biocatalysis. The 
obtained results seem to confirm the importance of positions N202, R239, G297, E305, and 
T306A, which were described in literature.[86] Although the position L105 seems to influence 
the side product formation of 16a-hydroxyprogesterone for the human CYP17A1 enzyme, this 
was not found to be the case for the bovine CYP17A1 enzyme.[108] For the bovine enzyme, the 
exact opposite of the findings of Swart et al. were observed. Here the wild-type showed side-
product formation, whereas the alanine mutant showed no formation of 16a-
hydroxyprogesterone. Even more interesting was the identification of three other positions 
(L206, V366 and V483) that seem to largely influence the 16a-hydroxyprogesterone formation 
by the bovine enzyme. After performing a preparative biocatalysis with the V483A variant, the 
side-product was isolated and analyzed by NMR, confirming that 16a-hydroxyprogesterone 
was obtained. Afterwards, molecular docking was performed with the homology model of 
wild-type and the V483A variant. Although 14 different docking results were obtained, only 
the docking results resembling the same substrate orientation as observed in the crystal 
structure with bound substrate were taken in consideration. Of these 14 results, only three 
resembled a similar orientation as found in the elucidated crystal structures of CYP17A1 
enzymes with bound substrate of different species. Here, in two the C16 atom was found to 
be oriented the closest to the heme-group with 4.0 Å and 4.1 Å. Therefore, the one result 
resembling the closest distance to the heme iron was further analyzed by an alignment of 
CYP17A1 wild-type. When comparing both structures, the orientation of the bound 
progesterone was slightly shifted in variant V483A. Therefore, the C17 atom was closer to the 
heme-iron, than observed for the wild-type enzyme. Hence, the V483A position might be 
important for correct substrate positioning. With alanine at position 483, the substrate has a 
little more freedom and therefore, might be able to move more freely in the active site, 
resulting in 17a-hydroxylation. As also the 16a-hydroxylation is still catalyzed by this variant, 
the idea of the substrate not being bound rigidly, seems to be likely. 
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Although these results are very compelling, unfortunately the expression level could not 
be determined, as the samples of lysed cells showed too high turbidity and SDS-PAGE analysis 
of the yeast samples showed no clear band for over-expression of the protein. Therefore, it 
remains unclear whether the different levels of activity are just linked to activity loss out of 
structural reasons, or if there were also differences in expression level. Additionally, the loss 
of function can also be a result of incorrect folding of the expressed proteins as observed for 
the human CYP17A1 variants.  
However, concluding from the results obtained, it seems likely that not only incorrect 
folding and expression levels are the main reason for the observed results. As the obtained 
data seems to resemble the findings and suggestions in literature, it seems more likely that 
the observed activities resemble the influence on activity through the alanine scanning. 
Additionally, the expression levels are a current topic of further investigation. 
4.4 First investigations on a dual screening assay 
The last section of the PhD thesis also describes the development of a screening assay. The 
focus was on the development of a dual screening system for substrate conversion and 
hydrogen peroxide formation in parallel in a high-throughput format. The goal was to find 
conditions to perform the final assay in water-in-oil droplets for obtaining a screening 
platform for a large enzyme library.  
Therefore, a fatty acid linked to (7-hydroxy-4-(trifluoromethyl)coumarin was used as 
substrate. Hence, the investigation of this assay started with the chemical synthesis of the 
substrate, followed by purification and NMR spectroscopy analysis. As the correct substrate 
was obtained, according to NMR spectroscopy analysis, the next step was to find a suitable 
hydrogen peroxide detection assay. 
First, The DCFH-DA probe was investigated. This probe is usually used in the detection of 
intracellular hydrogen peroxide levels. After oxidation, the highly fluorescent probe DCF stays 
in the cells. The idea for using this probe was that if the probe is usually used intracellular and 
is known to stay in the cells after oxidation, hopefully, the probe would also stay in the 
droplets. Although a linear relation between hydrogen peroxide concentration and 
fluorescent signal was observed, the sensitivity of the probe was not high enough with a 
detection limit of 2.5 µM. As the sensitivity of the previously established AmplifluTM Red assay 
was much higher (50 nM), this probe was further investigated on suitability for the dual 
screening approach. 
Therefore, with the first experiment the continuance of resorufin and in parallel of the 7,4-
HFC in the aqueous phase, when incubated with the HFE-7500 oil under vigorous shaking was 
investigated. For both probes, the tendency of diffusion into the oil phase at lower pH was 
observed. This is most likely explainable by the protonation degree of the probes at the 
different pH values. The pKa value of resorufin is 6.0 and for the 7,4-HFC, 7.26. At lower pH, 
the probes become less hydrophilic through loss of charge, making it more likely the probes 
will diffuse into the oil. Definitely a pH above the pKa values above both probes should be 
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used. For both probes, using pH 7.4 seemed to be a good compromise for also having a good 
working pH for enzymatic activity and still having the main part of both probes residing in the 
aqueous phase, necessary for detection.  
Next, assay conditions were investigated with cytochrome P450 BM3 wild-type and 
different variants, found in the literature.[24] An uncoupling variant (F87Y) was used as 
negative control, the A74G/F87V variant was used as positive control. With the same 
conditions used in the AmplifluTM Red assay, different substrate to NADPH ratios were 
investigated. By Degregorio et al. it was found, that the NADPH : substrate ratio is crucial for 
low uncoupling in general.[49] In their investigation, product formation increased with 
increased NADPH concentration, but reached a plateau at a certain point. Hydrogen peroxide 
formation also increased linearly but showed no plateau. Therefore, after obtaining high 
uncoupling levels for all investigated variants, the idea was to reduce the NADPH 
concentration. By doing so, the uncoupling extent of all variants was lowered and the ratio 
between product formation and hydrogen peroxide formation improved. However, it remains 
unclear where the difference in added NADPH and formed products arises from. It might be 
explained by the cytochrome P450 BM3 enzyme performing multiple hydroxylations of the 
substrate. As only one hydroxylation yields the 7,4-HFC, multiple hydroxylation is not 
detectable with the assay. The cytochrome P450 BM3 is in general known for its multiple 
hydroxylation of several substrates.[224] To further investigate this idea, GC-MS analysis of the 
obtained products should be performed in order to see if this was the problem. If the multiple 
hydroxylation accounts for the difference, this is not a major issue for the assay, as it still 
detects product formation and hydrogen peroxide formation. Only if the difference accounts 
for a background reaction not related with the enzymatic function, this would be a problem. 
Negative controls with NADPH and the substrate in combination with the AmplifluTM Red 
probe did not show any reaction. This at least indicates no direct interaction of substrate and 
NADPH with the AmplifluTM Red probe. 
Afterwards, the assay was further investigated by performing the assay with the variants 
created for the AmplifluTM Red assay. Judging from the obtained results, it seems as if the 
assay might be suitable in identifying new variants in a high-throughput screening, as the 
investigated enzyme concentration equals the final enzyme concentration and still the signal 
was detectable. Additionally, already one variant was found showing the same uncoupling 
extent as wild-type and F87V, but higher product formation. By investigating a library, 
probably new variants can be identified showing lower uncoupling and higher product 
formation. It will be interesting to analyze which residues lead to this result and even more 
interesting to perform molecular docking experiments with these variants and compare them 
to each other. Hopefully, this will increase the understanding of the occurrence of uncoupling. 
A point for further optimization might be the use of the GDH system for NADPH recycling 
in combination with very low concentrations of NADPH, as this may circumvent problems with 
the leak rate. As described above, especially too high NADPH concentrations can result in high 
Discussion 
 88 
uncoupling. By keeping the NADPH level at a low concentration over a longer time, product 





In the 1940s cytochrome P450 monooxygenases have been discovered and have been the 
focus of many studies ever since. Although they catalyze very interesting reactions that might 
find applications in the production of fine chemicals or pharmaceuticals, their low activity and 
stability often reduces their economic value.[153,225–228] Both properties, the activity and the 
stability, are influenced by the uncoupling of the catalytic cycle.[165,229]  
In this PhD thesis, an assay for the screening of activity and uncoupling of cytochrome P450 
enzymes was successfully developed.[179] After finding optimal conditions for the assay, 
concerning pH and enzyme concentration, the uncoupling of cytochrome P450 BM3 and five 
mutants (F87Y, R47L, Y51F, A82L and T268A) was investigated. With the results obtained, a 
comparison of data from literature was possible and revealed similarities. Additionally, 
through negative controls, the reliability of the assay could be further demonstrated. Although 
other methods have been described for the detection of hydrogen peroxide formation, the 
combination of NADPH consumption measurement and hydrogen peroxide formation in 
parallel was new and represents a very good basis for a pre-screening of large mutant libraries, 
followed by closer investigation of selected variants. 
For the investigation of the activity of the CYP11A1 system, consisting of CYP11A1 and Adx 
and AdR as redox partner system, the expression and purification for all three proteins was 
investigated first. For the protein CYP11A1 and Adx, good expression levels were achieved, 
whereas for AdR the protein concentration obtained was very low. The purification of all three 
proteins was partially accomplished but left room for improvement. Therefore, in the Master 
thesis of Christopher Grimm, the pH and temperature stability of all three proteins was further 
investigated in order to improve conditions used for ion exchange chromatography and to 
investigate possible conditions for in vitro biocatalysis. As unfortunately even with further 
investigation of the expression of AdR, no improvement was achieved, a whole-cell system 
was further investigated. Here, the product formation could be increased 8-fold in comparison 
to the published data, from 0.27% conversion to 2.2% conversion over 24 h by using a different 
detergent for substrate solubilization, which might have led to a better substrate supply to 
the enzyme. 
Due to the low activity and stability, a different P450 system, the CYP17A1 enzyme, was 
subsequently investigated, first by in vitro biocatalysis with the human CYP17A1 expressed in 
E. coli. Therefore, a suitable redox partner system needed to be found for efficient electron 
supply of the enzyme. In in vitro biocatalysis, in combination with the Pdx/PdR system of P. 
putida the CYP17A1 enzyme showed the highest conversion with 91% after 24 h. To 
investigate the activity of the enzyme further, all active site residues in 4 Å proximity to the 
bound substrate were exchanged with alanine. After expression of the variants, almost no 
correctly folded protein was obtained for the variants. Also, after investigating different 
buffers to possibly enhance the stability, no improvements were achieved. Therefore, a 
whole-cell approach with the bovine enzyme was chosen in order to investigate the activity 
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of the alanine variants. Here the importance of positions N202, R239, G297, E305, and T306A, 
described in literature to be important for catalytic activity, was confirmed. Most importantly, 
three positions that alter the regioselectivity of the enzyme were identified. The reaction of 
the V483A mutant was therefore also further investigated by preparative biocatalysis. 
Afterwards the new product was separated by preparative HPLC and identified as 16α-
hydroxyprogesterone as confirmed by NMR spectroscopy analysis.  
In the last part of the thesis, another screening approach for possible high-throughput 
screening was investigated. In contrast to the other screening approach, here the 
investigation of the substrate conversion and the hydrogen peroxide formation were 
optimized for application in droplets. After finding that DCFH-DA was not sensitive enough 
towards hydrogen peroxide, the AmplifluTM Red probe was used. As both fluorescent products 
were found to stay in the aqueous phase above pH 7.4, the conditions investigated for the 
AmplifluTM Red assay were applied and only NADPH to substrate ratio was investigated by 
using an uncoupling variant, an active variant from literature and the cytochrome P450 BM3 
wild-type enzyme. After finding a good ratio, the five variants used for the investigation of the 
AmplifluTM Red assay were investigated in the same concentration later on found in the 
droplets (1 cell per 4 pL), and one variant showed improved product formation compared to 
wild-type. This finding clearly shows the applicability of the assay for high-throughput 





Cytochrom P450 Monooxygenasen wurden in den 1940er Jahren entdeckt und wurden 
seither intensiv erforscht. Obwohl sie sehr interessante Reaktionen katalysieren, die 
Anwendung in der Produktion von Feinchemikalien und Pharmazeutika finden könnten, wird 
ihre Wirtschaftlichkeit meist durch ihre Aktivität und Stabilität negativ beeinflusst.[153,225–228] 
Beide Eigenschaften, die Aktivität und die Stabilität, werden durch die Entkopplung des 
katalytischen Zyklus beeinflusst.[165,229]  
Im Rahmen dieser Doktorarbeit, wurde ein Assay für das „screening“ auf Aktivität und 
Entkopplung erfolgreich entwickelt.[179] Nachdem optimale Reaktionsbedingungen für das 
Assay identifiziert waren, wurde die Entkopplung von Cytochrom P450 BM3 und fünf 
Mutanten (F87Y, R47L, Y51F, A82L and T268A) mit verschiedenen Substraten untersucht. 
Obwohl bereits viele andere Wasserstoffperoxid Detektionsmethoden beschrieben wurden, 
war die Kombination einer parallelen Bestimmung der NADPH Abnahme und der 
Wasserstoffperoxid Bildung neu. Dieser parallele Ansatz stellt eine gute Basis für ein „pre-
screening“ großer Mutantenbibliotheken dar, worauf eine detaillierte Untersuchung von 
ausgewählten Varianten folgt. 
Um die Aktivität des CYP11A1 Systems, bestehend aus CYP11A1, Adx und AdR als Redox 
Partner System, untersuchen zu können, wurde zunächst die Expression und Aufreinigung 
aller drei Proteine untersucht. Für die Proteine CYP11A1 und Adx, wurden gute Expression 
Levels erreicht, wohingegen die Konzentration für AdR sehr gering war. Für alle drei Proteine 
wurde nach Aufreinigungsversuchen eine konzentrierte Lösung erhalten, die jedoch noch 
andere Proteine enthielt. Daher wurde in der Masterarbeit von Christopher Grimm, die pH 
und Temperaturstabilität aller drei Proteine untersucht, um die Bedingungen während der 
Ionenaustauschchromatographie als Aufreinigungsmethode optimieren zu können und 
optimale Bedingungen für in vitro Biokatalysen zu finden. Leider wurde trotz weiterer 
Expressionsversuche mit AdR keine Verbesserung erzielt, wodurch ein Ganzzellsystem als 
nächstes untersucht wurde. Für dieses System konnte die Produktbildung auf 2.2%, achtfach 
erhöht werden, im Vergleich zu den publizierten 0.27% Umsatz nach 24 h durch die 
Verwendung eines anderen Detergenz zur Lösung des Substrates Cholesterol, wodurch 
vermutlich die Bereitstellung des Substrates für das Enzym erleichtert wurde. 
Auf Grund der beobachteten geringen Aktivität und Stabilität, wurde anschließend ein 
weiteres P450 System untersucht, das CYP17A1 Enzym. Zunächst wurden in vitro Biokatalysen 
mit dem humanen CYP17A1 durchgeführt, welches in E. coli exprimiert wurde. Nachdem 
verschiedene Redox-Partner Systeme getestet wurden, erzielte das Pdx/PdR System von 
P. putida in Kombination mit dem CYP17A1 Enzym den höchsten Umsatz, mit 91% nach 24 h. 
Um die Aktivität des Enzyms näher zu untersuchen, wurden alle Aminosäuren in einem 
Abstand von 4 Å zum gebundenen Substrat durch Alanine ersetzt. Alle Varianten wurden 
exprimiert, jedoch konnte kaum richtig gefaltetes Protein erhalten werden. Auch nachdem 
verschiedene Puffer untersucht wurden, zur eventuellen Stabilitätserhöhung, konnte keine 
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Verbesserung festgestellt werden. Deshalb wurde auch hier auf einen Ganzzellansatz 
zurückgegriffen. Dieser bestand aus dem Enzym aus Rind welches in S. cerevisiae exprimiert 
wurde. Mit diesem System, wurde die Bedeutung der Positionen N202, R239, G297, E305 und 
T306A bestätigt, die in der Literatur als wichtig für die katalytische Aktivität beschrieben 
werden. Am wichtigsten waren drei Positionen, die die Regioselektivität des Enzyms 
verändern. Die Reaktion der V483A-Mutante wurde daher auch durch präparative Biokatalyse 
weiter untersucht. Danach wurde das neue Produkt durch präparative HPLC getrennt und als 
16α-Hydroxyprogesteron identifiziert, was mittels NMR-Spektroskopie bestätigt werden 
konnte. 
Im letzten Teil der Arbeit wurde ein weiterer Screening-Ansatz für ein mögliches 
Hochdurchsatz-Screening untersucht. Im Gegensatz zum bereits beschriebenen Screening-
Ansatz wurde hier die Untersuchung der Substratumwandlung und der 
Wasserstoffperoxidbildung für den Einsatz in „droplets“ optimiert. Nachdem festgestellt 
wurde, dass DCFH-DA gegenüber Wasserstoffperoxid nicht empfindlich genug war, wurde das 
AmplifluTM Red / HRP System verwendet. Da beide fluoreszierenden Produkte oberhalb von 
pH 7,4 in der wässrigen Phase blieben, wurden die für den AmplifluTM Red Assay untersuchten 
Bedingungen angewendet. Das NADPH-Substrat-Verhältnis wurde mit einer 
Entkopplungsvariante, einer aktiven Variante aus der Literatur und dem Cytochrom P450 BM3 
Wildtyp-Enzym untersucht. Nach Ermittlung eines guten Verhältnisses wurden die fünf für die 
Untersuchung des AmplifluTM Red Assays verwendeten Varianten in der gleichen 
Konzentration untersucht, die später in den „droplets“ gefunden wird (1 Zelle pro 4 pL). Hier 
zeigte eine Variante eine verbesserte Produktbildung im Vergleich zum Wildtyp. Dieser 
Befund zeigt deutlich die Anwendbarkeit des Assays für Hochdurchsatzscreening in 
„droplets“. 
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7 Material and Methods 
7.1 Materials 
7.1.1 Strains 
For recombinant expression of proteins and cloning experiments different Escherichia coli 
(E. coli) strains and one Saccharomyces cerevisiae (S. cerevisiae) strain were used (Table 14).  
 
Table 14: List of used strains for cloning and protein expression experiments. 
species strain genotype company 
E. coli BL21 (DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] 
∆hsdS λ DE3 = λ sBamHIo ∆EcoRI-B 




am Main, Germany) 
E. coli TOP10 (DE3) F- mcrA Δ( mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 Δ lacX74 recA1 
araD139 Δ( araleu)7697 galU galK 




E. coli JM109 (DE3) endA1, recA1, gyrA96, thi, hsdR17 
(rk–, mk+), relA1, supE44,  
Δ( lac-proAB), 
[F´ traD36, proAB, laqIqZΔM15] 
New England 
Biolabs (Frankfurt 
am Main, Germany) 





E. coli SHuffle®Express fhuA2 lacZ::T7 gene1 [Ion] ompT 
ahpC gal λatt::pNEB3-r1-pNEB3-
cDsbC (SpecR,IacIq)  ΔtrxB sulA11 
R(mcr-73::miniTn10--TetS)2 




am Main, Germany) 
S. 
cerevisiae 
GRF18 Mata his3-11 his3-15 leu2-3 leu2-
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7.1.2 Plasmids 
Table 15: List of used plasmids. 
Plasmid description Received from / company 
pET22_BM3 Harbors the gene for Cytochrome 
P450 BM3 from B. megaterium  
Constructed by Jan 
Muschiol, former PhD 
student of Prof. Dr. Uwe T. 
Bornscheuer, Greifswald 
University (Germany) 
pET28a_BMR Harbors the gene for the reductase-
domain of Cytochrome P450 BM3 
from B. megaterium 
Constructed by Jan 
Muschiol, former PhD 
student of Prof. Dr. Uwe T. 
Bornscheuer, Greifswald 
University (Germany) 
pTrc99A_P450scc Harbors the gene for bovine 
CYP17A1[188] 
Prof. Dr. Rita Bernhardt, 
University of Saarland 
(Germany) 
pET28a_P450scc_BMR Harbors a construct for the 
expression of a chimera protein of 
P450scc and BMR 
Constructed during this 
work 
pBad_Adx,  Harbors the gene for the bovine Adx Prof. Dr. D. B. Janssen, 
University of Groningen 
(The Netherlands) 
pKKHC_Adx Harbors the gene for the bovine 
Adx[230] 
Prof. Dr. Rita Bernhardt, 
University of Saarland 
(Germany) 
pBar1607_AdR Harbors the gene for the bovine 
AdR[231] 
Prof. Dr. Rita Bernhardt, 
University of Saarland 
(Germany) 
pET28_AdR Harbors the gene for the bovine 
AdR[231] 
Prof. Dr. D. B. Janssen, 
University of Groningen 
(The Netherlands) 
pBar_Triple Harbors the genes for bovine 
CYP11A1, Adx and AdR with three 
ribosom binding sites[89] 
Dr. Ludmila Novikova, 
Lomonosov Moscow State 
University (Russia) 
pET28a_Pdx Harbors the gene of Pdx from 
P. putida[232] 
Prof. Dr. Vlada B. Urlacher, 
Heinrich- Heine- University 
Düsseldorf (Germany) 
pET28a_PdR Harbors the gene of PdR from 
P. putida[232] 
Prof. Dr. Vlada B. Urlacher, 
Heinrich- Heine- University 
Düsseldorf (Germany) 
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pET28a_CPR Harbors gene for CPR from C. 
apicola with N-terminal 22 amino 
acids deletion and N-terminal His-
tag[145] 
Prof. Dr. Vlada B. Urlacher, 
Heinrich- Heine- University 
Düsseldorf (Germany) 
pQE-30-HyPer3 Harbors gene for HyPer-3 
expression, natural H2O2 sensor-
protein from E. coli (OxyR) which 
was genetically modified[67] 
Addgene, Cambridge 
(United Kingdom) 
pCW17A1Δ19H Harbors gene for N-terminal 
truncated human CYP17A1 (19 
residues), C-terminal His4-tag[86,110] 
Prof. Dr. Emily E. Scott, 
University of Michigan 
(United States) 
YEp5117a Harbors gene for bovine CYP17A1, 
shuttle vector for amplification in 
E.  coli and expression of the protein 
in S. cerevisiae[197] 




7.1.3 Enzymes  
Table 16: List of used enzymes. 
Enzyme Company 
Catalase from bovine liver Sigma-Aldrich (Steinheim, Germany) 
Cholesterol oxidase from Streptomyces spec. Sigma-Aldrich (Steinheim, Germany) 
DpnI New England BioLabs® Inc. (Ipswich, USA) 
GDH 105 Codexis (Redwood, USA) 
Horseradish peroxidase Sigma-Aldrich (Steinheim, Germany) 
Superoxide dismutase Sigma-Aldrich (Steinheim, Germany) 
OptiTaq Roboklon (Berlin, Germany) 
Taq Roboklon (Berlin, Germany) 
 
7.1.4 Oligo nucleotides 
All used oligonucleotides were synthesized by Thermo Fisher Scientific (Waltham, USA).  
 
Table 17: List of primer used for sequencing (fw – forward, rev – reverse). 
Primer Sequence (from 5’ to 3’) Purpose 




eLMO Seq2 GCCAATATTACGGAGATGCTGGC 
eLMO Seq 3 GATCCCTCGAACTTGAAGAGATG 
eLMO Seq 4 TGTAAAACGACGGCCAGT  
eLMO Seq 5 CAGGAAACAGCTATGACC  
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T7 fw mod CCCGCGAAATTAATACGACTCAC  Sequencing 
primer for all pET 
plasmids 
T7 term CTAGTTATTGCTCAGCGGT 





LMO032_CYP17a_mid_fw CTGTTAGACATATTCCCTGTGCTGAAG Sequencing 








LMO049 pCW17A1 Seq 1 CGAAGAAAACCGGTGCAAAATACC Sequencing 




LMO050 pCW17A1 Seq2 CTTTCAAAAGATTCACTCGTTGACC 
LMO051 pCW17A1 Seq3 GAAGTCATTATTAATCTTTGGGCAC 
LMO052 pCW17A1 Seq4 GAGGCTCAGGCGGAAGGTTCAAC 
LMO053 pCW17A1 Seq5 GTATTTTGCACCGGTTTTCTTCGC 
LMO054 pCW17A1 Seq6 CGGTTGTTGCTCGCAATATCGAG 
LMO089_BM3_Seq1 GCCAACTGCTCCTGCGTTTTCC Sequencing 
primers for the 
Cytochrome 




Table 18: List of used primerd for site directed mutagenesis (QC - QuikChangeTM, fw – forward, rev – reverse) 
Primer Sequence (from 5’ to 3’) Purpose 








used for introduction 
of different mutations 
into the Cytochrome 
P450 BM3 gene 
pET22b_BM3_A82L_rev CCCGTCTCCCAGAAAATCACGTA
CAAATTTAAG 
LMO030 QC BM3 F87Y fw GTTATATACAAGCTGGACGCATG 
LMO031 QC BM3 F87Y rev GCTTGTATATAACCCGTCTCCTGC 







LMO045 QC BM3 F87V fw GTTAGTTACAAGCTGGACGCATG QuikChangeTM primers 
used for introduction 
of different mutations 
into the Cytochrome 
P450 BM3 gene 
LMO046 QC BM3 F87V rev GCTTGTAACTAACCCGTCTCCTGC 
LMO047 QC BM3 A74G GTCAAGGGCTTAAATTTGTACGT
G 
LMO048 QC BM3 A74G CAAATTTAAGCCCTTGACTTAAGT
TTTTATC 
LMO087_BM3_QC_I401P_fw GTGCGTGTCCCGGTCAGCAGTTC  




Primer used for 
introduction of a His6-






LMO055 pCW17A1 QC T306A 
fw 
GTTGAAGCCACTACTTCCGTCG  





LMO057_QC_pCW_ F114A_fw CATCGCTGCCGCTGACTCAGG  




LMO060_QC_pCW_Y201A_rev CTTCGTTAGCGTTCTGAATCACG QuikChangeTM primers 
used for introduction 
of different mutations 
into the human 
CYP17A1 gene 






























LMO072_QC_pCW_G297A_rev GATGTCAGCGATGGTGGTCAG QuikChangeTM primers 
used for introduction 
of different mutations 
into the human 
CYP17A1 gene 











LMO079_QC_pCW_I371A_fw CTATGCTTGCTCCACACAAAGCC  

















primers used for 
introduction of 
different mutations 
into the bovine 
CYP17A1 gene 


































used for introduction 
of different mutations 
into the bovine 
CYP17A1 gene 

















LMO114_YEp_E305A_rev GGTGGTCGCCACACCAGCCC  
LMO115_YEp_V366A_fw CGGCCTGCGGCCCCTACG  
LMO116_YEp_V366A_rev GTAGGGGCCGCAGGCCGG  
LMO117_YEp_I371A_fw CTACGCTGGCCCCCCACAAGG  












LMO124_YEp_T306A_rev CGTGGTGGCCTCCACACCAGC  
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Table 19: All used oligonucleotides for fast cloning (fw – forward, rv/rev – reverse). 






Primer used for the fast 

















7.1.5 Chemicals and consumables  
All chemicals and reagents used were purchased from Sigma Aldrich (Munich, Germany) if 
not stated otherwise.  
7.1.6 Kits 
Table 20: List of used Kits. 
Kit Producer 
innuPrep Plasmid Kit Analytik Jena AG (Jena, Germany) 
PierceTM BCA Protein Assay Kit Thermo Fisher Scientific (Waltham, USA) 
Chaperon Plasmid Set TaKaRa Bio Inc (Kusatu, Japan) 
 
Table 21: Plasmid List of the “Chaperone Plasmid Sets” Kit from TaKaRa Bio Inc. 
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7.1.7 Media, additives and inductors 
Table 22: Media recipes used for liquid cultures. 
Medium, buffer or 
solution 
Components and preparation 
10x SOC 10 mmol•L-1 NaCl, 2.5 mmol•L-1 KCl, 10 mmol•L-1 MgCl2, 20 mmol•L-1 
MgSO4, 20 mmol•L-1 glucose, solved in aq. dest., filter sterile 
10x TB salts 164.4 g K2HPO4 • 3 H2O, 23.2 g KH2PO4 in 1 L aq. dest. 
Glycerol solution 60 % (w/v) in aq. dest., autoclave 
LB medium 1% (w/v) peptone/tryptone, 1% (w/v) NaCl and 0.5% (w/v) yeast 
extract in aq. dest., autoclave 
LB-SOC 10x SOC added 1:10 to sterile LB-medium 
TB medium 8 g glycerol, 12 g peptone/tryptone, 24 g yeast extract in 900 mL aq. 
dest., autoclave, add 100 mL 10x TB-salts 
YNB medium 13.4g yeast nitrogen base in 1000 mL aq. dest., autoclave 
YPD medium 1% (w/v) yeast extract, 2% (w/v) peptone in aq. dest., autoclave, 
adding sterile filtered 10% (w/v) D-glucose in aq. dest. in 1:10 ratio 
 
In order to create agar plates the above mentioned liquid media recipes were used and 
12% (w/v) agar-agar was added to the solution before autoclaving.  
 
Table 23: Recipes for concentrated used antibiotic and inductor stock solutions. 
Antibiotic / inductor / Additives Components and preparation 
1000x ampicillin 100 mg mL-1 in aq. dest., filter sterile 
1000x chloramphenicol 50 mg mL-1 in ethanol, filter sterile 
1000x kanamycin 100 mg mL-1 in aq. dest., filter sterile 
1000x IPTG 1 mol L-1 in aq. dest., filter sterile 
  200x D-galactose 400 g L-1 in aq. dest., keep at 60°C until dissolved, filter 
sterile 
1000x δ-aminolevulinic acid 0.5 M in aq. dest, filter sterile 
 
7.1.8 Buffers and solutions 
7.1.8.1 Chemical Competent E. coli cells 
Table 24: Buffers and solution recipes needed for the preparation of chemical competent E. coli cells. 
Buffer / solution Components and preparation 
Tfb I buffer 100 mM RbCl, 50 mM MnCl2, 30 mM KOAc, 10 mM CaCl2 and 15% 
glycerol in aq. dest., adjust pH to 5.8, filter sterile 
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Tfb II buffer 100 mM RbCl, 75 mM CaCl2, 10 mM MOPS and 15% glycerol in aq. 
dest., adjust pH to 7.0, filter sterile 
MgCl2 solution 1 M in aq. dest., filter sterile 
 
7.1.8.2 Electrocompetent E. coli cells 
Buffer / solution Components and preparation 
10% glycerin solution 100 mL glycerine, adjust volume with aq. dest to 1 L, autoclave 
 
7.1.8.3 Chemical Competent S. cerevisiae cells 
Table 25: Buffers and solution recipes needed for the preparation of chemical competent S. cerevisiae cells. 
Buffer / solution Components and preparation 
TE buffer (pH 7.5) 10 mM TRIS, 1 mM EDTA in aq. dest., adjust pH to 7.5 with 
HCl, filter sterile 
LP-Mix 40% polyethylene glycol 4000, 0.1 M lithium acetate in TE 
buffer, filter sterile 
Sheared Salmon sperm DNA Ready-to-use; 10 mg mL-1; catalog number: 15632-011; 
Thermo Fisher Scientific (Waltham, USA)  
 
7.1.8.4 Agarosegel electrophorese 
Table 26: Buffers and solution recipes needed for agarose gel electrophorese.  
Buffer / solution Components and preparation 
50x TAE buffer (pH 8.5) 242 g TRIS, 57.1 mL glacial acetic acid, 18.6 g EDTA in 1000 mL aq. 
dest 
agarose gel (1%) 1 g agarose in 100 mL 1x TAE buffer, dissolved by heating in 
microwave oven, per 50 mL gel 3 µL RotiStain (Carl Roth, 
Karlsruhe) were added for visualization under UV light 
Loading buffer For all PCR approaches buffer C was used, already containing a 
loading buffer (Roboklon, Berlin) 
 
7.1.8.5 Protein purification 
7.1.8.5.1 CYP102A1 
Table 27: Buffers used for purification and storage of Cytochrome P450 BM3. 
Buffer Components and preparation 
BM3 equilibration buffer 50 mM sodium phosphate in aq. dest., adjust pH to 7.4 
BM3 wash buffer 20 mM imidazole in 50 mM sodium phosphate buffer, adjust pH 
to 7.4 
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BM3 elution buffer 100 mM imidazole in 50 mM sodium phosphate buffer, adjust 
pH to 7.4 
BM3 storage buffer 50 mM sodium phosphate, 20% (v/v) glycerol in aq. dest., adjust 
pH to 7.4 
 
7.1.8.5.2 CYP11A1 
Table 28: Buffers used for purification of CYP11A1 with IMAC using hand columns. 
Buffer Components and preparation 
CYP11A1 lysis buffer 50 mM potassium phosphate buffer, 20% (v/v) glycerol, 1.5% 
sodium cholate, 500 mM sodium acetate, 1.5% Tween-20, 
0.1 mM EDTA, 0.1 mM DTT, 0.1 mM PMSF, adjust pH to 7.4 
CYP11A1 equilibration 
and wash buffer 
50 mM potassium phosphate buffer, 20% (v/v) glycerol, 1% 
sodium cholate, 500 mM sodium acetate, 1% Tween-20, 0.1 mM 
EDTA, 0.1 mM DTT, 0.1 mM PMSF, adjust pH to 7.4 
CYP11A1 elution buffer 50 mM sodium phosphate buffer 150 mM imidazole, 20% (v/v) 
glycerol, 1% sodium cholate, 500 mM sodium acetate, 1% 
Tween-20, 0.1 mM EDTA, 0.1 mM DTT, 0.1 mM PMSF, adjust pH 
to 7.4 
CYP11A1 storage buffer 50 mM potassium phosphate, 20% (v/v) glycerol, 1% sodium 
cholate, 0.05% Tween-20, 0.1 mM EDTA and 0.1 mM DTT, adjust 
pH to 7.4 
 
Table 29: Buffer used for purification of CYP11A1 by Ion exchange chromatography. 
Buffer Components and preparation 
CYP11A1 buffer used for 
purification using SP-
Sepharose 
20 mM potassium phosphate, 20% (v/v) glycerol, 0.1 mM DTT, 
0.1 mM EDTA, 10 mM imidazole, 1% sodium cholate, 0.1% 
Tween-20, adjust pH to 7.4 
 
7.1.8.5.3 Adx 
Table 30: Buffers used for purification of Adx using DEAE-Sepharose, Phenylsepharose or a column packed with Superdex 
G200. 
Buffer Components and preparation 
Adx equilibration buffer 50 mM sodium phosphate; adjust pH to 7.4 
Adx elution buffer 50 mM sodium phosphate, 1 M KCl; adjust pH to 7.4 
 
7.1.8.5.4 AdR 
Table 31: Buffers used for purification of AdR using columns packed with Source Q, 2-5 ADP Sepharose or DEAE-Sepharose. 
Buffer Components and preparation 
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AdR equilibration buffer 10 mM potassium phosphate, 1 mM EDTA, 1 mM PMSF; 
adjust pH to 8 
AdR elution buffer (2-5 
ADP Sepharose) 
10 mM potassium phosphate, 1 mM EDTA, 1 mM PMSF, 
400 mM NaCl; adjust pH to 8 
AdR elution buffer (DEAE 
Sepharose) 
10 mM potassium phosphate, 1 mM EDTA, 1 mM PMSF, 
500 mM NaCl; adjust pH to 8 
 
7.1.8.5.5 Pdx 
Table 32: Buffers used for purification and storage of Pdx. 
Buffer Components and preparation 
Pdx equilibration buffer 500 mM NaCl, 10 mM β-mercaptoethanol in 50mM sodium 
phosphate buffer, adjust pH to 7.4 
Pdx wash buffer 500 mM NaCl, 20 mM imidazole, 10 mM β-mercaptoethanol in 
50 mM sodium phosphate buffer, adjust pH to 7.4 
Pdx elution buffer 500 mM NaCl, 500 mM imidazole, 10 mM β-mercaptoethanol in 
50 mM sodium phosphate buffer, adjust pH to 7.4 
Pdx storage buffer 50 mM TRIS, 10 mM β-mercaptoethanol, 20% (v/v) glycerol in aq. 
dest., adjust pH to 7.4 
 
7.1.8.5.6 PdR 
Table 33: Buffers used for purification and storage of PdR. 
Buffer Components and preparation 
PdR equilibration buffer 300 mM NaCl, 5% (v/v) glycerol in 50 mM sodium phosphate 
buffer, adjust pH to 7.4 
PdR wash buffer 300 mM NaCl, 10 mM imidazole, 5% (v/v) glycerol in 50 mM 
sodium phosphate buffer, adjust pH to 7.4 
PdR elution buffer 300 mM NaCl, 150 mM imidazole, 5% (v/v) glycerol in 50 mM 
sodium phosphate buffer, adjust pH to 7.4 




Table 34: Buffers used for purification and storage of CPR (adapted from Girhard et al. 2013[145]). 
Buffer Components and preparation 
CPR equilibration buffer 50 mM TRIS, 500 mM NaCl in aq. dest., adjust pH to 7.5 
CPR wash buffer 50 mM TRIS, 500 mM NaCl, 15 mM imidazole in aq. dest., adjust 
pH to 7.5 
CPR elution buffer 50 mM TRIS, 500 mM NaCl, 100 mM imidazole in aq. dest., adjust 
pH to 7.5 
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CPR storage buffer 50 mM TRIS, 25 mM NaCl, 5% (v/v) glycerol in aq. dest., adjust pH 
to 7.5 
 
7.1.8.5.8 Human CYP17A1 
Table 35: Buffers used for purification and storage of human CYP17A1 (adapted from Petrunak et al. 2014[110]) 
Buffer Components and preparation 
CYP17A1 equilibration buffer 50 mM TRIS, 300 mM NaCl, 0.2% (v/v) Emulgen 913, 20% 
(v/v) glycerol in aq. dest., adjust pH to 7.4 
CYP17A1 wash buffer 50 mM TRIS, 300 mM NaCl, 100 mM glycine, 0.2% (v/v) 
Emulgen 913, 20% (v/v) glycerol in aq. dest., adjust pH to 
7.4 
CYP17A1 elution buffer 50 mM TRIS, 300 mM NaCl, 100 mM glycine, 80 mM 
histidine, 0.2% (v/v) Emulgen 913, 20% (v/v) glycerol in aq. 
dest., adjust pH to 7.4 
CYP17A1 storage buffer 50 mM TRIS, 50 mM NaCl, 100 mM glycine, 20% (v/v) 
glycerol in aq. dest., adjust pH to 7.4 
 
7.1.8.5.9 HyPer-3 
Table 36: Buffers used for purification and storage of HyPer-3 (adapted from Bilan et al. 2013[67]). 
Buffer Components and preparation 
HyPer-3 equilibration buffer 
        and wash buffer 
40 mM TRIS, 150 mM KCl, 10 mM MgSO4, 5 mM β-
mercaptoethanol in aq. dest., adjust pH to 7.5 
HyPer-3 elution buffer 40 mM TRIS, 150 mM KCl, 10 mM MgSO4, 400 mM imidazol 
in aq. dest., adjust pH to 7.5 
HyPer-3 storage buffer 40 mM TRIS, 150 mM KCl, 10 mM MgSO4, 5 mM β-




Table 37: Buffers and solution recipes needed for SDS-PAGE.  
Buffer / solution Components and preparation 
Lower TRIS buffer 18.2 g TRIS, 0.1 g SDS in 100 mL aq. dest., adjust pH to 8.8 
Upper TRIS buffer 6 g TRIS, 0.1 g SDS in 100 mL aq. dest., adjust pH to 6.8 
APS solution 10% ammonium persulfate in aq. dest. 
Separation gel (12%) 2.677 mL aq. dest., 2 mL lower TRIS buffer, 3.33 mL acrylamide 
solution, mix by inverting, add 40 µL APS solution and 4 µL TEMED, 
pour gel immediately 
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Stacking gel (4%) 2.47 mL aq. dest., 1 mL upper TRIS buffer, 3.33 mL acrylamide 
solution, mix by inverting, add 40 µL APS solution and 4 µL TEMED, 
pour gel immediately 
Loading buffer 20% (w/v) glycine, 6% (w/v) 2-mercaptoethanol, 0.0025% 
bromophenol blue in Upper TRIS buffer 
Protein Ladder Roti®-Mark STANDARD (Carl Roth, Karlsruhe, Germany) 
PageRulerTM Unstained Protein Ladder (Thermo Fisher Scientific, 
Waltham, USA) 
Running buffer 3.03 g TRIS, 14.4 g glycine, 1 g SDS in 1000 mL aq. dest., adjust pH to 
8.4 
Staining solution 1 g Coomassie-brilliant-blue G250, 100 mL glacial acidic acid, 300 mL 
ethanol, 600 mL aq. dest. 
Destaining solution 300 mL ethanol, 100 mL glacial acidic acid, 600 mL aq. dest. 
 
7.1.8.7 Ampliflu RedTM Assay 
Table 38: Buffers and solutions used for the Ampliflu RedTM assay. 
Buffer / solution Components and preparation 
Buffer A 50 mM sodium phosphate in aq. dest., adjust pH to 7.4 
Ampliflu RedTM stock 
solution (100x) 
10 mM Ampliflu RedTM in DMSO 
HRP stock solution 
(100x) 
20 U mL-1 HRP in aq. dest. 
Ampliflu RedTM assay 
solution 
1x Ampliflu RedTM, 1x HRP in 50 mM sodium phosphate (pH 7.4) 
 
7.1.8.8 Biocatalysis 
Table 39: List of used buffers and solutions for biocatalytic approaches. 
Biocatalytic 
approach 




HEPES buffer 20 mM HEPES, 50 mM KCl and 0.1 mM DTT, 
adjust pH to 7.3  
 2x DOPC vesicle solution 
containing cholesterol 
Preparation of vesicles with 3.4 mg mL-1 
DOPC, 3.5 mM cholesterol (added with 
DOPC, before vesicle preparation) 
 20x D-Glucose 2 mM glucose, dissolve in ddH2O 
 20x GDH solution 10 mg mL-1 GDH 105, dissolve in ddH2O 
 10x NAD(P)H stock 1,5 mM NAD(P)H, dissolve in ddH2O 





Microelement solution I 4.07 g L-1 FeCl2·6H2O, 0.28 g L-1 CaCl2·2H2O, 
0.28 g L-1 CoCl2·6H2O, 0.19 g L-1 ZnCl2·4H2O, 
0.26 g L-1 CuSO4·5H2O, 0.07 g L-1 H3BO4, 
dissolve in ddH2O 
 Microelement solution II 0.28 g L-1 Na2MoO4·2H2O, dissolve in ddH2O 









10 mM progesterone, dissolve in EtOH 





10 mM progesterone, dissolve in EtOH 
 
7.1.8.9 Dual screening approach 
Table 40: Used chemicals and buffers for the investigations on the dual screening approach. 
Chemical/Buffer Company/Preparation 
Assay buffer 50 mM sodium phosphate, dissolve in aq. dest.; adjust pH to 
7.4 (additionally, other pH values were investigated) 
HFE-7500 3MTM NovotecTM; 
Referred to as HFE-7500 
Fluorochem Ltd. (Hadfield, United Kingdom) 
 
7.1.9 Equipment 
Table 41: Used equipment. 
Equipment Name Producer 
Agarose 
electrophoresis 
Mini-Sub Cell GT 
Compact XS/S 
Bio-Rad (Munich, Germany) 





MC1 Analytic AC 120S 
Kern & Sohn GmbH 
(Belingen, Germany) 
Ohaus (Parsippany, USA) 
Sartorius (Göttingen, 
Germany) 




Thermo Fisher Scientific 
(Waltham, USA) 
Thermo Fisher Scientific 
(Waltham, USA) 







Thermo Fisher Scientific 
(Waltham, USA) 
Thermo Fisher Scientific 
(Waltham, USA) 
Biozym Scientific (Oldendorf, 
Germany) 
Cell lysis  Sonoplus HD/UW 2070 
Equipped with: 
Ultrasonic horn MS72 
Ultrasonic horn KE76 
Bandelin (Berlin, Germany) 
 
Bandelin (Berlin, Germany) 
 
Cleanbench HeraSafe KS15 Thermo Fisher Scientific 
(Waltham, USA) 
FPLC ÄKTApurifier GE Healthcare 
(Buckinghamshire, United 
Kingdom) 







Heating-/stirring plate RCT basic IKA Labortechnik (Staufen, 
Germany) 
Homogenization FastPrep-24 MP Biomedicals, Inc. 
(Eschwege, Germany) 
HPLC LaChrom L7100  
 
Equipped with 
L7100 pump, L7420 UV-Detector, 
L7200 Autosampler, D7000 
Interface 
Merck Hitachi (Darmstadt, 
Germany  
 











Infors AG (Bottmingen, 
Switzerland) 
Infors AG (Bottmingen, 
Switzerland) 
pH-meter PH211 Hanna Instruments 
(Vöhringen, Germany) 
Photometer Jasco V-550 with PSC-498T 
Temperature controller 
Jasco Analytical Instruments 
(Easton USA) 




Peqlab (Erlangen, Germany) 
Shimadzu (Duisburg, 
Germany) 




Standard Power Pack 25 




Protein electrophoresis Minigel-Twin  Biometra (Göttingen, 
Germany) 















DNA Engine Tetrad® 2 
Analytic Jena (Jena, 
Germany) 
Analytic Jena (Jena, 
Germany) 
BioRad (Hercules, USA) 
Thermoshaker Thermomixer comfort Eppendorf (Hamburg, 
Germany) 
UV table Benchtop UV Transiluminator UVP (Upland, USA) 
Vortex Vortex Genie 2 Scientific Industries 
(Bohemia, USA) 
96-well plate reader Infinite® M200PRO Tecan Trading AG 
(Männedorf, Switzerland) 
7.2 Methods 
7.2.1 Microbiological and Molecular-biological Methods 
7.2.1.1 Strain maintenance 
For storage of transformants and strains, they were kept on agar plates (LB for E. coli and 
YPD for S. cerevisiae) and stored at 4°C. If a selection method could be used, the plates 
contained the according substances. For longer storage at 4°C, fresh plates were prepared 
every 6 – 8 weeks. 
For long-term storage, also glycerol stocks were prepared for each strain / transformant. 
Here, 1 mL overnight culture was mixed 1:1 with a 60% glycerol solution. These vials were 
stored at -80°C. 
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7.2.1.2 Preparation of overnight cultures 
For the preparation of overnight cultures, 5 mL medium containing appropriate selection 
marker(s) (LB for E. coli and YPD for S. cerevisiae) were inoculated with single colonies picked 
from agar plates or 10 µL glycerol stock. These cultures were grown overnight (E. coli at 37°C 
and S. cerevisiae at 30°C). 
7.2.1.3 Preparation of competent cells 
7.2.1.3.1 Preparation of chemical competent E. coli cells 
For the preparation of chemical competent E. coli cells, 100 mL LB medium were inoculated 
from an overnight culture and grown at 37°C at 200 rpm until OD600 of 0.5 was reached. Next, 
the cells were harvested for 15 min at 4°C and 4000 g. The pellet was resuspended in 30 mL 
pre-cooled Tfb I buffer. Afterwards 3.2 mL 1 M pre-cooled MgCl2 was added and the cells were 
kept on ice for 15 min. After another centrifugation step for 10 min at 4000 g and 4°C, the 
supernatant was discarded, and the cell pellet was resuspended in 4 mL pre-cooled Tfb II 
buffer. The suspension was incubated on ice for 15 min, followed by separation into 50 µL 
aliquots, which were shock-frozen in liquid nitrogen. The aliquots were stored at -80°C until 
usage. 
7.2.1.3.2 Preparation of electrocompetent E. coli cells 
Electrocompetent E. coli cells were prepared by inoculating 500 mL LB medium with 5 mL 
overnight culture. Cells were grown at 37°C and 180 rpm until OD600 of 0.6 was reached. 
Afterwards the cells were cooled on ice for 20 min and centrifuged for 30 min at 4500g at 4°C. 
The cell pellet was than washed three times but resuspended the first time in 500 mL pre-
cooled 10% glycerin solution, the second time in 250 mL ice cold 10% glycerin solution, the 
third time in 20 mL ice cold 10% glycerin solution and finally in 1.5 mL ice cold 10% glycerin 
solution. All centrifugation steps were carried out for 30 min at 4°C and 4500g. The residual 
1.5 mL were split into 50 µL aliquots and stored at -80°C until usage. 
7.2.1.3.3 Preparation of chemical competent S. cerevisiae cells 
For S. cerevisiae, competent cells were always freshly produced and used immediately 
(7.2.1.4.3). 
7.2.1.4 Transformation 
7.2.1.4.1 Transformation of chemical competent E. coli cells 
For each transformation, one aliquot of frozen competent cells was thawed on ice for 
10 min. After incubation with 50 ng µL-1 plasmid DNA on ice for 30 min, the cells were heat-
shocked at 42°C for 45 s in a water bath. Then, the cells were incubated for 5 min on ice and 
500 µL LB-SOC was added. The mixture was incubated at 37°C and 180 rpm for one hour and 
afterwards spread on LB agar plates containing the appropriate antibiotic(s). The plates were 
incubated at 37°C overnight and afterwards stored at 4°C. 
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7.2.1.4.2 Transformation of electrocompetent E. coli cells 
One aliquot of electrocompetent E. coli cells was mixed with 25 ng plasmid DNA (in a 
maximal volume of 10 µL aq. dest). The cells were kept on ice for 30 min and filled into pre-
cooled electroporation cuvettes. After electroporation for 5 ms at 2500V, 1 mL pre-warmed 
LB-medium was added. The solution was incubated for one hour at 37°C and 180 rpm and 
spread on selection plates. The plates were incubated at 37°C overnight and afterwards stored 
at 4°C. 
7.2.1.4.3 Transformation of chemical competent S. cerevisiae cells 
S. cerevisiae cells were grown in 5 mL YPD medium at 30 °C and 180 rpm shaking velocity 
until an OD600 of 0.8 was reached. For each transformation 1.4 mL of the culture were 
harvested with 10000g for 5 min. The supernatant was discarded, and 1 µg plasmid DNA and 
100 µg shredded salmon sperm DNA were added. Afterwards 500 µL LP-Mix and 55 µL DMSO 
were added. After inverting the tube four times, the mixture was incubated for 15 min at room 
temperature. The heat shock was then performed at 42°C for 15 min. The mixture was 
afterwards diluted with 500 µL sterile TE buffer and the cells were harvested for 1 min at 
1000g and washed with 1 mL TE buffer. After centrifugation for 2 min at 2000 g, the cell pellet 
was resuspended in 100 µL TE buffer and platted on YNB agar plates containing the selection 
marker. The plates were incubated at 30°C for three to five days and afterwards stored at 4°C. 
7.2.1.5 Cultivation and Protein Expression 
7.2.1.5.1 CYP102A1 (P450 BM3) 
P450 BM3 was expressed in E. coli BL21 (DE3). For overexpression, 400 mL TB-Amp medium 
supplemented with ampicillin in a 2-L baffled Erlenmeyer flask were inoculated with 4 mL 
overnight culture. Untill OD600 of 0.6 was reached, the cells were grown at 37°C and 160 rpm. 
Then, overexpression was started by addition of 0.25 mM IPTG. The heme-precursor δ-Ala in 
a final concentration of 0.5 mM, was added at the same time. Afterwards, cultivation was 
continued for 48 h at 30°C. The cells were harvested at 4500g for 30 min at 4°C. If not used 
directly, the cell pellets were stored at -20°C until further usage. 
7.2.1.5.2 CYP11A1 
7.2.1.5.2.1 Investigation of Expression using different E. coli strains 
In order to investigate the expression of CYP11A1, E. coli TOP10 (DE3), BL21 (DE3), C41 
(DE3), C43 (DE3) and SHuffle (DE3) were transformed with the pTrc99A_P450scc plasmid. A 
volume of 20 mL LB-Amp medium was inoculated with a certain amount of overnight culture 
to obtain an OD600 of 0.08. Initial growth was performed at 37°C and 135 rpm shaking velocity. 
When the cultures had reached OD600 of 0.5, the temperature was lowered to 30°C or 17°C. 
After addition of 1 mM IPTG and 0.5 mM δ-Ala the cultivation was accomplished overnight at 
30°C and over two days at 17°C. For cell lysis, the pellet was resuspended in 50 mM sodium 
phosphate buffer pH7.5 containing 0.2% Triton-X100 and 1 mM EDTA. Afterwards CO 
difference spectra were recorded. 
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7.2.1.5.2.2 Expression according to Janocha et al. 
Following the protocol of Janocha et al.[188] 50 mL TB-Amp medium were inoculated with 
E. coli JM109 (DE3) ells harboring the pTrc99A_P450scc plasmid and grown at 37°C with 
180 rpm shaking velocity. After reaching OD600 of 1.0, 0.5 mM IPTG and 1 mM δ-Ala were 
added and the incubation temperature lowered to 28°C. With a shaking velocity of 135 rpm, 
cultivation was carried on for another 24 h. After harvesting the cells at 4.000g for 25 min, the 
cell pellet was resuspended in a 50 mM sodium phosphate buffer pH7.0, containing 300 mM 
NaCl, 10 µM cholesterol and 0.1% (w/v) sodium cholate. 
7.2.1.5.2.3 Expression according to Lepesheva et al. 
According to the protocol of Lepesheva et al.[190] 50 mL TB-Amp medium were inoculated 
with E. coli JM109 (DE3) cells harboring the pTrc99A_P450scc plasmid and different 
chaperone plasmids. After growing the cell culture at 37°C and 180 rpm shaking velocity until 
OD600 of 0.6 was reached, the temperature was lowered to 28°C. Induction was accomplished 
by addition of 0.5 mM IPTG. At the same time also 0.5 mM δ-Ala were added (and 3% ethanol 
for one sample). Afterwards cultivation was carried on for 48 h and the cells were harvested 
at 4.000g for 20 min. The cell pellet was resuspended in 20 mM sodium phosphate buffer pH 
7.4, containing 1 mM EDTA, 1 mM DTT and 20% glycerol. After cell lysis, 1% Emulgen 913 was 
drop wise added for 1 h on ice, followed by another centrifugation step at 17.000g for 45 min. 
7.2.1.5.2.4 Expression experiment for determination of optimal timepoint for harvesting 
With the above described conditions of Lepesheva et al. two flasks containing 500 mL TB-
Amp-Chl medium each, E. coli JM109 (DE3) harboring the pTrc99A_P450scc and the pGro7 
plasmid were cultivated. At each sample timepoint (0, 16, 20, 24, 40, 44, 48, 64, 68, 72 h) the 
OD600 of both cultivations was measured. Additionally, 50 mL sample were taken from one 
of the flasks in an alternating fashion. 
7.2.1.5.2.5 Final cultivation conditions  
E. coli C43 (DE3) cells without λ-phage resistance harboring the pTrc99A_P450scc plasmid 
and the pGro7 plasmid, were cultivated in 200 mL TB-Amp-Chl medium in a 2 L baffled flask. 
After reaching OD600 of 0.6, protein expression was induced by addition of 0.5 mM IPTG and 
0.5% L-arabinose. At the same time, 0.5 mM δ-Ala were added. Afterwards, the cultivation 
temperature was lowered to 28°C and the shaking velocity reduced to 95 rpm. After 72 h, the 
cells were harvested and kept on ice or frozen at -20°C. 
7.2.1.5.3 Adx 
With E. coli BL21 (DE3) cells, harboring the pKKHc_Adx plasmid, the protein Adx was 
overexpressed. A volume of 400 mL TB medium containing ampicillin in a 2 L flask was 
inoculated with 4 mL overnight culture and grown at 37°C and 180 rpm until OD600 of 0.5 was 
reached. Overexpression was induced by the addition of 1 mM IPTG. 0.3 mM FeSO4 were 
added at the same time. Cultivation continued at 30°C and 160 rpm for 48 h. Cells were 
harvested by centrifugation at 4500g at 4°C for 30 min. The cell pellet was than either kept on 
ice and used directly or stored at -20°C. 
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7.2.1.5.4 AdR 
For the expression of AdR E. coli BL21 (DE3) were transformed with pET28_AdR and with 
both pET28_AdR and pGro7. E. coli JM109 cells without phage resistance were transformed 
with pBar1607_AdR and with both pBar1607_AdR and pGro7. The cells harboring the 
pET28_AdR plasmid were cultivated in LB-Kan medium, whereas the cells harboring the 
pBar1607_AdR plasmid were cultivated in TB-Amp medium. For cells harboring additionally 
the pGro7 plasmid chloramphenicol was added. All cells were cultivated in 100 ml at 37°C and 
135 rpm until an OD600 of 0.6 was reached. The expression was induced with 1 mM IPTG. 
Afterwards the temperature was lowered to 20°C and cells were harvested after 24 h. 
7.2.1.5.5 Pdx 
Overexpression of the protein Pdx was achieved by cultivation of E. coli BL21 (DE3) 
harboring the pET28a_Pdx plasmid. In a 2 L flask, 400 mL TB medium containing kanamycin 
were inoculated with 4 mL overnight culture. Cells were grown at 37°C and 180 rpm until an 
OD600 of 0.8 was reached. Overexpression was induced by the addition of 1 mM IPTG. At the 
same time, 0.3 mM FeSO4 were added and the temperature was lowered to 30°C. The shaking 
velocity was also lowered to 140 rpm. Cells were harvested after 48 h at 4500g for 30 min at 
4°C. If not used directly, the cell pellets were stored at -20°C until further usage. 
7.2.1.5.6 PdR 
For the overexpression of PdR, E. coli BL21 (DE3) cells were used harboring the pET28a_PdR 
plasmid. With 4 mL overnight culture, 400 mL TB medium containing kanamycin in a 2 L flask 
were inoculated and grown at 37°C and 140 rpm until OD600 of 0.6 was reached. After 
induction with 1 mM IPTG, the incubation temperature was lowered to 20°C. Overexpression 
was stopped after another 48 h cultivation time and the cells were harvested at 4500g at 4°C 
for 30 min. The cell pellets were either used directly and kept on ice or stored at -20°C until 
further usage. 
7.2.1.5.7 BMR 
The reductive domain of P450 BM3 was overexpressed in E. coli BL21 (DE3), harboring the 
pET28a_BMR plasmid. From an overnight culture, 400 mL TB medium containing kanamycin 
were inoculated in a ratio of 1:100. Cells were grown at 37°C and 180 rpm until overexpression 
was induced with 1 mM IPTG when an OD600 of 0.6 was reached. After lowering the cultivation 
temperature to 30°C and reducing the shaking velocity to 160 rpm, overexpression continued 
for 24 h. Cells were harvested by centrifugation at 4500g for 30 min at 4°C. The resulting cell 
pellet was kept on ice or stored at -20°C for later usage. 
7.2.1.5.8 CPR 
The protein CPR was overexpressed in E. coli BL21 (DE3) cells, harboring the 
pET28a_CPR_His plasmid (adapted from Girhard et al. 2013[145]). 50 mL TB medium containing 
kanamycin was inoculated with 500 µL overnight culture and grown until OD600 of 0.8 was 
reached at 37°C and 180 rpm. Overexpression was started by addition of 0.25 mM IPTG. The 
cultivation temperature was lowered to 25°C and the shaking velocity reduced to 140 rpm. 
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After another 24 h of cultivation, cells were harvested at 4500g for 30 min at 4°C. If used 
directly, the cell pellet was kept on ice or for later usage stored at -20°C. 
7.2.1.5.9 CYP17A1 
7.2.1.5.9.1 Human CYP11A1 
Human CYP17A1 (adapted with slight modifications from Petrunak et al. 2014[110]): 
For expression of a truncated version (deletion of residues 1-19) of human CYP17A1, E. coli 
JM109 was used, harboring the pCW17A1Δ19H plasmid. The overnight culture was grown at 
250 rpm at 37°C. After 18 h 400 mL TB medium containing ampicillin were inoculated with 
4 mL overnight culture. Until OD600 of 0.5 was reached, cultivation conditions were kept the 
same. After induction of the overexpression with 0.5 mM IPTG and the addition of 0.5 mM δ-
Ala, the temperature was lowered to 28°C and the shaking velocity reduced to 140 rpm. After 
72 h, the cells were harvested by centrifugation at 4500g at 4°C for 30 min. Cells were kept on 
ice for direct use or stored at -20°C. 
7.2.1.5.9.2 Bovine CYP11A1 
Bovine CYP17A1 (adapted with slight modifications from Shkumatov et al. 2002[197]): 
The bovine CYP17A1 was expressed in S. cerevisiae, harboring the YEp5117α plasmid. A 
volume of 20 mL YPD medium was inoculated with a single colony picked from an agar plate 
and grown over night at 30 °C and 180 rpm. For the cultivation, 45 mL YPD in a 300 mL 
Erlenmeyer flask were inoculated with 5 mL overnight culture and grown at 30°C and 180 rpm. 
After 24h 5mL D-galactose (20% Stock in ddH2O) and 500 µL progesterone (10 mM Stock in 
ethanol) were added.  
7.2.1.5.10 HyPer-3 
The HyPer-3 protein was expressed using E. coli Shuffle (DE3) cells. With 2 mL overnight 
culture, 200 mL fresh LB medium, supplemented with ampicillin, was inoculated. The cell 
culture was grown at 37°C and 180 rpm for [67] 
7.2.1.6 Cell disruption 
For SDS-PAGE samples, samples were normalized on the basis of their cell counts. 
Therefore, 7 / OD600 samples were taken and harvested by centrifugation at 14000g for 10 min 
at 4°C. The cell pellet was resuspended in 500 µL buffer and lysed by sonication twice on ice 
for 1 min (50% power, 20% cycle). The cell lysate was separated from cell debris by 
centrifugation at 14000g for 15 min at 4°C. Afterwards, the supernatant was transferred to a 
new reaction tube and the pellet, containing insoluble proteins was resuspended in 500 µL 
buffer. 
In order to lyse bigger samples, the cells were harvested at 4°C and 4000g for 1h. The cell 
pellet was resuspended in three times the volume of its weight (5 mL buffer per 1 g cell pellet). 
Cell lyses was obtained by sonication twice, on ice for 6 min (50% power, 20% cycle). 
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7.2.2 Molecular Biological Methods 
7.2.2.1 Plasmid isolation 
Plasmids were isolated by usage of the innuPREP Plasmid Mini Kit (Analytik Jena). All steps 
were performed as described in the manufacturer’s manual, except for the elution step. Here, 
50 µL or 100 µL (for 5 mL or 10 mL culture volume) sterile aq. dest, pre-warmed to 70°C was 
used. 
7.2.2.2 PCR methods 
7.2.2.2.1 Site-directed mutagenesis 
For most site-directed mutagenesis approaches, a standard PCR mixture was used (Table 
42). 
Table 42: Standard PCR mixture as applied for site-directed mutagenesis. Only the concentration of DMSO was variable.  
component One reaction (40 µL) 
PCR buffer C (10x) 5 µL 
DMSO 0.4  µL 
Template DNA 25 ng 
5’ oligo 2  µL 
3’ oligo 2  µL 
dNTPs 2  µL 
OptiTaq 1  µL 
ddH2O Adjust volume to 40 µL 
 
After site-directed mutagenesis was performed, a DpnI digest followed for each approach 
to digest template DNA. Afterwards, the 5 µL were used to transform E. coli TOP10 cells. These 
were grown overnight on agar plates containing appropriate selection marker. For each 
variant, 2 clones were picked to inoculate overnight cultures. From these overnight cultures, 
plasmids were isolated and send of for sequencing to Eurofins genomics (Ebersberg, 
Germany). 
7.2.2.2.1.1 CYP102A1 
For pET22_BM3, site directed mutagenesis was carried out with a standard PCR mixture 
(Table 42) using pET22_BM3 as template. The temperature program was optimized for the 
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Table 43: Temperature program used for the site-directed mutagenesis of P450 BM3. 
step Temperature [°C] Time [s]  
Initial denaturation 95 180  
Denaturation 95 15  
35* Annealing 58 30 
Elongation 72 540 
Final elongation 72 1080  
 15 ¥  
 
7.2.2.2.1.2 CYP11A1 
In order to exchange lysine 193 with glutamic acid in the pTrc99A_P450scc plasmid, site-
directed mutagenesis was performed using a slightly different Master Mix (Table 44). The 
temperature program was similar to the program used for site directed mutagenesis of the 
Cytochrome P450 BM3 gene (Table 43). Only the annealing temperature was different with 
55°C, only 25 cycles were used for amplification, elongation was performed for 390 s and final 
elongation for 780 s. 
 
Table 44: Composition of the Mastermix for 8x25 µL= 200 µL used for site-directed mutagenesis of the CYP11A1 gene. 
Component Volume [µl] 
10x buffer C 25  
dNTPs 5  
primer fw 2,5  
primer rev 2,5  
template (62,7 ng µl-1) 7  
DMSO 1  
Opti Taq 2,5  
ddH2O 110,5  
 
7.2.2.2.1.3 Human CYP17A1 
For the alanine screening performed with the human CYP17A1, site-directed mutagenesis 
was used to exchange different residues to alanine, using pCW17A1Δ19H as template. To the 
standard PCR mixture (Table 42) 0.4 µL DMSO were added and only 0.5 µL of each primer and 
0.5 µL OptiTaq were used. As temperature program, a touch-up program was applied. 
Standard time intervals and temperatures were the same as for the site-directed mutagenesis 
of P450 BM3 (Table 43). Initial denaturation and denaturation were the same. Annealing 
temperature for the first cycle was set to different temperatures depending on the primers 
annealing temperatures. For F114A, Y201A, N202A, I205A, I206A, L209A and R239A an initial 
annealing temperature of 52°C was used, for G297A, G301A, E305A, V482A and V483A 51°C 
and for V336A and I371A 53°C. This temperature was increased for the first 5 cycles by one 
degree each cycle and kept for another 30 cycles afterwards at initial annealing temperature 
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plus 5°C (equals actual annealing temperature. Elongation time was set to 420 s. And final 
elongation to 840 s. 
7.2.2.2.1.4 Bovine CYP17A1 
For the generation of different variants of the bovine CYP17A1, site directed mutagenesis 
was performed, using Yep5117a as template. The standard PCR mixture (Table 42Table 42) 
was changed, by using 0.5 µL of each primer, 100 ng template DNA and only 0.5 µL 
polymerase. The temperature program was similar to the program used for the creation of 
P450 BM3 variants (Table 43). Only, the annealing temperatures were different variants 
(annealing temperatures: 58°C for L482A & V483A; 59°C for G297A & D298A; 60°C for L105A, 
R239A & G301A; 61°C for V201A & L206A; 62°C for N202A, I205A, E305A, T306A, V366A & 
I371A; 64°C for F114A) and a touch-up PCR was performed. Therefore, for the first 5 cycles 
the annealing temperature was lowered 5 degrees from the actual annealing temperature and 
increased with each cycle by one degree. Afterwards, 20 cycles with the actual annealing 
temperature followed.  
7.2.2.2.2 Colony PCR 
In general colony PCR was applied to identify clones harboring the freshly introduced 
plasmid. 
7.2.2.2.2.1 E. coli 
Each clone was picked and streaked out on a master agar plate. The remaining cells were 
suspended in 10 µL colony PCR master mix (Table 45). After amplification (Table 46), all 
samples were analyzed by agarose gel electrophorese. 
 
Table 45: Master Mix E. coli colony PCR. 
component 5 samples [µL] 
PCR buffer C (10x) 5 
DMSO 2.5 
5’ oligo 1 
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Table 46: Temperature program fort the colony PCR of E. coli. 
step Temperature [°C] Time [s]  
Initial denaturation 98 300  
Denaturation 95 30  
40* Annealing Primer dependent 30 
Elongation 72 60 kbp-1 
Final elongation 72 120 kbp-1  
 15           ¥  
 
7.2.2.2.2.2 S. cerevisiae 
Each picked colony was first put on a new agar plate. The remaining cells were lysed by 
incubation in 20 µL 20 mM NaOH at 95°C for 10 min. A volume of 2 µL was used as template 
DNA in the colony PCR master mix (Table 47). After amplification (Table 48) all samples were 
analyzed by agarose gel electrophoresis. 
 
Table 47: Master Mix S. cerevisiae colony PCR. 
component 1 reaction [µL] 
ddH2O 14.55  
PCR buffer C (10x) 2  
dNTPs 0.4  
5’ oligo 0.4  
3’ oligo 0.4  
Taq-polymerase 0.25  
Template DNA 2  
Total 20 
 
Table 48: Temperature program S. cerevisiae colony PCR. 
step Temperature [°C] Time [s]  
Initial denaturation 95 300  
Denaturation 95 30  
30* 
 
Annealing Primer dependant 30 
Elongation 72 60 kbp-1 
Final elongation 72 120 kbp-1  
 15 ¥  
 
7.2.2.2.3 Fast cloning 
As backbone pET28a(+)_BMR was chosen and amplified with primers binding directly in 
front of the BMR gene. Those primer had 30bp overhangs coding for the start and end 
sequence of P450scc. As insert the P450scc gene was amplified from the pTrc99a_scc plasmid. 
Material and Methods 
 119 
The whole gene without the stop codon was amplified adding also 30bp fitting overhangs to 
both ends. After dpnI digest a PCR clean-up was performed. After determining the 




(𝑏𝑎𝑠𝑒	𝑝𝑎𝑖𝑟𝑠 ∗ 650	𝑑𝑎𝑙𝑡𝑜𝑛𝑠) 
Equation 1: Equation for calculating concentration of correctly folded Cytochrome P450 enzyme, from values determined 
by the recorded difference spectrum. 
For the fast cloning approach a molar ratio of backbone to insert of one to three was 
chosen.  
7.2.2.2.4 DpnI digestion 
After each performed PCR, DpnI (New England BioLabs® Inc., Ipswich, USA) digest of the 
template PCR needs to be performed. A volume of 0.5 µL enzyme solution was added to 10 
µL of sample volume. The digestion was performed at 37°C for 2 h, followed by a heat 
inactivation of the enzyme at 80°C for 20 min. 
7.2.2.3 Quantification of DNA  
7.2.2.3.1 NanoDrop 
Determination of DNA concentrations was achieved by usage of the UV-Vis photometer 
NanoDrop. The device measures absorbance at a wavelength of λ=260 nm. Additionally, other 
important wavelengths are measured to assure the purity of the DNA sample. 
7.2.2.3.2 Agarose gel electrophoresis 
For separation of DNA fragments or plasmids by size, agarose gel electrophoresis was 
applied. The agarose gel was prepared with TAE buffer, which was heated until boiling in the 
microwave oven to solve the appropriate amount of agarose. 5 µL of RotiÒ-GelStain (Carl 
Roth) were added per 100 mL agarose solution for later visualization of DNA. The gel was 
casted and left for cooling. Samples were prepared by mixing with 6x loading dye (1:6). After 
applying 6 µL of each sample and 5 µL DNA ladder (1kbp DNA ladder, Carl Roth), the gel was 
run at 110 V for 25 min. The final result was investigated after illumination on a UV table. 
7.2.3 Biochemical Methods 
7.2.3.1 Protein purification 
7.2.3.1.1 Hand columns 
In general, approximately the same protocol was used for all proteins if hand columns were 
used for purification (CYP102A1, CYP11A1, Pdx, PdR, CPR, BMR, human CYP17A1 and HyPer-
3). When the cell pellet was stored at -20°C, it was thawed slowly on ice and washed two times 
with equilibration buffer. After cell lyses in equilibration buffer, by sonication, the crude cell 
lysate was separated by centrifugation at 10000g for 1 h at 4°C. After filtering the supernatant 
with a 0.45 µm filter, the His-tagged enzyme was purified on a Ni-NTA hand column 
(Roti®garose-His/Ni Beads, Carl Roth GmbH & Co. KG, Germany). First, the column was washed 
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and preequilibrated with five column volumes (5 CV) of equilibration buffer, followed by 
loading of the filtered supernatant. After washing the column with 2 CV of wash buffer, the 
protein was eluted. Elution was obtained with 2 CV of elution buffer. Only eluate with strong 
color (for P450: red-brownish, for Adx & Pdx dark brown and for AdR, PdR, CPR, BMR and 
Hyper-3 yellow-greenish) was collected. Afterwards, the eluted protein sample was desalted 
and stored in storage buffer or used immediately. 
7.2.3.1.2 CYP11A1 
In addition to using hand columns for the purification of CYP11A1, purification experiments 
using the ion exchange technique with a column packed with SP-Sepharose were performed. 
For purification, the ÄKTApurifier was used. After equilibrating the whole system with the 
used buffer, the column was washed with 5 CV equilibration buffer. Afterwards the protein 
was loaded onto the column and elution was accomplished by a linear gradient over 5 CV 
changing gradually from the equilibration buffer to the elution buffer. 
7.2.3.1.3 Adx 
For the purification of Adx, anion exchange chromatography using a column packed with 
DEAE-Sepharose were performed. For purification, the ÄKTApurifier was used. After 
equilibrating the whole system with the used buffer, the column was washed with 5 CV 
equilibration buffer. Afterwards the protein was loaded onto the column and elution was 
accomplished by a linear gradient over 10 CV changing gradually from the equilibration buffer 
to the elution buffer. 
Additionally gelfiltration was accomplished using Superdex G200 material. For this 
approach, also the system was equilibrated with equilibration buffer and afterwards, the 
column was washed with equilibration buffer. The protein was loaded on the column and the 
protein eluted with the same buffer.  
Furthermore, hydrophobic interaction chromatography with a column packer with 
Phenylsepharose was performed. The same method as for the affinity chromatography was 
applied.  
7.2.3.1.4 AdR 
For AdR anion exchange chromatography was performed using a column packed with 
Source Q material. For purification, the ÄKTApurifier was used. After washing the whole 
system with the used buffer, the column was also equilibrated with 5 CV equilibration buffer. 
After loading the protein solution on the column, elution was accomplished by a linear 
gradient over 10 CV changing gradually from the equilibration buffer to the elution buffer. 
Additionally, affinity chromatography was performed using 2-5 ADP-Sepharose and anion 
exchange chromatography using a column packed with DEAE-Sepharose. Here, the same 
procedure was used as described for anion exchange chromatography. 
7.2.3.2 Desalting 
All obtained elution fraction from protein purification were desalted using PD-10 columns 
(GE Healthcare, Freiburg, Germany). Desalting was performed as suggested from the 
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manufacturer. Which buffer was used for elution from the column was different for all 
proteins. For most, the storage buffer was used. 
7.2.3.3 Protein quantification 
7.2.3.3.1 BCA assay 
Protein concentrations of samples was determined using the PierceTM BCA Assay Kit 
(Thermo Fisher Scientific, Waltham, USA). The assay was performed according to the 
manufacturer’s instructions for the 96-well plate format. After incubation for at least 30 min 
at 37°C, the absorbance of all samples at λ=562 nm was determined. BSA standard solutions 
were always prepared fresh with the same buffer, the samples contained. 
7.2.3.3.2 CO assay for P450 enzymes 
The final P450 concentration obtained was determined using the CO assay as described by 
Omura et al. 1964.[32] The 2 mL sample was mixed with 2 μM safranin T as a redox indicator 
(Zitat: F.P. Guengerich et al., Measurement of cytochrome P450 and NADPH-cytochrome P450  
reductase. Nat Protoc, 2009, 4(9), followed by addition of one spatula tip of sodium 
dithionite. By slowly inverting the tube, the solution was mixed and 1 mL each was transferred 
in a new cuvette. In one cuvette approximately 1 bubble min-1 CO-gas is applied for 1 min. The 
other sample is measured as blank. Then, a spectrum is recorded between λ=400 nm and 
λ=500 nm (Table 49). With this difference spectrum, the concentration of Cytochrome P450 




1	𝑐𝑚 ∙ 91	𝑚𝑀FG𝑐𝑚FG 
Equation 2: Equation for calculating concentration of correctly folded Cytochrome P450 enzyme, from values determined by 
the recorded difference spectrum. 
 
Table 49: Settings used for the recording of CO difference spectra using the Jasco device. 
Parameter Setting 
Wavelength 500 - 400 nm 
Photometric mode Abs 
Response medium 
UV/Vis bandwidth 0.2 nm 
Scan speed 200 nm/min 
Delta interval 1 nm 
Scan mode Continuous 
Number of cycles 1 
Vertical scale Auto 1 - 0 
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7.2.3.4 Substrate binding spectra of Cytochrome P450 enzymes 
With the same general settings (Table 49), as described for the CO difference spectrum, 
substrate binding spectra can be recorded between 500 nm and 350 nm. Therefore, a 
Cytochrome P450 sample is measured as blank sample. After addition of substrate solution 
(10 mM cholesterol in 45% aqueous 2-hydroxypropyl-β-cyclodextrin diluted to final 
concentration of 0.2 mM for CYP11A1; 10 mM progesterone in pure ethanol, diluted to a final 
concentration of 0.2 mM for CYP17A1) the difference spectra were recorded, resembling the 
substrate binding spectra. 
7.2.3.5 Investigation of the sensitivity of HyPer-3 towards hydrogen peroxide 
With 5 µM of the purified HyPer-3 protein in storage buffer, were incubated with 20 mM, 
10 mM, 5 mM, 2.5 mM, 1 mM and without hydrogen peroxide. The absorption was monitored 
at 420 nm and 500 nm over 10 min. 
7.2.3.6 AmplifluTM Red Assay 
For the parallel detection of hydrogen peroxide production and NADPH consumption, the 
AmplifluTM Red assay was performed in a microtiter plate-based format. In general, 100 µL 
sample were mixed with 100 µL of the AmplifluTM Red assay solution. For all measurements 
standards were incubated with different hydrogen peroxide concentrations (100 µM, 50 µM, 
25 µM, 10 µM, 5 µM, 2.5 µM and 1 µM), enabling a correct calculation of the exact hydrogen 
peroxide concentrations in the investigated samples. Absorption measurement was 
accomplished at λ=560 nm for resorufin and λ=340 nm for NADPH detection. If fluorescence 
measurement was performed for excitation λexcitation=550 nm and for emission 
λemission=590 nm were used. If an enzymatic reaction was investigated, a 1.2 µM stock solution 
of Cytochrome P450 BM3 wild-type and variants was added and diluted in a ration of 1:4 in 
the final reaction. All samples were measured in triplicates. 
7.2.3.6.1 Investigating the optimal enzyme concentration for the AmplifluTM Red Assay 
In order to investigate the optimal enzyme concentration used for the AmplifluTM Red 
assay, purified 50 µL Cytochrome P450 BM3 solutions containing 5 µM, 2.5 µM, 1.2 µM and 
0.6 µM enzyme were incubated with 50 µM NADPH and 100 µL of the AmplifluTM Red solution. 
The reaction was monitored by absorption measurements over a reaction time of 8 min. All 
samples were measured in triplicates. 
7.2.3.6.2 Investigation of the hydrogen peroxide formation and NADPH depletion of Cytochrome P450 
BM3 wild-type and 5 mutants 
For the investigation of the hydrogen peroxide formation and NADPH depletion in the 
reaction of Cytochrome P450 BM3 wild-type and 5 different mutants, 50 µL purified enzyme 
(1.2 µM in buffer A), 10 µL substrate solution (1 mM in ethanol: lauric acid, oleic acid, palmitic 
acid, pentadecanoic acid and 1-octanol or for measurements without substrate only ethanol), 
10 µL NADPH (1 mM stock in buffer A) and 30 µL buffer A were incubated with 100 µL of the 
AmplifluTM Red Assay solution. Both, the NADPH and resorufin concentration were detected 
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by absorption measurement in parallel over 10 min reaction time. As negative controls, the 
enzyme solutions were incubated without addition of NADPH or substrate with AmplifluTM 
Red Assay solution. Additionally, all substrates solutions were incubated separately as well as 
NADPH and substrate with NADPH in combination, without enzyme present were incubated 
with the AmplifluTM Red Assay solution. All samples were measured in triplicates. 
7.2.3.6.3 Control reactions to investigate the AmplifluTM Red Assay further 
With Cytochrome P450 BM3 wild-type several control reactions were performed. The 
enzyme (1.2 µM stock, 1:4 diluted in final reaction; in 50 mM sodium phosphate buffer pH 7.4) 
was incubated with and without NADPH. Additionally, for one sample no HRP was added and 
one sample contained NADPH and 20 U mL-1 Catalase. A last sample contained NADPH and 
2 U mL-1 superoxide dismutase (SOD). The concentrations of NADPH and resorufin were 
determined by absorption measurement over a reaction time of 30 min. All samples were 
measured in triplicates. 
7.2.3.6.4 Investigating the uncoupling of CPR from C. apicola 
In order to investigate the uncoupling of CPR from C. apicola, the protein was incubated 
with different NADPH concentrations. Therefore, 0.2 µM purified CPR in buffer A, were 
incubated with 22 µM, 12 µM and 6 µM NADPH (final concentration). 2 U mL-1 of SOD were 
added. For one sample additionally, 20 U mL-1 catalase were added. NADPH and resorufin 
concentrations were determined by absorption measurement over a reaction time of 30 min. 
All samples were measured in triplicates. 
7.2.3.7 Biocatalysis 
7.2.3.7.1 In vitro biocatalysis with the bovine CYP11A1 
Biocatalysis with the purified bovine CYP11A1 enzyme was in general performed in 20mM 
HEPES buffer with a pH of 7.3 containing KCl and DTT. Each sample had a final volume of 1 mL 
containing 1.7mg DOPC and 1.75mM cholesterol. For biocatalysis, 0.4 µM CYP11A1 was used, 
Pdx was used in a concentration of 5 µM, Adx 0.5 µM, PdR 0.4 µM, BMR 5 µM and 1.5 mM 
NAD(P)H. For NAD(P)H recycling 0.1 mM glucose and GDH 105 was added in an unknown 
concentration to some samples. All samples were incubated at 37°C for 16 h and 300 rpm 
shaking velocity, if not indicated otherwise (t0=sample immediately extracted after 0 h) 
 
Table 50: Overview of the sample composition from the first biocatalytic approach. The concentration of the Glucose- 
Dehydrogenase (GDH 105 from Codexis) was unknown.  
sample CYP11A1 Pdx Adx PdR CPR Glucose GDH NADH NADPH 
1 + + - + - + + + - 
2 + - - - + + + - + 
3 + - + + - + + + - 
4 + - - - - + + + - 
5 - + - + - + + + - 
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6 - - - - + + + - + 
7 - - + + - + + + - 
8 + + - + - - - + - 
9 (t0) + - - - + - - - + 
 
Table 51: Overview of the sample compositions from the second biocatalysis approach.  
sample P450 BMR Pdx PdR NADPH NADH timepoint temperature 
1 + + - - + - t0  
2 + + - - + - 10 min 20 
3 + + - - + - 1h 20 
4 + + - - + - o.n. 20 
5 + + - - - - o.n. 20 
6 + + - - + - 10 min 30 
7 + + - - + - 1h 30 
8 + + - - + - o.n. 30 
9 + + - - - - o.n. 30 
10 + - + + - + t0  
11 + - + + - + 10 min 20 
12 + - + + - + 1h 20 
13 + - + + - + o.n. 20 
14 + - + + - - o.n. 20 
15 + - + + - + 10 min 30 
16 + - + + - + 1h 30 
17 + - + + - + o.n. 30 
18 + - + + - - o.n. 30 
19 + - - - + + t0  
20 + - - - + + o.n. 20 
21 + - - - + + o.n. 30 
22 - + - - + + t0  
23 - + - - + + o.n. 20 
24 - + - - + + o.n. 30 
25 - - + + + + t0  
26 - - + + + + o.n. 20 
27 - - + + + + o.n. 30 
28 + + + + + + o.n. 30 
29 + + + + + + o.n. 30 
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7.2.3.7.2 Whole cell biocatalysis with the bovine CYP11A1 
With E. coli TOP10 (DE3) cells harboring the pBar_Triple plasmid, coding for all three 
proteins of the CYP11A1 system, whole cell biocatalysis according to Makeeva et al. was 
performed.[89] A volume of 50 mL TB-Amp medium was inoculated with 1% overnight culture. 
After incubation at 37°C and 160 rpm shaking velocity for four hours, 1 mM IPTG, 0.5 mM δ-
Ala and 50 µL of each microelement solution were added. The incubation temperature was 
lowered to 29°C and after another two hours of cell growth, 0.5 mM cholesterol (final 
concentration) were added. At 24°C and 180 rpm shaking velocity, whole cell biocatalysis was 
performed for 74 h. In the end 10 mL of the cultivation were extracted and analyzed by HPLC. 
7.2.3.7.3 Human CYP17A1 
In the in vitro biocatalysis approach, E. coli JM109 (DE3) cell lysate containing human 
CYP17A1 was used. For each sample 100 µM progesterone were incubated with 4 µM 
CYP17A1, 0.5 µM PdR & 2.5 µM Pdx or 2.5 µM CPR and 100 µM NAD(P)H. For the Pdx/PdR 
system NADH was used and for CPR NADPH. All samples were incubated at 30°C at 600 rpm 
shaking velocity for 24 h, if not stated otherwise.  
 
Table 52: Sample composition for the investigation of the redox partner system for human CYP17A1. 
sample CYP17A1 Pdx/PdR CPR NADH NADPH substrate 
1 (t0) + + + + + + 
2 + + - + - + 
3 + + - - - + 
4 + - + - + + 
5 + - + - - + 
6 + - - + + + 
7 - + + + + + 
 
Table 53: Sample composition for the biocatalytic comparison between CYP17A1 wild-type (wt) and T306A (T) (++ = double 
the original concentration). 
sample CYP17A1 Pdx/PdR NADH substrate 
1 t0 + wt + + + 
2 - + + + 
3 + wt + + + 
4 + wt + ++ + 
5 + wt + - + 
6 + wt - + + 
7 + wt + + - 
8 + T306A + + + 
9 + T306A + ++ + 
10 + T306A - + + 
11 + T306A + - + 
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With CYP17A1 wild-type and the alanine variants, biocatalysis using crude lysate was 
performed using 0.5 µM PdR, 2.5 µM Pdx or 2.5 µM CPR and 25 µM NAD(P)H for the 
transformation of 100 µM progesterone. All samples were incubated at 30°C at 600 rpm 
shaking velocity for 24 h. For each variant, one sample contained CPR, one sample Pdx/PdR. 
As negative controls for each variant one sample contained no redox partner system, one 
sample was incubated without substrate present. 
7.2.3.7.4 Bovine CYP17A1 
7.2.3.7.4.1 Whole cell biocatalysis 
Whole cell biocatalysis with the bovine CYP17A1 was performed according to Shkumatov 
et al. with slight modifications.[197] The bovine CYP17A1 was expressed in S. cerevisiae, 
harboring the YEp5117α plasmid. A volume of 20 mL YPD medium was inoculated with a single 
colony picked from an agar plate and grown over night at 30°C and 180 rpm. For the 
cultivation, 39.5 mL YPD in a 300 mL Erlenmeyer flask were inoculated with 5 mL overnight 
culture and grown at 30°C and 180 rpm. After 24 h, 5 mL D-galactose (20% Stock in ddH2O) 
and 500 µL progesterone (10 mM Stock in ethanol) were added. After another 24 h of growth, 
cultivation was determined.  
For the investigation of the time dependent conversion, at different timepoints (4, 6, 8, 10, 
12, 14, 16, 24 h) 2 mL samples were taken, extracted and analyzed by HPLC. For whole cell 
biocatalysis with the alanine variants, only 2 samples were taken for each flask (0 h and 24 h). 
7.2.3.7.4.2 Preparative whole cell biocatalysis with bovine CYP17A1 V483A 
The afore mentioned whole cell biocatalysis approach was scaled up. In a total volume of 
1 L split in two times 500 mL YPD in two 5 L Erlenmeyer flasks, 100 mg progesterone were 
converted (314.14 µM). The cultivation time was expanded to 72 h. At the end, 2 mL samples 
were taken for the usual HPLC analysis. The rest of the supernatant was stored at -20°C until 
further usage. 
7.2.3.8 Investigation of the stability of human CYP17A1 wild-type and 12 alanine variants 
In order to investigate, whether the stability of the human CYP17A1 wild-type enzyme and 
the different alanine variants showed higher percentage of correct folded enzyme in other 
buffers, the cell pellets were resuspended in different buffers and lysed. As buffers, sodium 
phosphate buffer (50 mM sodium phosphate buffer pH 7.4, 20 % (w/v) glycerol; buffer 1), a 
Tris-HCl buffer (50 mM TRIS-HCl pH 8, 1 mM EDTA, 20% (w/v) glycerol; buffer 2), the buffer 
best suitable for IMAC purification of CYP11A1 (50 mM potassium phosphate pH7.4, 20% 
(w/v) glycerol, 1.5% sodium cholate, 500 mM sodium acetate, 1.5% Tween-20, 0.1 mM EDTA, 
0.1 mM DTT, 0.1 mM PMSF from Mosa et al. 2014[192], buffer 3), another TRIS-HCl buffer, 
containing EDTA and sorbitol (50mM TRIS pH 8, 1 mM EDTA, 0.6 M sorbitol from Dhir et al. 
2007[199]; buffer 4), a potassium phosphate buffer (100mM potassium phosphate pH7.4, 
50mM NaCl from Khatri et al. 2014[198]; buffer 5) and a MOPS buffer (50mM MOPS pH7.4 from 
Barnes et al. 1991[200]; buffer 6) were used. 
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Afterwards, CO difference spectra were recorded in order to investigate whether more 
correct folded protein was obtained. Additionally, substrate binding was investigated with 
progesterone as substrate in buffer 2. Furthermore, the melting temperatures were 
investigated using the NanoTemper device with the standard settings and a temperature 
range from 20°C to 90°C. 
7.2.3.9 Dual screening 
7.2.3.9.1 Investigating the substrate to NADPH ratio 
To investigate the optimal substrate (11-(4-trifluoromethylcoumarin-7-yloxy)undecanoic 
acid) to NADPH ratio in the dual screening approach, purified Cytochrome P450 BM3 wild-
type, A74G/F87V and F87Y were used (1.2 µM stock, diluted 1:4 in final reaction). And 
different substrate to NADPH ratios used, with constant substrate concentration (10 µM). 
NADPH consumption was monitored at λ=340 nm, product formation at λexcitation=420 nm and 
λemission=500 nm (gain: 100%) and hydrogen peroxide formation at λexcitation=550 nm and 
λemission=590 nm (gain: 50%). The reaction was performed in 50 mM sodium phosphate buffer 
adjusted to pH7.4. All samples were measured in triplicates. 
7.2.3.9.2 Investigating the product formation and hydrogen peroxide formation of five Cytochrome 
P450 BM3 variants 
For the investigation of the uncoupling and product formation in parallel of the five 
Cytochrome P450 BM3 variants (R47L, Y51F, A82L, T268A and I401P), 100 µM substrate (11-
(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid) and 25 µM NADPH were used. The 
enzyme concentration was not determined, but the OD600 of the final culture determined. 
Afterwards, the amount of cells in the pellet were calculated and the concentration set to 1 
cell per 4 pL. With the obtained cell lysate (in 50 mM sodium phosphate buffer, pH7.4) 
biocatalysis was performed. Product formation was monitored at λexcitation=420 nm and 
λemission=500 nm (gain: 100%) and hydrogen peroxide formation at λexcitation=550 nm and 
λemission=590 nm (gain: 50%). The reaction was performed in 50 mM sodium phosphate buffer 
adjusted to pH7.4. All samples were measured in triplicates. 
7.2.3.10 SDS-PAGE 
Protein samples were analyzed under denaturizing conditions by SDS-PAGE analysis. The 
samples were prepared by mixing 20 µL sample with 10 µL loading buffer. The mixture was 
incubated at 95°C for 10 min and afterwards centrifuged briefly for 15 s at 10000g. All samples 
and the protein marker were loaded on the before poured gels and run with 25 mA per gel for 
approximately 45 min or until the running front reached the bottom of the gel. Afterwards the 
gels were stained by incubation in staining solution overnight (Coomassie staining). The next 
day the background of the gels was destained with destaining solution, which was exchanged 
at least twice. The gels were incubated in the destaining solution, until clear protein bands 
and only little to no background color could be observed. 




7.2.4.1.1 Sample preparation for GC-MS analysis 
The samples were prepared following the method described by Saraiva et al.  in 2011 with 
slight modifications.[233] After extracting the samples three times with n-hexane (same volume 
as sample) and evaporation of the solvent under a nitrogen stream, the hydroxyl groups of e 
steroids were derivatized using a mixture of MSTFA (N-methyl-N-(trimethylsilyl)- 
trifluoroacetamide), DTT (1,4-dithioerythritol) and TMIS (trimethyliodosilane). Therefore, a 
volume of 50 μL of the derivatization mixture MSTFA:DTE:TMIS (5000:10:10) was added and 
the sample was incubated at 60°C for one hour. 
7.2.4.1.2 GC-MS analysis of cholesterol and pregnenolone 
The derivatized compounds were analyzed on a BPX5 column (length: 25 m, 
diameter: 0.25 µm). As temperature program, a method at temperatures between 240°C and 
300°C was used (Table 54) using the standard settings of the GC-MS ( 
Table 55). 
 
Table 54: Temperature program used for the analysis of cholesterol and pregnenolone. 
Temperature [°C] Time 
240 Hold 3 min 
Increase with 10°C min-1 6 min 
300 Hold 10 min 
 
Table 55: General settings for GC-MS analysis of cholesterol and pregnenolone. 
parameter setting 
pressure 101.3 kPa 
Total flow 13.4 mL min-1 
Column flow 0.95 mL min-1 
Linear velocity 41.8 cm s-1 
Purch flow 3 mL min-1 
Split 10 
Injector temperature 250°C 
Ion source 240°C 
Interface temperature 310°C 
 
7.2.4.1.3 Sample preparation of whole cell biocatalysis with the CYP11A1 system 
The 10 mL samples were extracted twice, once with 20 mL and once with 10 mL ethyl 
acetate. The organic solvent was separated and evaporated using a rotary evaporator. The 
remaining solids were resuspended in 1 mL 50% aqueous acetonitrile. After centrifugation at 
5000 x g for 30 min, the supernatant of the sample was analyzed by HPLC. 
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7.2.4.1.4 HPLC analysis of whole cell biocatalysis samples 
For HPLC analysis of the samples obtained from whole cell biocatalysis, an isocratic method 
with 52% acetonitrile, 48% water and 0.01% acetic acid were used as mobile phase, at a flow 
rate of 1 mL min-1. As column, the LiChrospher®100 RP-18 (5 μm), a reversed phase C18 
column was used. 
7.2.4.2 CYP17A1 
7.2.4.2.1 Extraction of Steroids 
All 2 mL samples were extracted twice with 2 mL ethyl acetate. The solvent was evaporated 
at room temperature overnight and the sample was resolved in 200 µL methanol. 
7.2.4.2.2 HPLC analysis of Steroids 
A volume of 10 µL of the steroid samples was analyzed with a Kromasil C18 column at room 
temperature under isocratic conditions with acetonitrile:water (60:40) as solvent in a flow 
rate of 1 mL min-1. Or on a LiChrospher® 100 RP-18e (5 µm) column, under the same 
conditions but using acetonitrile:water (40:60) as solvent in a flowrate of 0.8 mL min-1 for 
better separation of all compounds. 
7.2.4.2.3 Extraction of the preparative biocatalysis 
The supernatant of the preparative biocatalysis was extracted trice with 330 mL ethyl 
acetate. Using a rotary evaporator, all solvent was removed, and the residual oily, brown fluid 
was diluted with 500 µL DMSO and 5 mL methanol.  
7.2.4.2.4 Preparative HPLC separation 
For preparative HPLC, 2 mL sample volume were applied per run. As column, a 250x25 mm 
LiChrospher® 100 RP-18e (5 µm) column with acetonitrile:water (40:60) as solvent in a 
flowrate of 30 mL min-1 were used. The different peak fractions were collected manually into 
different flasks. The acetonitrile-water mixture was evaporated using a liquid nitrogen 
evaporator. Afterwards, the residual water was removed in a lyophilizer overnight. 
7.2.4.3 NMR 
NMR analysis was performed with a Bruker Avance II 300 equipped with 5 mm PABBO BB-
1H/D T-GRD Z104275/0398 probehead. Tetramethylsilane was used for the calibration of all 
measurements. As solvent CDCl3 was used to solve the samples. The 1H NMR was recorded at 
200 MHz and the 13C NMR at 75 MHz. 
7.2.5 Chemical methods 
7.2.5.1 AmplifluTM Red Assay 
7.2.5.1.1 Comparison between the spectra of AmplifluTM Red, NADPH and ABTS 
The spectra of AmplifluTM Red, resorufin, ABTS, ABTS. and NADPH in a range of wavelength 
from 275 nm to 700 nm was recorded in buffer A. Final concentrations of AmplifluTM Red and 
ABTS were 10 µM and for NADPH a final concentration of 50 µM was used.  
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7.2.5.1.2 Hydrogen peroxide detection range of the AmplifluTM Red Assay 
For the investigation of the detection range of the AmplifluTM Red Assay, 100 µL of buffer 
A containing different concentrations of hydrogen peroxide (100 µM, 50 µM, 25 µM, 10 µM, 
5 µM, 2.5 µM, 1 µM, 0.5 µM, 250 nM, 100 nM, 50 nM, 25 nM and 10 nM) were incubated with 
100 µL of the standard assay solution. The samples were investigated by both, absorption and 
fluorescence measurement. All samples were measured in triplicates. 
7.2.5.1.3 pH range of the AmplifluTM Red Assay 
For the investigation of the pH range of the AmplifluTM Red Assay the standard hydrogen 
peroxide solutions were produced in buffer A adjusted to pH6.0, 6.5, 7.0, 7.4, 8.0, 8.5 and 9.0. 
100 µL of these samples were incubated with 100 µL of the AmplifluTM Red assay solution 
adjusted to the same pH values. Absorption was monitored over 30 min. All samples were 
measured in triplicates. 
7.2.5.1.4 Signal stability of the AmplifluTM Red Assay 
The signal stability of the AmplifluTM Red Assay was investigated by monitoring the created 
absorption of resorufin upon incubation with the different standard hydrogen peroxide 
solution over 20 min of time. In an additional experiment, 50 µL of crude lysate of E. coli 
TOP10 (DE3) cells (5 mL buffer per 1 g wet cell mass) were incubated with 100 µL AmplifluTM 
Red solution and with 50 µL of the standard hydrogen peroxide solutions with the double 
concentration, to yield the same final concentrations. These samples were incubated for 3 h. 
All samples were measured in triplicates. 
7.2.5.2 Preparation of DOPC vesicles 
40 mg DOPC were dissolved in 3 mL chloroform, afterwards 300 µL methanol were added. 
This mixture was poured into a round bottom flask and carefully overlayed with 20 mL buffer. 
Using a rotary evaporator with an oil bath temperature of 40°C, the solvent was slowely 
evaporated leading to the spontaneous formation of vesicles, visible through a change of 
color.  
7.2.5.3 Dual screening approach 
7.2.5.3.1 Synthesis of 11-(4-trifluoromethylcumarin-7-yloxy)undecanoate 
According to Neufeld et al. 2014, undecanoic acid was chemically linked to the 7,4-HFC 
derivate 7-hydroxy-4-trifluoromethylcoumarin.[24]  
First, 1.25 mmol 7-hydroxy-4-trifluoromethylcoumarin were incubated with 1.42 mmol 
anhydrous potassium carbonate (K2CO3) for 2 h at room temperature in 10 mL DMF. After 
addition of 1.32 mmol methyl 11-bromo undecanoate, the reaction mixture was heated in an 
oil bath to 90°C and incubated for 15 h. Next, the mixture was slowly cooled to room 
temperature under constant stirring. To the cooled reaction mixture, 100 mL ethyl acetate 
were added. With 30 mL of a saturated sodium bicarbonate solution, the reaction mixture was 
washed twice, followed by two washing steps with 30 mL of brine. After drying the organic 
phase with magnesium sulfate, the organic solvent was evaporated to complete dryness.  
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The residual powder was resuspended in 10 mL THF and cooled in an ice bath. Drop-wise 
10 mL of a 0.62 M potassium hydroxide solution was added. After incubating the reaction 
mixture for 2 h on ice, the ice bath was removed and the flask was kept at room temperature 
for another 2 h. Full conversion was confirmed by TLC with different standard and a sample of 
the reaction mixture. A mixture of petrol ether:ethyl acetate in a ratio of 7:3 was used as 
mobile phase.  
The reaction was stopped by addition of 40 mL ice-cold 1 M HCl and the product extracted 
four times with 30 mL dichloromethane. The pooled organic phase was dried with magnesium 
sulfate and the residual volume reduce to approximately 2 mL. The final product was purified 
on a silica column using petrol ether:ethyl acetate in a ratio of 7:3 as mobile phase. 10 mL 
fractions were collected and analyzed by TLC. The fractions containing the product were 
combined and the organic solvent was evaporated using a rotary evaporator.  
10 mg of the product were analyzed by NMR, confirming that the correct product was 
obtained in high purity.  
7.2.5.3.2 Investigating the detection range of HDCF-DA for hydrogen peroxide 
In order to investigation the detection limit of HDCF-DA, the probe was solved in 50 mM 
sodium phosphate buffer adjusted to pH 7.4. A final concentration of 100 µM of HDCF-DA was 
imcubated with 100 µM, 50 µM, 25 µM, 12.5 µM, 5 µM, 2.5 µM, 1.25 µM and 0.5 µM 
hydrogen peroxide (final concentrations). Fluorescence was measured with an excitation 
wahelength of λexcitation=490 nm and an emission wavelength of λemission=520 nm (gain: 50%) in 
96-well plates  
7.2.5.3.3 Signal stability of resorufin and 7-Hydroxy-4-trifluoromethylcoumarin in HFE-7500 
In order to determine in which phase the two probes reside after incubation, 50 mM 
sodium phosphate buffers, adjusted to pH 6.0, 6.5, 7.0, 7.4, 8, 8.5 and 9.0 were used. 50 µM 
of each probe were separately solved in the different buffers (resorufin from a 10 mM stock 
in DMSO). 500 µL of the HFE-7500 oil were overlaid with 500 µL of the different buffers, 
containing the probes. Next, the vails containing the oil and buffer were incubated at 25°C 
and shaken at 1200 rpm. At timepoint 0 h, 2 h, 4 h, 8 h and 24 h, 20 µL samples were taken 
from the buffer. The 20 µL samples were diluted with 80 µL buffer and analyzed with an 
excitation wavelength of λexcitation=560 nm and an emission of wavelength λemission=590 nm 
(gain: 84%) for resorufin, and an excitation wavelength of λexcitation=400 nm and an emission 
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7.2.6 Bioinformatic methods 
7.2.6.1 Used software 
Table 56: List of used important software. 
Software Purpose Developer 
ACD/NMR Processor 
Academic Edition 
Evaluation of NMR-spectra Advanced Chemistry 
Development, Inc.  
Chem Draw 12.0 Creation of chemical molecule 
structures and reaction schemes 
Cambridge Soft 
Geneious Construction of primers and virtual 
cloning, DNA sequence analysis 
and management 
Biomatters, Ltd. 
i-controlTM Software to control the Tecan 
device 
Tecan Trading AG  
PyMol Protein structure visualization Schrödinger, LLC. 
YASARA[205] Generation of homology models 
and docking experiments  
E. Krieger 
 
7.2.6.2 Homology Modeling with YASARA 
The homology model of bovine CYP17A1 was constructed with the YASARA software.[205] 
The software, automatically starts by performing a BLAST search in order to find already 
crystallized sequences, that show high homologies to the submitted template protein. With 
each of these found protein crystals and alignment is performed, which leads in the end to 
the creation of several possible homology models. In addition, a chimera model, consisting of 
the best evaluated parts of all created homology models is created. After a refinement of the 
model with the lowest energy, the YASARA macro md_refine was run, which performs a 
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Figure A 1: Sequence alignement of bovine (CP17A_BOVIN) and human (CP17A_HUMAN) CYP17A1, CYP17A1 












Figure A 2: Chromatogram of the HPLC analysis of the preparative whole-cell biocatalysis of 100 mg progesterone with the 
bovine CYP17A1 V483A in a total cultivation volume of 1 L after 72 h. As column, a Kromasil C18 column was used with a 
flowrate of 0.8 mL min-1 of the mobile phase consisting of ACN:H2O in a ratio of 40:60. The product 17a-hydroxyprogesterone 
can be found at a retention time of 8.683 min, 17a,20a-dihydroxyprogesterone can be found at a retention time of 5.280 min 
and 16a-hydroxyprogesterone can be found at a retention time of 3.880 min. The completely consumed substrate 



















1H NMR (300 MHz, CDCl3): δ 0.68 (s, 3H), 0.98-1.28 (m, 6H), 1.38-1.87 (m, 11H), 1.98-2.07 (m, 2H) ,2.18 (s, 3H) 
,2.25-2.50 (m, 4H), 2.54 (d, J= 6.5 Hz, 1H), 4.83-4.88 (m, 1H), 5.74 (s, 1H). 
 
Figure A 4: 1H-NMR of 16α-hydroxyprogesterone obtained from the preparative biocatalysis. (Figure from second 
publication[202]) 
 
13C NMR (75 MHz, CDCl3): δ 14.60 (C-18), 17.48 (C-19), 20.77 (C-11),31.82 (C-7), 31.83 (C-21), 32.81 (C-6), 34.05 
(C-2), 35.26 (C-8), 35.31 (C-15), 35.76 (C-1), 38.69 (C-10), 38.74 (C-12), 44.92 (C-13), 53.63 (C-14), 53.84 (C-9), 72.19 
(C-17), 73.68 (C-16), 124.24 (C-4), 170.65 (C-5), 199.47 (C-3), 208.40 (C-20). 
 
 
Figure A 5: 13C-NMR of 16α-hydroxyprogesterone obtained from the preparative biocatalysis. (Figure from second 
publication[202]) 
2D NMR techniques were used to annotate the signals. The here observed signals are consistent for data faoun in 
literature for 16α-hydroxyprogesterone.*  
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* a) S. Kille, F. E. Zilly, J. P. Acevedo, M. T. Reetz, Nature Chem. 2011, 3, 738; b) D. Mizrachi, Z. Wang, K. K. Sharma, M. K. 
Gupta, K. Xu, C. R. Dwyer, R. J. Auchus, Biochemistry 2011, 50, 3968; c) D. N. Kirk, H. C. Toms, C. Douglas, K. A. White, K. E. 
Smith, S. Latif, R. W. P. Hubbard, J. Chem. Soc., Perkin Trans. 2 1990, 1567. 
 
9.2 Dual screening approach 
 
Figure A 6: 1H-NMR of the synthetized 11-(4-trifluoromethylcoumarin-7-yloxy)undecanoic acid in CDCl3. 
1H NMR result as published by Neufeld et al. in 2014: “(CDCl3): δ = 1.24–1.40 (m, 12 H, 4-H 
to 9-H), 1.47 (mc, 2 H, 10-H), 1.63 (mc, 2 H, 3-H), 1.82 (mc, 2 H, 11-H), 2.35 (t, J = 7.5 Hz, 2 H, 2-
H), 4.04 (t, J = 6.5 Hz, 2 H, 12-H), 6.61 (s, 1 H, 3-HAr), 6.86 (d, J = 2.5 Hz, 1 H, 8-HAr), 6.91 (dd, J 
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